• Prognostic and Predictive Biomarkers in Familial Breast Cancer.
    • Deb S, Chakrabarti A, Fox SB.
    • Cancers (Basel). 2023 Feb 20;15(4):1346. doi: 10.3390/cancers15041346.
    • A de novo ERBB3 mutation resulted in Olaparib resistance after successful conversion therapy for a GBC patient bearing BRCA1 mutation.
    • Yang JX, Jia ZY, Liu FT, Wu WG, Li XC, Zou L, Li HF, Zhang F, Bao RF, Peng SY, Lau WY, Liu Y, Li ML, Liu YB.
    • Front Oncol. 2023 Feb 20;13:1078388. doi: 10.3389/fonc.2023.1078388.
    • Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
    • Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, Mahmood RD, Murphy AD, Hasan J, Mitchell CL, Salih Z, Wheeler C, Buckley E, Truelove J, King G, Ainaoui Y, Bhaskar SS, Shaw J, Evans DGR, Kilerci B, Pearce SP, Brady G, Dive C, O'Connor JPB, Wallace AJ, Rothwell DG, Edmondson RJ, Jayson GC.
    • Clin Cancer Res. 2023 Feb 17:CCR-22-3282. doi: 10.1158/1078-0432.CCR-22-3282. Epub ahead of print.

    •• Identifier: NCT02855697: Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer (MOLTO). (ClinicalTrials.gov . Accessed 2023 Feb 18.)

    • Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
    • Terp SK, Stoico MP, Dybkær K, Pedersen IS.
    • Clin Epigenetics. 2023 Feb 14;15(1):24. doi: 10.1186/s13148-023-01440-w.
    • Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer.
    • Jasiak A, Koczkowska M, Stukan M, Wydra D, Biernat W, Izycka-Swieszewska E, Buczkowski K, Eccles MR, Walker L, Wasag B, Ratajska M.
    • Exp Mol Pathol. 2023 Feb 13:104856. doi: 10.1016/j.yexmp.2023.104856. Epub ahead of print.
    • PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality.
    • Yakovlev V, Sullivan SA, Fields E, Temkin SM.
    • Front Oncol. 2023 Feb 13;13:1124147. doi: 10.3389/fonc.2023.1124147.
    • Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study.
    • Leblanc E, Narducci F, Ferron G, Mailliez A, Charvolin JY, El Hajj H, Guyon F, Fourchotte V, Lambaudie E, Crouzet A, Fouche Y, Gouy S, Collinet P, Caquant F, Pomel C, Golfier F, Vaini-Cowen V, Fournier I, Salzet M, Tresch E, Probst A, Lemaire AS, Le Deley MC, Hudry D.
    • Cancers (Basel). 2023 Feb 10;15(4):1141. doi: 10.3390/cancers15041141.

    •• Identifier: NCT01608074: Radical Fimbriectomy for Young BRCA Mutation Carriers (Fimbriectomy). (ClinicalTrials.gov . Accessed 2023 Feb 12.)

    • Dr. Walden on the RNA Expression of Homologous Recombination Genes in CRC.
    • Walden D.
    • OncLive. OncLive TV. 2023 Feb 10.
    • Homologous repair deficiency-associated genes in invasive breast cancer revealed by WGCNA co-expression network analysis and genetic perturbation similarity analysis.
    • Chen H, Liu Y, Yin Z, Chen H, Wang Y, Qian Y.
    • Cell Cycle. 2023 Feb 9:1-24. doi: 10.1080/15384101.2023.2174339. Epub ahead of print.
    • Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
    • Perez-Fidalgo JA, Guerra E, García Y, Iglesias M, Hernández-Sosa M, Estevez-García P, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A.
    • Int J Gynecol Cancer. 2023 Feb 9:ijgc-2022-004028. doi: 10.1136/ijgc-2022-004028. Epub ahead of print.
    • Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
    • Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, Maldi E, Artioli G, Mammoliti S, Zanchi L, Sikokis A, Biglia N, Parisi A, Mandato VD, Carella C, Cormio G, Marinaccio M, Puppo A, Paolini B, Borsotti L, Scotto G, Turinetto M, Sangiolo D, Di Maio M, Valabrega G.
    • Cancers (Basel). 2023 Feb 6;15(4):1032. doi: 10.3390/cancers15041032.
    • Comprehensive Analysis of Germline Drivers in Endometrial Cancer.
    • Gordhandas S, Rios-Doria E, Cadoo KA, Catchings A, Maio A, Kemel Y, Sheehan M, Ranganathan M, Green D, Aryamvally A, Arnold AG, Salo-Mullen E, Manning-Geist B, Sia T, Selenica P, Da Cruz Paula A, Vanderbilt C, Misyura M, Leitao MM, Mueller JJ, Makker V, Rubinstein M, Friedman CF, Zhou Q, Iasonos A, Latham A, Carlo MI, Murciano-Goroff YR, Will M, Walsh MF, Issa Bhaloo S, Ellenson LH, Ceyhan-Birsoy O, Berger MF, Robson ME, Abu-Rustum N, Aghajanian C, Offit K, Stadler Z, Weigelt B, Mandelker DL, Liu YL.
    • J Natl Cancer Inst. 2023 Feb 6:djad016. doi: 10.1093/jnci/djad016. Epub ahead of print.
    • Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor.
    • Wang S, Xia Y, Huang P, Xu C, Qian Y, Fang T, Gao Q.
    • J Oncol. 2023 Feb 6;2023:1453739. doi: 10.1155/2023/1453739.
    • Atypical ATMs: Broadening the Phenotypic Spectrum of ATM-associated Hereditary Cancer.
    • Borja NA, Silva-Smith R, Huang M, Parekh DJ, Sussman D, Tekin M.
    • Front Oncol. 2023 Feb 3;13:1068110. doi: 10.3389/fonc.2023.1068110.
    • Pyrosequencing assay for BRCA1 methylation analysis: results from a cross-validation study.
    • Sahnane N, Rivera D, Libera L, Carnevali I, Banelli B, Facchi S, Gismondi V, Paudice M, Cirmena G, Vellone VG, Sessa F, Varesco L, Tibiletti MG.
    • J Mol Diagn. 2023 Feb 3:S1525-1578(23)00005-3. doi: 10.1016/j.jmoldx.2023.01.003. Epub ahead of print.
    • Distinct breast cancer phenotypes in BRCA 1/2 carriers based on ER status.
    • Rosenberg S, Devir M, Kaduri L, Grinshpun A, Miner V, Hamburger T, Granit A, Nissan A, Maymon O, Peretz T.
    • Breast Cancer Res Treat. 2023 Feb 2. doi: 10.1007/s10549-022-06851-6. Epub ahead of print.
    • Homologous Recombination Deficiency in Ovarian Cancer: From the Biological Rationale to Current Diagnostic Approaches.
    • Mangogna A, Munari G, Pepe F, Maffii E, Giampaolino P, Ricci G, Fassan M, Malapelle U, Biffi S.>
    • J Pers Med. 2023 Feb 2;13(2):284. doi: 10.3390/jpm13020284.
    • Potential prognostic role of somatic mutations in a set of cancer susceptibility genes in ovarian carcinoma: A follow-up multicentric study from Pakistan.
    • Masood A, Sarfaraz R, Zaki S, Shami A, Khaliq S, Naseem N.
    • Cancer Biomark. 2023 Feb 1. doi: 10.3233/CBM-220267. Epub ahead of print.
    • BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity.
    • Wu B, Qi L, Chiang HC, Pan H, Zhang X, Greenbaum A, Stark E, Wang LJ, Chen Y, Haddad BR, Clagett D, Isaacs C, Elledge R, Horvath A, Hu Y, Li R.
    • J Immunother Cancer. 2023 Feb;11(2):e005852. doi: 10.1136/jitc-2022-005852.
    • Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.
    • Chatterji S, Krzoska E, Thoroughgood CW, Saganty J, Liu P, Elsberger B, Abu-Eid R, Speirs V.
    • Lancet Oncol. 2023 Feb;24(2):e74-e85. doi: 10.1016/S1470-2045(22)00633-7.
    • Review

    •• Podcast:

    In conversation with... Valerie Speirs.

    • Genetic variants in African-American and Hispanic patients with breast cancer.
    • Dutta P, Keung MY, Wu Y, Vadgama JV.
    • Oncol Lett. 2022 Dec 16 [eCollection 2023 Feb];25(2):51. doi: 10.3892/ol.2022.13637.
    • Uterine Cavity Lavage Mutation Analysis in Lithuanian Ovarian Cancer Patients.
    • Žilovic D, Vaicekauskaite I, Ciurliene R, Sabaliauskaite R, Jarmalaite S.
    • Cancers (Basel). 2023 Jan 30;15(3):868. doi: 10.3390/cancers15030868.
    • BRCA1 interactors, RAD50 and BRIP1, as prognostic markers for triple negative breast cancer severity.
    • Laha S, Muhseena K, Das SP, Das R.
    • Front Genet. 2023 Jan 30;12:1035052. doi: 10.3389/fgene.2023.1035052.
    • Factors Influencing Residual Glandular Breast Tissue after Risk-Reducing Mastectomy in Genetically Predisposed Individuals Detected by MRI Mammography.
    • Dietzel F, Kolberg L, Vesper AS, Hoffmann J, Nestle-Krämling C, Zwiefel K, Friebe V, Sawicki LM, Bruckmann NM, Jannusch K, Morawitz J, Antoch G, Fehm TN, Kirchner J, Mohrmann S.
    • Cancers (Basel). 2023 Jan 29;15(3):829. doi: 10.3390/cancers15030829.
    • MR imaging phenotypes and features associated with pathogenic mutation to predict recurrence or metastasis in breast cancer.
    • Shao Z, Yu J, Cheng Y, Ma W, Liu P, Lu H.
    • BMC Cancer. 2023 Jan 27;23(1):97. doi: 10.1186/s12885-023-10555-5.
    • Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer.
    • Liu J, Mroczek M, Mach A, Stępień M, Aplas A, Pronobis-Szczylik B, Bukowski S, Mielczarek M, Gajewska E, Topolski P, Król ZJ, Szyda J, Dobosz P.
    • Cancers (Basel). 2023 Jan 27;15(3):779. doi: 10.3390/cancers15030779.
    • Inflammatory cytokines-enriched microenvironment plays key roles for the development of breast cancers.
    • Takeuchi Y, Gotoh N.
    • Cancer Sci. 2023 Jan 26. doi: 10.1111/cas.15734. Epub ahead of print.
    • Review
    • Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management.
    • McGee RB, Oak N, Harrison L, Xu K, Nuccio R, Blake AK, Mostafavi R, Lewis S, Taylor LM, Kubal M, Ouma A, Hines-Dowell SJ, Cheng C, Furtado LV, Nichols KE.
    • Clin Cancer Res. 2023 Jan 24:ccr.22.2482. doi: 10.1158/1078-0432.CCR-22-2482. Epub ahead of print.
    • Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene.
    • Fierheller CT, Alenezi WM, Serruya C, Revil T, Amuzu S, Bedard K, Subramanian DN, Fewings E, Bruce JP, Prokopec S, Bouchard L, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Tischkowitz M, Campbell IG, Pugh TJ, Greenwood CMT, Ragoussis J, Tonin PN.
    • Genes (Basel). 2023 Jan 20;14(2):277. doi: 10.3390/genes14020277.
    • Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.
    • Han S, Camp SY, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker CA, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri TK, AlDubayan SH, Van Allen EM.
    • medRxiv [Preprint]. 2023 Jan 19:2023.01.18.23284664. doi: 10.1101/2023.01.18.23284664.
    • Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.
    • Jin J, Cao J, Li B, Li T, Zhang J, Cao J, Zhao M, Wang L, Wang B, Tao Z, Hu X.
    • Cancer. 2023 Jan 18. doi: 10.1002/cncr.34618. Epub ahead of print.
    • Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients.
    • Sokolenko AP, Moiseyenko FV, Iyevleva AG, Ivantsov AO, Dolmatov GD, Shelekhova KV, Gulo EV, Topal AX, Artemieva EV, Abduloeva NH, Rysev NA, Barsova DA, Levchenko NV,, Volkov NM, Egorenkov VV, Moiseyenko VM, Imyanitov EN.
    • Int J Mol Sci. 2023 Jan 18;24(3):1870. doi: 10.3390/ijms24031870.
    • Association of the Telomerase Reverse Transcriptase rs10069690 Polymorphism with the Risk, Age at Onset and Prognosis of Triple Negative Breast Cancer.
    • Zins K, Peka E, Miedl H, Ecker S, Abraham D, Schreiber M.
    • Int J Mol Sci. 2023 Jan 17;24(3):1825. doi: 10.3390/ijms24031825.
    • CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
    • Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L.
    • Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y.
    • Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
    • Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K, Shiroki R, Saya H.
    • Cancer Med. 2023 Jan 16. doi: 10.1002/cam4.5617. Epub ahead of print.
    • Shallow Whole-Genome Sequencing of Cell-Free DNA (cfDNA) Detects Epithelial Ovarian Cancer and Predicts Patient Prognosis.
    • Bak SE, Kim H, Ho JY, Cho EH, Lee J, Youn SM, Park SW, Han MR, Hur SY, Lee SJ, Choi YJ.
    • Cancers (Basel). 2023 Jan 15;15(2):530. doi: 10.3390/cancers15020530.
    • Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom [Clinically relevant molecular pathological diagnostics in breast cancer].
    • Rodepeter FR, Teply-Szymanski J, Romey M, Grass A, Erber R, Lebeau A, Mack EKM, Tarawneh TS, Gremke N, Boekhoff J, Wündisch T, Wagner U, Jank P, Denkert C.
    • Pathologie (Heidelb). 2023 Jan 11. German. doi: 10.1007/s00292-022-01175-0. Epub ahead of print.
    • Review. [Article in German]
    • Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    • Kim J, Jeong K, Jun H, Kim K, Bae JM, Song MG, Yi H, Park S, Woo GU, Lee DW, Kim TY, Lee KH, Im SA.
    • Hum Genomics. 2023 Jan 6;17(1):2. doi: 10.1186/s40246-022-00447-3.
    • PLA2G7/PAF-AH as Potential Negative Regulator of the Wnt Signaling Pathway Mediates Protective Effects in BRCA1 Mutant Breast Cancer.
    • Liao Y, Badmann S, Kraus F, Topalov NE, Mayr D, Kolben T, Hester A, Beyer S, Mahner S, Jeschke U, Trillsch F, Czogalla B, Burges A.
    • Int J Mol Sci. 2023 Jan 3;24(1):882. doi: 10.3390/ijms24010882.
    • Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
    • Takamatsu S, Yoshihara K, Baba T, Shimada M, Yoshida H, Kajiyama H, Oda K, Mandai M, Okamoto A, Enomoto T, Matsumura N.
    • Br J Cancer. 2023 Jan 2. doi: 10.1038/s41416-022-02122-9. Epub ahead of print.
    • Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
    • Shu T, Zhou Z, Bai J, Xiao X, Gao M, Zhang N, Wang H, Xia X, Gao Y, Zheng H.
    • Gynecol Oncol. 2023 Jan;168:135-143. doi: 10.1016/j.ygyno.2022.11.013. Epub 2022 Nov 25.
    • Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.
    • Nourieh M, Vibert R, Saint-Ghislain M, Cyrta J, Vincent-Salomon A.
    • Histopathology. 2023 Jan;82(1):162-169. doi: 10.1111/his.14794.
    • Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    • Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I.
    • JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258.

    •• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 30.)

    • STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    • Ding L, Wang Q, Martincuks A, Kearns MJ, Jiang T, Lin Z, Cheng X, Qian C, Xie S, Kim HJ, Launonen IM, Färkkilä A, Roberts TM, Freeman GJ, Liu JF, Konstantinopoulos PA, Matulonis U, Yu H, Zhao JJ.
    • J Immunother Cancer. 2023 Jan;11(1):e005627. doi: 10.1136/jitc-2022-005627.
    • Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer.
    • Byun JM, Cho HJ, Lee DS, Yoon HK, Kim YN, Im DH, Kim DH, Lee KB, Sung MS, Jeong DH.
    • Taiwan J Obstet Gynecol. 2023 Jan;62(1):107-111. doi: 10.1016/j.tjog.2022.09.006.
    • Widespread genomic/molecular alterations of DNA helicases and their clinical/therapeutic implications across human cancer.
    • Qin X, Wang J, Wang X, Huang T, Fang Z, Yan L, Fan Y, Xu D.
    • Biomed Pharmacother. 2022 Dec 29;158:114193. doi: 10.1016/j.biopha.2022.114193. Epub ahead of print.
    • CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
    • Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCS Group, Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommoss FKF, Kruitwagen RFPM, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Tołoczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van-Wagensveld L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommoss S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M.
    • Cancer. 2022 Dec 26. doi: 10.1002/cncr.34582. Epub ahead of print.
    • Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment.
    • Jackson LM, Moldovan GL.
    • NAR Cancer. 2022 Dec 22;4(4):zcac042. doi: 10.1093/narcan/zcac042.
    • Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
    • Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI.
    • J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25. Epub ahead of print.
    • Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images.
    • Lazard T, Bataillon G, Naylor P, Popova T, Bidard FC, Stoppa-Lyonnet D, Stern MH, Decencière E, Walter T, Vincent-Salomon A..
    • Cell Rep Med. 2022 Dec 20;3(12):100872. doi: 10.1016/j.xcrm.2022.100872. Epub 2022 Dec 13.

    •• Commentary:

    HRD-related morphology discovery in breast cancer by controlling for confounding factors.

    • Ovarian cancer mutational processes drive site-specific immune evasion.
    • Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP.
    • Nature. 2022 Dec 14. doi: 10.1038/s41586-022-05496-1. Epub ahead of print.
    • BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
    • Darabi S, Braxton DR, Xiu J, Carneiro BA, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry WS, Demeure MJ.
    • Medicina (Kaunas). 2022 Dec 10;58(12):1818. doi: 10.3390/medicina58121818.
    • Detection of BRCA1, and BRCA2 in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting.
    • McFarland TR, Thomas VM, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, Agarwal N, Swami U.
    • Biomedicines. 2022 Dec 7;10(12):3170. doi: 10.3390/biomedicines10123170.
    • Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.
    • Cassani C, Rossi C, Camnasio CA, Urtis M, Fiandrino G, Grasso M, Zanellini F, Lucioni M, D’Ambrosio G, Di Toro A, Rossi M, Roccio M, Ferrari A, Secondino S, Nappi RE, Arbustini E, Paulli M, Spinillo A, Cesari S.
    • Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054.
    • BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.
    • Choi E, Mun GI, Lee J, Lee H, Cho J, Lee YS.
    • Biomed Pharmacother. 2022 Dec 6;158:114090. doi: 10.1016/j.biopha.2022.114090. Epub ahead of print.
    • RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer.
    • Walens A, Van Alsten SC, Olsson LT, Smith MA, Lockhart A, Gao X, Hamilton AM, Kirk EL, Love MI, Gupta GP, Perou CM, Vaziri C, Hoadley KA, Troester MA.
    • Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2136-2147. doi: 10.1158/1055-9965.EPI-22-0590.
    • Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
    • Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, Pavlick D, Gjoerup O, Ross JS, Harmon R, Chung J, Decker B, Dennis L, Frampton GM, Molinero L, Oesterreich S, Venstrom JM, Oxnard GR, Hegde PS, Sokol ES.
    • Nat Commun. 2022 Dec 5;13(1):7495. doi: 10.1038/s41467-022-35245-x.
    • NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer.
    • Jung K, Lee S, Na HY, Kim JW, Lee JC, Hwang JH, Kim JW, Kim J.
    • Sci Rep. 2022 Dec 3;12(1):20937. doi: 10.1038/s41598-022-24732-2.
    • Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.
    • van Wagensveld L, van Baal JOAM, Timmermans M, Gaillard D, Borghuis L, Coffelt SB, Rosenberg EH, Lok CAR, Nijman HW, Kooreman LFS, Sanders J, de Bruijn M, Wessels LFA, van der Wiel R, Rausch C, Broeks A, Kruitwagen RFPM, van der Aa MA, Sonke GS, Schouten PC, Van de Vijver KK, Horlings HM.
    • Cancers (Basel). 2022 Dec 2;14(23):5965. doi: 10.3390/cancers14235965.
    • The BRCAness Landscape of Cancer.
    • Guo M, Wang SM.
    • Cells. 2022 Dec 1;11(23):3877. doi: 10.3390/cells11233877.
    • The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.
    • Garsed DW, Pandey A, Fereday S, Kennedy CJ, Takahashi K, Alsop K, Hamilton PT, Hendley J, Chiew YE, Traficante N, Provan P, Ariyaratne D, Au-Yeung G, Bateman NW, Bowes L, Brand A, Christie EL, Cunningham JM, Friedlander M, Grout B, Harnett P, Hung J, McCauley B, McNally O, Piskorz AM, Saner FAM, Vierkant RA, Wang C, Winham SJ, Pharoah PDP, Brenton JD, Conrads TP, Maxwell GL, Ramus SJ, Pearce CL, Pike MC, Nelson BH, Goode EL, DeFazio A, Bowtell DDL.
    • Nat Genet. 2022 Dec 1:1-9. doi: 10.1038/s41588-022-01230-9. Epub ahead of print.

    •• Research news: Study Unearths Features Found in Long-Term Survivors of Advanced Ovarian Cancer. (GenomeWeb)

    • Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations.
    • Sanders BE, Wolsky R, Doughty ES, Wells KL, Ghosh D, Ku L, Pressey JG, Bitler BB, Brubaker LW.
    • Gynecol Oncol Rep. 2022 Oct 6 [eCollection 2022 Dec];44:101077. doi: 10.1016/j.gore.2022.101077.
    • CHEK2 Pathogenic Germline Variants in Patients With NSCLC.
    • Sorscher S.
    • JTO Clin Res Rep. 2022 Nov 19 [eCollection 2022 Dec];3(12):100439. doi: 10.1016/j.jtocrr.2022.100439.

    •• Original research:

    A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.

    • Pathway-level mutation analysis in primary high-grade serous ovarian cancer and matched brain metastases.
    • Duchnowska R, Supernat AM, Pęksa R, Łukasiewicz M, Stokowy T, Ronen R, Dutkowski J, Umińska M, Iżycka-Świeszewska E, Kowalczyk A, Och W, Rucińska M, Olszewski WP, Mandat T, Jarosz B, Bieńkowski M, Biernat W, Jassem J.
    • Sci Rep. 2022 Nov 29;12(1):20537. doi: 10.1038/s41598-022-23788-4.
    • Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers.
    • Evans DG, Sithambaram S, van Veen EM, Burghel GJ, Schlecht H, Harkness EF, Byers H, Ellingford JM, Gandhi A, Howell SJ, Howell A, Forde C, Lalloo F, Newman WG, Smith MJ, Woodward ER.
    • J Med Genet. 2022 Nov 28:jmg-2022-108790. doi: 10.1136/jmg-2022-108790. Epub ahead of print.
    • Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes.
    • Gonzalez-Bosquet J, Cardillo ND, Reyes HD, Smith BJ, Leslie KK, Bender DP, Goodheart MJ, Devor EJ.
    • Int J Mol Sci. 2022 Nov 26;23(23):14814. doi: 10.3390/ijms232314814.
    • Deep Interactive Learning-based ovarian cancer segmentation of H&E-stained whole slide images to study morphological patterns of BRCA mutation.
    • Ho DJ, Chui MH, Vanderbilt CM, Jung J, Robson ME, Park CS, Roh J, Fuchs TJ.
    • J Pathol Inform. 2022 Nov 26 [eCollection 2023];14:100160. doi: 10.1016/j.jpi.2022.100160.
    • Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.
    • Viet Le B, Podszywalow-Bartnicka P, Piwocka K, Skorski T.
    • Cancers (Basel). 2022 Nov 24;14(23):5795. doi: 10.3390/cancers14235795.
    • Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.
    • Murciano-Goroff YR, Schram AM, Rosen EY, Won H, Gong Y, Noronha AM, Janjigian YY, Stadler ZK, Chang JC, Yang SR, Mandelker D, Offit K, Berger MF, Donoghue MTA, Bandlamudi C, Drilon A.
    • Nat Commun. 2022 Nov 23;13(1):7182. doi: 10.1038/s41467-022-34109-8.
    • The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer.
    • Bizzarri N, D'Indinosante M, Marchetti C, Tudisco R, Turchiano F, Scambia G, Fagotti A.
    • Int J Clin Oncol. 2022 Nov 22. doi: 10.1007/s10147-022-02272-z. Epub ahead of print.
    • Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.
    • Poon DM, Azad A, Castro E, Kanesvaran R, Sartor O.
    • Front Oncol. 2022 Nov 21;12:1101678. doi: 10.3389/fonc.2022.1101678.

    •• Original research:

    Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA.

    •• Original research:

    Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.

    • Precision Medicine Provides Continued Benefit in mCRPC.
    • George DJ, Scott R.
    • OncLive. 2022 Nov 21.
    • Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    • Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S.
    • Breast Cancer Res. 2022 Nov 18;24(1):80. doi: 10.1186/s13058-022-01572-6.
    • Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites.
    • Miceska S, Škof E, Novakovic S, Stegel V, Jericevic A, Grcar Kuzmanov B, Smrkolj Š, Cvjeticanin B, Bebar S, Globocnik Kukovica M, Kloboves-Prevodnik V.
    • Cancer Cytopathol. 2022 Nov 18. doi: 10.1002/cncy.22664. Epub ahead of print.
    • Blood Test Signals BRCA Breast Cancer 2 Years Before Diagnosis.
    • Davenport L.
    • Medscape. 2022 Nov 17.
    • Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.
    • Ogony J, Hoskin TL, Stallings-Mann M, Winham S, Brahmbhatt R, Arshad MA, Kannan N, Peña A, Allers T, Brown A, Sherman ME, Visscher DW, Knutson KL, Radisky DC, Degnim AC.
    • Breast Cancer Res Treat. 2022 Nov 16. doi: 10.1007/s10549-022-06786-y. Epub ahead of print.
    • Details Emerge About Why Cancers Caused by BRCA Mutations Recur.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 16.

    •• Original research:

    Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.

    • Development of a novel BRCAness score that predicts response to PARP inhibitors.
    • Oshi M, Gandhi S, Wu R, Asaoka M, Yan L, Yamada A, Yamamoto S, Narui K, Chishima T, Ishikawa T, Endo I, Takabe K.
    • Biomark Res. 2022 Nov 12;10(1):80. doi: 10.1186/s40364-022-00427-8.
    • Investigation of mRNA Expression Levels of Tip60 and Related DNA Repair Genes in Molecular Subtypes of Breast Cancer.
    • Miser-Salihoglu E, Demokan S, Karanlik H, Karahalil B, Önder S, Cömert S, Yardim-Akaydin S.
    • Clin Breast Cancer. 2022 Nov 12:S1526-8209(22)00235-X. doi: 10.1016/j.clbc.2022.10.012. Epub ahead of print.
    • Study Suggests a PARP Inhibitors Has Wider Cancer Applications.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 9.

    •• Original research:

    A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.

    • Molecular Management of High-Grade Serous Ovarian Carcinoma.
    • Punzón-Jiménez P, Lago V, Domingo S, Simón C, Mas A.
    • Int J Mol Sci. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777.
    • Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.
    • Shah JB, Pueschl D, Wubbenhorst B, Fan M, Pluta J, D'Andrea K, Hubert AP, Shilan JS, Zhou W, Kraya AA, Llop Guevara A, Ruan C, Serra V, Balmaña J, Feldman M, Morin PJ, Nayak A, Maxwell KN, Domchek SM, Nathanson KL.
    • Nat Commun. 2022 Nov 7;13(1):6728. doi: 10.1038/s41467-022-34523-y.

    •• Research news: Details Emerge About Why Cancers Caused by BRCA Mutations Recur. (Inside Precision Medicine)

    • Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer.
    • Vidula N, Lipman A, Kato S, Weipert C, Hesler K, Azzi G, Elkhanany A, Juric D, Rodriguez E, Faulkner C, Makhlouf P, Price K, O'Shaughnessy J, Bardia A.
    • NPJ Breast Cancer. 2022 Nov 4;8(1):117. doi: 10.1038/s41523-022-00490-2.
    • Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.
    • Han H, Park CK, Cho NH, Lee J, Jang WS, Ham WS, Choi YD, Cho KS.
    • Int J Mol Sci. 2022 Nov 3;23(21):13426. doi: 10.3390/ijms232113426.
    • The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    • Atwal A, Snowsill T, Dandy MC, Krum T, Newton C, Evans DG, Crosbie EJ, Ryan NAJ.
    • Int J Cancer. 2022 Nov 1;151(9):1626-1639. doi: 10.1002/ijc.34165. Epub 2022 Jul 6.
    • Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    • Musacchio L, Califano D, Bartoletti M, Arenare L, Lorusso D, Losito NS, Cormio G, Greggi S, Raspagliesi F, Valabrega G, Salutari V, Pisano C, Spina A, Russo D, Del Sesto M, Canzonieri V, Ferraù F, Zannoni GF, Loizzi V, Ghizzoni V, Casanova C, Tuninetti V, Ducceschi M, Del Vecchio V, Scalone S, Priolo D, Perrone F, Scambia G, Pignata S.
    • Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22.

    Identifier: NCT02408536: Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer (MITO 22). (ClinicalTrials.gov)

    • Druggable gene alterations in Japanese patients with rare malignancy.
    • Ohmoto A, Hayashi N, Fukada I, Yamazaki M, Yunokawa M, Kasuga A, Shinozaki E, Ueki A, Tonooka A, Takeuchi K, Mori S, Kiyotani K, Takahashi S.
    • Neoplasia. 2022 Nov;33:100834. doi: 10.1016/j.neo.2022.100834. Epub 2022 Sep 8.
    • Somatic Inactivation of Breast Cancer Predisposition Genes in Tumours Associated with Pathogenic Germline Variants.
    • Lim BWX, Li N, Mahale S, Mcinerny S, Zethoven M, Rowley SM, Huynh J, Wang T, Lee JEA, Friedman M, Devereux L, Scott RJ, Sloan EK, James PA, Campbell IG.
    • J Natl Cancer Inst. 2022 Oct 31:djac196. doi: 10.1093/jnci/djac196. Epub ahead of print.
    • BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling.
    • Shaashua L, Ben-Shmuel A, Pevsner-Fischer M, Friedman G, Levi-Galibov O, Nandakumar S, Barki D, Nevo R, Brown LE, Zhang W, Stein Y, Lior C, Kim HS, Bojmar L, Jarnagin WR, Lecomte N, Mayer S, Stok R, Bishara H, Hamodi R, Levy-Lahad E, Golan T, Porco JA Jr, Iacobuzio-Donahue CA, Schultz N, Tuveson DA, Lyden D, Kelsen D, Scherz-Shouval R.
    • Nat Commun. 2022 Oct 31;13(1):6513. doi: 10.1038/s41467-022-34081-3.
    • Common germline risk variants impact somatic alterations and clinical features across cancers.
    • Namba S, Saito Y, Kogure Y, Masuda T, Bondy ML, Gharahkhani P, Gockel I, Heider D, Hillmer A, Jankowski J, MacGregor S, Maj C, Melin B, Ostrom QT, Palles C, Schumacher J, Tomlinson I, Whiteman DC, Okada Y, Kataoka K.
    • Cancer Res. 2022 Oct 26:CAN-22-1492. doi: 10.1158/0008-5472.CAN-22-1492. Epub ahead of print.
    • TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
    • Khaled NB, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN.
    • Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240.
    • Single-cell genomic variation induced by mutational processes in cancer.
    • Funnell T, O'Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, Lee H, Salehi S, Vázquez-García I, Shi H, Leventhal E, Masud T, Eirew P, Yap D, Zhang AW, Lim JLP, Wang B, Brimhall J, Biele J, Ting J, Au V, Van Vliet M, Liu YF, Beatty S, Lai D, Pham J, Grewal D, Abrams D, Havasov E, Leung S, Bojilova V, Moore RA, Rusk N, Uhlitz F, Ceglia N, Weiner AC, Zaikova E, Douglas JM, Zamarin D, Weigelt B, Kim SH, Da Cruz Paula A, Reis-Filho JS, Martin SD, Li Y, Xu H, de Algara TR, Lee SR, Llanos VC, Huntsman DG, McAlpine JN; IMAXT Consortium, Shah SP, Aparicio S.
    • Nature. 2022 Oct 26. doi: 10.1038/s41586-022-05249-0. Epub ahead of print.
    • Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer.
    • Lobanova O, Medvedieva N, Fishchuk L, Dubitska O, Cheshuk V, Vereshchako R, Zakhartseva L, Rossokha Z, Gorovenko N.
    • Breast Cancer Res Treat. 2022 Oct 25. doi: 10.1007/s10549-022-06774-2. Epub ahead of print.
    • A Case of Thyroid Carcinoma Showing Thymus-Like Differentiation With Breast Cancer Susceptibility Gene 2 Mutation: A Case Report and Literature Review.
    • Kuroki M, Shibata H, Iinuma R, Okuda H, Ohashi T, Ogawa T, Horikawa Y.
    • Cureus. 2022 Oct 25;14(10):e30655. doi: 10.7759/cureus.30655.
    • Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis.
    • Klotz DM, Kuhlmann JD, Link T, Goeckenjan M, Hofbauer LC, Göbel A, Rachner TD, Wimberger P.
    • Front Oncol. 2022 Oct 21;12:974885. doi: 10.3389/fonc.2022.974885.
    • APC germline pathogenic variants and epithelial ovarian cancer: causal or coincidental findings?
    • Vibert R, Le Gall J, Buecher B, Mouret-Fourme E, Bataillon G, Becette V, Trabelsi-Grati O, Moncoutier V, Dehainault C, Carriere J, Schwartz M, Suybeng V, Bieche I, Colas C, Vincent-Salomon A, Stoppa-Lyonnet D, Golmard L.
    • J Med Genet. 2022 Oct 21:jmedgenet-2022-108467. doi: 10.1136/jmg-2022-108467. Epub ahead of print.
    • Case report
    • Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.
    • Chen G, Zhu YJ, Chen J, Miao F, Wu N, Song Y, Mao BB, Wang SZ, Xu F, Chen ZM.
    • Neoplasma. 2022 Oct 21:220721N738. doi: 10.4149/neo_2022_220721N738. Epub ahead of print.
    • Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells.
    • Deshpande M, Paniza T, Jalloul N, Nanjangud G, Twarowski J, Koren A, Zaninovic N, Zhan Q, Chadalavada K, Malkova A, Khiabanian H, Madireddy A, Rosenwaks Z, Gerhardt J.
    • Mol Cell. 2022 Oct 20;82(20):3781-3793.e7. doi: 10.1016/j.molcel.2022.08.017. Epub 2022 Sep 12.

    Commentary:

    BRCA1 protects against its own fragility.

    • IN VIVO ASSIGNMENT OF METHYLMALONIC ACID IN BREAST TISSUE USING 2D MAGNETIC RESONANCE SPECTROSCOPY AND RELATIONSHIP WITH BREAST DENSITY, MENOPAUSAL STATUS AND CANCER RISK.
    • Santamaría G, Naude N, Bennett I, Vosburgh K, Ganau S, Bargalló X, Malycha P, Mountford C.
    • NMR Biomed. 2022 Oct 19:e4851. doi: 10.1002/nbm.4851. Epub ahead of print.
    • DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
    • Ebata T, Yamashita S, Takeshima H, Yoshida H, Kawata Y, Kino N, Yasugi T, Terao Y, Yonemori K, Kato T, Ushijima T.
    • Gynecol Oncol. 2022 Oct 14:S0090-8258(22)01881-9. doi: 10.1016/j.ygyno.2022.10.008. Epub ahead of print.
    • Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
    • Okawa Y, Iwasaki Y, Johnson TA, Ebata N, Inai C, Endo M, Maejima K, Sasagawa S, Fujita M, Matsuda K, Murakami Y, Nakamura T, Hirano S, Momozawa Y, Nakagawa H.
    • J Hepatol. 2022 Oct 12:S0168-8278(22)03137-3. doi: 10.1016/j.jhep.2022.09.025. Epub ahead of print.
    • PARP-inhibition reprograms macrophages toward an anti-tumor phenotype.
    • Wang L, Wang D, Sonzogni O, Ke S, Wang Q, Thavamani A, Batalini F, Stopka SA, Regan MS, Vandal S, Tian S, Pinto J, Cyr AM, Bret-Mounet VC, Baquer G, Eikesdal HP, Yuan M, Asara JM, Heng YJ, Bai P, Agar NYR, Wulf GM.
    • Cell Rep. 2022 Oct 11;41(2):111462. doi: 10.1016/j.celrep.2022.111462.
    • Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
    • Miller RE, Elyashiv O, El-Shakankery KH, Ledermann JA.
    • Onco Targets Ther. 2022 Oct 4;15:1105-1117. doi: 10.2147/OTT.S272199.
    • The DNA damage induced immune response: Implications for cancer therapy.
    • Barros EM, McIntosh SA, Savage KI.
    • DNA Repair (Amst). 2022 Oct 3;120:103409. doi: 10.1016/j.dnarep.2022.103409. Epub ahead of print.
    • NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer.
    • Devanaboyina M, Kaur J, Whiteley E, Lin L, Einloth K, Morand S, Stanbery L, Hamouda D, Nemunaitis J.
    • Oncol Rev. 2022 Oct 3;16:10568. doi: 10.3389/or.2022.10568.
    • Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients.
    • Dogan I, Aydin E, Yazici H, Saip P.
    • Eur J Breast Health. 2022 Oct 1;18(4):323-328. doi: 10.4274/ejbh.galenos.2022.2022-5-2.
    • Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing; A Korean Gynecologic Oncology Group study (KGOG 3047).
    • Sa JK, Kim J, Kang S, Kim SW, Song T, Shim SH, Choi MC, No JH, Song JY, Kim D, Kim YM, Kim JH, Lee JW.
    • Int J Cancer. 2022 Oct 1;151(7):1086-1097. doi: 10.1002/ijc.34150. Epub 2022 Jun 27.
    • Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.
    • Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, Uliana V, Zanoni D, Tommasi C, Bortesi B, Bonatti F, Piacentini F, Cortesi L, Camisa R, Sgargi P, Michiara M, Musolino A.
    • Breast. 2022 Oct;65:145-150. doi: 10.1016/j.breast.2022.07.012. Epub 2022 Jul 31.
    • Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    • Beinse G, Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, Garinet S, Leroy K, Delanoy N, Blons H, Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Bats AS, Borghese B, Alexandre J.
    • Br J Cancer. 2022 Oct;127(6):1123-1132. doi: 10.1038/s41416-022-01900-9. Epub 2022 Jun 25.
    • Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations.
    • Siegmund SE, Manning DK, Davineni PK, Dong F.
    • Mod Pathol. 2022 Oct;35(10):1458-1467. doi: 10.1038/s41379-022-01083-x. Epub 2022 Jul 28.
    • A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
    • Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML.
    • Nat Cancer. 2022 Oct;3(10):1181-1191. doi: 10.1038/s43018-022-00439-1. Epub 2022 Oct 17.

    •• Identifier: NCT02401347: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    •• Identifier: NCT04756765: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    •• Research news: Study Suggests a PARP Inhibitors Has Wider Cancer Applications. (Inside Precision Medicine)

    • Modulation of DNA Methylation/Demethylation Reactions Induced by Nutraceuticals and Pollutants of Exposome Can Promote a C > T Mutation in the Breast Cancer Predisposing Gene PALB2.
    • Courant F, Bougras-Cartron G, Abadie C, Frenel JS, Cartron PF.
    • Epigenomes. 2022 Sep 30;6(4):32. doi: 10.3390/epigenomes6040032.
    • Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient HCC.
    • An J, Oh JH, Oh B, Oh YJ, Ju JS, Kim W, Kang HJ, Sung CO, Shim JH.
    • Hepatology. 2022 Sep 30. doi: 10.1002/hep.32812. Epub ahead of print.
    • Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.
    • Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, Mehine M, Chou J, Capanu M, Mandelker D, Stadler ZK, Birsoy O, Jairam S, Yang C, Li Y, Wong D, Benhamida JK, Ladanyi M, Zhang L, O'Reilly EM.
    • Mol Diagn Ther. 2022 Sep 30. doi: 10.1007/s40291-022-00614-1. Epub ahead of print.
    • Deciphering the expression patterns of homologous recombination-related lncRNAs identifies new molecular subtypes and emerging therapeutic opportunities in epithelial ovarian cancer.
    • Hua T, Zhang XC, Wang W, Tian YJ, Chen SB.
    • Front Genet. 2022 Sep 29;13:901424. doi: 10.3389/fgene.2022.901424.
    • Integrated proteomics identifies PARP inhibitor-induced pro-survival signaling changes as potential vulnerabilities in ovarian cancer.
    • Deng O, Dash S, Nepomuceno TC, Fang B, Yun SY, Welsh EA, Lawrence HR, Marchion D, Koomen JM, Monteiro AN, Rix U.
    • J Biol Chem. 2022 Sep 29:102550. doi: 10.1016/j.jbc.2022.102550. Epub ahead of print.
    • RNA sequencing and bioinformatics analysis revealed PACSIN3 as a potential novel biomarker for platinum resistance in epithelial ovarian cancer.
    • Han GH, Shim JE, Yun H, Kim J, Kim JH, Cho H.
    • J Gene Med. 2022 Sep 28:e3452. doi: 10.1002/jgm.3452. Epub ahead of print.
    • BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K/AKT signaling pathway.
    • Liu X, Liu H, Zeng L, Lv Y.
    • PeerJ. 2022 Sep 28;10:e14052. doi: 10.7717/peerj.14052.
    • Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
    • Bonnet E, Haddad V, Quesada S, Baffert KA, Lardy-Cléaud A, Treilleux I, Pissaloux D, Attignon V, Wang Q, Buisson A, Heudel PE, Bachelot T, Dufresne A, Eberst L, Toussaint P, Bonadona V, Lasset C, Viari A, Sohier E, Paindavoine S, Combaret V, Pérol D, Ray-Coquard I, Blay JY, Trédan O.
    • J Pers Med. 2022 Sep 27;12(10):1595. doi: 10.3390/jpm12101595.
    • Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer.
    • Nero C, Boldrini L, Lenkowicz J, Giudice MT, Piermattei A, Inzani F, Pasciuto T, Minucci A, Fagotti A, Zannoni G, Valentini V, Scambia G.
    • Int J Mol Sci. 2022 Sep 26;23(19):11326. doi: 10.3390/ijms231911326.
    • Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial.
    • Chen J, Li Y, Wang H, Li T, Gu Y, Wang W, Shan Y, Yin J, Wang Y, Qin M, Li S, Pan L, Peng S, Jin Y.
    • Cancers (Basel). 2022 Sep 24;14(19):4649. doi: 10.3390/cancers14194649.
    • What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.
    • Perrone E, Tudisco R, Pafundi PC, Guido D, Ciucci A, Martinelli E, Zannoni GF, Piermattei A, Spadola S, Ferrante G, Marchetti C, Scambia G, Fagotti A, Gallo D.
    • Cancers (Basel). 2022 Sep 22;14(19):4588. doi: 10.3390/cancers14194588.
    • Identification of Shared Neoantigens in BRCA1-Related Breast Cancer.
    • Ruangapirom L, Sutivijit N, Teerapakpinyo C, Mutirangura A, Doungkamchan C.
    • Vaccines (Basel). 2022 Sep 22;10(10):1597. doi: 10.3390/vaccines10101597.
    • PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment-A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters.
    • Stanowska O, Kuczkiewicz-Siemion O, Debowska M, Olszewski WP, Jagiello-Gruszfeld A, Tysarowski A, Prochorec-Sobieszek M.
    • J Clin Med. 2022 Sep 21;11(19):5524. doi: 10.3390/jcm11195524.
    • Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
    • Gasimli K, Raab M, Tahmasbi Rad M, Kurunci-Csacsko E, Becker S, Strebhardt K, Sanhaji M.
    • Int J Mol Sci. 2022 Sep 17;23(18):10892. doi: 10.3390/ijms231810892.
    • Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter.
    • de Jong VMT, Pruntel R, Steenbruggen TG, Bleeker FE, Nederlof P, Hogervorst FBL, linn SC.
    • Fam Cancer. 2022 Sep 16. doi: 10.1007/s10689-022-00314-z. Epub ahead of print.
    • Mitotic DNA synthesis is caused by transcription-replication conflicts in BRCA2-deficient cells.
    • Groelly FJ, Dagg RA, Petropoulos M, Rossetti GG, Prasad B, Panagopoulos A, Paulsen T, Karamichali A, Jones SE, Ochs F, Dionellis VS, Puig Lombardi E, Miossec MJ, Lockstone H, Legube G, Blackford AN, Altmeyer M, Halazonetis TD, Tarsounas M.
    • Mol Cell. 2022 Sep 15;82(18):3382-3397.e7. doi: 10.1016/j.molcel.2022.07.011. Epub 2022 Aug 23.
    • Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
    • Hamid AB, Frank LE, Bouley RA, Petreaca RC.
    • PLoS One. 2022 Sep 15;17(9):e0273736. doi: 10.1371/journal.pone.0273736.
    • BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair.
    • Jimenez-Sainz J, Mathew J, Moore G, Lahiri S, Garbarino J, Eder JP, Rothenberg E, Jensen RB.
    • Elife. 2022 Sep 13;11:e79183. doi: 10.7554/eLife.79183.
    • B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    • Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, Fenor de la Maza MD, Rescigno P, Westaby D, Chandran K, Riisnaes R, Ferreira A, Miranda S, Calì B, Alimonti A, Bressan S, Nguyen AHT, Shen MM, Hawley JE, Obradovic A, Drake CG, Bertan C, Baker C, Tunariu N, Yuan W, de Bono JS.
    • Eur Urol. 2022 Sep 13:S0302-2838(22)02633-1. doi: 10.1016/j.eururo.2022.09.004. Epub ahead of print.
    • UBE2T regulates epithelial-mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer.
    • Cui P, Li H, Wang C, Liu Y, Zhang M, Yin Y, Sun Z, Wang Y, Chen X.
    • J Ovarian Res. 2022 Sep 10;15(1):103. doi: 10.1186/s13048-022-01034-9.
    • Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution.
    • Yu X, Lin W, Spirtos A, Wang Y, Chen H, Ye J, Parker J, Liu CC, Wang Y, Quinn G, Zhou F, Chambers SK, Lewis C, Lea J, Li B, Zheng W.
    • BMC Med. 2022 Sep 9;20(1):283. doi: 10.1186/s12916-022-02489-9.
    • CDH1 (E-cadherin) Gene Methylation in Human Breast Cancer: Critical Appraisal of a Long and Twisted Story.
    • Bücker L, Lehmann U.
    • Cancers (Basel). 2022 Sep 8;14(18):4377. doi: 10.3390/cancers14184377.
    • Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    • Lønning PE, Nikolaienko O, Pan K, Kurian AW, Eikesdal HP, Pettinger M, Anderson GL, Prentice RL, Chlebowski RT, Knappskog S.
    • JAMA Oncol. 2022 Sep 8. doi: 10.1001/jamaoncol.2022.3846. Epub ahead of print.
    • Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk.
    • Tenedini E, Piana S, Toss A, Marino M, Barbieri E, Artuso L, Venturelli M, Gasparini E, Mandato VD, Marchi I, Castellano S, Luppi M, Trenti T, Cortesi L, Tagliafico E.
    • JCO Precis Oncol. 2022 Aug [2022 Sep 8];6:e2200138. doi: 10.1200/PO.22.00138.
    • Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients.
    • Grech CT, Pils D, Aust S, Grimm C, Polterauer S, Reinthaller A, Müllauer L, Reischer T, Bekos C.
    • J Pers Med. 2022 Sep 7;12(9):1467. doi: 10.3390/jpm12091467.
    • Multiple Perspectives Reveal the Role of DNA Damage Repair Genes in the Molecular Classification and Prognosis of Pancreatic Adenocarcinoma.
    • Li Y, Zhang K, Peng L, Chen L, Gao H, Chen H.
    • Int J Mol Sci. 2022 Sep 6;23(18):10231. doi: 10.3390/ijms231810231.
    • PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.
    • Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F.
    • Cancers (Basel). 2022 Sep 5;14(17):4332. doi: 10.3390/cancers14174332.
    • Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma.
    • Mafficini A, Simbolo M, Shibata T, Hong SM, Pea A, Brosens LA, Cheng L, Antonello D, Sciammarella C, Cantù C, Mattiolo P, Taormina SV, Malleo G, Marchegiani G, Sereni E, Corbo V, Paolino G, Ciaparrone C, Hiraoka N, Pallaoro D, Jansen C, Milella M, Salvia R, Lawlor RT, Adsay V, Scarpa A, Luchini C.
    • Mod Pathol. 2022 Sep 2. doi: 10.1038/s41379-022-01143-2. Epub ahead of print.
    • Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.
    • Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK.
    • Clin Cancer Res. 2022 Sep 1;28(17):3669-3676. doi: 10.1158/1078-0432.CCR-21-1278.
    • BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome.
    • Blatnik A, Ribnikar D, Šetrajcic Dragoš V, Novakovic S, Stegel V, Grcar Kuzmanov B, Boc N, Peric B, Škerl P, Klancar G, Krajc M.
    • Breast Cancer. 2022 Sep;29(5):921-927. doi: 10.1007/s12282-022-01354-0. Epub 2022 Apr 5.
    • Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    • Chen T, Yu T, Zhuang S, Geng Y, Xue J, Wang J, Ai L, Chen B, Zhao Z, Li Y, Wang J, Liang H, Xu Y, Gu Y.
    • Br J Cancer. 2022 Sep;127(5):916-926. doi: 10.1038/s41416-022-01836-0. Epub 2022 May 26.
    • Effects of the Methylation Levels for the Breast Cancer Associated Genes BCSG1 and BRCA1 on Cellular Proliferation and Migration.
    • Li J, Li P, Li J, Yang H, Liu G, Shen P, Jiang G.
    • Genet Test Mol Biomarkers. 2022 Sep;26(9):422-429. doi: 10.1089/gtmb.2021.0304.
    • RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.
    • Liu P, Lin C, Liu L, Lu Z, Tu Z, Liu H.
    • J Biol Chem. 2022 Sep;298(9):102354. doi: 10.1016/j.jbc.2022.102354. Epub 2022 Aug 9.
    • Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma.
    • Tanaka T, Takehara K, Yamashita N, Okazawa-Sakai M, Kuraoka K, Teramoto N, Taguchi K, Yamashiro K, Kato H, Mizunoe T, Suzuki R, Yamamoto D, Ueki A, Saito T.
    • J Gynecol Oncol. 2022 Sep;33(5):e67. doi: 10.3802/jgo.2022.33.e67.
    • Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics.
    • Konishi I, Abiko K, Hayashi T, Yamanoi K, Murakami R, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M; Kyoto Study Group for Ovarian Cancer Research.
    • J Gynecol Oncol. 2022 Sep;33(5):e83. doi: 10.3802/jgo.2022.33.e83.
    • A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.
    • Zhang SS, Lee JK, Tukachinsky H, Schrock AB, Nagasaka M, Ou SI.
    • JTO Clin Res Rep. 2022 Aug 6 [eCollection 2022 Sep];3(9):100387. doi: 10.1016/j.jtocrr.2022.100387.

    •• Letter, Commentary:

    CHEK2 Pathogenic Germline Variants in Patients With NSCLC.

    • Comment on: BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
    • Jia D, Li L, Wang P.
    • Target Oncol. 2022 Sep;17(5):605-606. doi: 10.1007/s11523-022-00903-z. Epub 2022 Aug 1.
    • Comment. Letter.

    Original research:

    BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.

    Reply, Letter:

    Author's Reply to Jia et al.: "BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis".

    • Clinico-genomic characterization of ATM and HRD in Pancreas Cancer: Application for Practice.
    • Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, Keane F, Balogun F, Yu KH, Kelsen DP, Crane C, Capanu M, Iacobuzio-Donahue C, O'Reilly EM.
    • Clin Cancer Res. 2022 Aug 30:CCR-22-1483. doi: 10.1158/1078-0432.CCR-22-1483. Epub ahead of print.
    • Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology.
    • van der Wiel AMA, Schuitmaker L, Cong Y, Theys J, Van Hoeck A, Vens C, Lambin P, Yaromina A, Dubois LJ.
    • Cancers (Basel). 2022 Aug 27;14(17):4157. doi: 10.3390/cancers14174157.
    • Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA.
    • Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N.
    • Front Oncol. 2022 Sep 15;12:966534. doi: 10.3389/fonc.2022.966534.

    •• Commentary:

    Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.

    • Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice.
    • Dotolo S, Esposito Abate R, Roma C, Guido D, Preziosi A, Tropea B, Palluzzi F, Giacò L, Normanno N.
    • Biomedicines. 2022 Aug 24;10(9):2074. doi: 10.3390/biomedicines10092074.
    • Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.
    • Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De La Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F.
    • Cancers (Basel). 2022 Aug 21;14(16):4040. doi: 10.3390/cancers14164040.
    • Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer.
    • Oda K, Aoki D, Tsuda H, Nishihara H, Aoyama H, Inomata H, Shimada M, Enomoto T.
    • Cancer Sci. 2022 Aug 17. doi: 10.1111/cas.15518. Epub ahead of print.
    • Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.
    • Hollis RL, Meynert AM, Michie CO, Rye T, Churchman M, Hallas-Potts A, Croy I, McCluggage WG, Williams ARW, Bartos C, Iida Y, Okamoto A, Dougherty B, Barrett JC, March R, Matakidou A, Roxburgh P, Semple CA, Harkin DP, Kennedy R, Herrington CS, Gourley C.
    • Clin Cancer Res. 2022 Aug 15;28(16):3546-3556. doi: 10.1158/1078-0432.CCR-22-0368.
    • Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients.
    • Tao J, Sun D, Zhou H, Zhu J, Zhang X, Hou H.
    • Pathol Res Pract. 2022 Aug 13;238:154074. doi: 10.1016/j.prp.2022.154074. Epub ahead of print.
    • Stat3 Tyrosine 705 and Serine 727 Phosphorylation Associate With Clinicopathological Characteristics and Distinct Tumor Cell Phenotypes in Triple-Negative Breast Cancer.
    • Stenckova M, Nenutil R, Vojtesek B, Coates PJ.
    • Pathol Oncol Res. 2022 Aug 9;28:1610592. doi: 10.3389/pore.2022.1610592.
    • Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants.
    • Brewer T, Yehia L, Bazeley P, Eng C.
    • Am J Hum Genet. 2022 Aug 4;109(8):1520-1533. doi: 10.1016/j.ajhg.2022.07.005.

    Research news: PTEN Mutation Syndrome Leads to Breast Cancers With Distinct Molecular Alterations. (GenomeWeb)

    • What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
    • Petrylak DP, Watkins SP, Loehr A.
    • Front Oncol. 2022 Aug 1;12:951348. doi: 10.3389/fonc.2022.951348.
    • BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    • Cremona M, Vandenberg CJ, Farrelly AM, Madden SF, Morgan C, Kalachand R, McAlpine JN, Toomey S, Huntsman DG, Grogan L, Breathnach O, Morris P, Carey MS, Scott CL, Hennessy BT.
    • Br J Cancer. 2022 Aug;127(3):488-499. doi: 10.1038/s41416-022-01823-5. Epub 2022 Apr 30.
    • Fibroblast testing can inform medical management in individuals with mosaic variants detected on hereditary cancer panels.
    • Sutcliffe EG, Mester JL, Susswein LR, Roberts ME, Marshall ML, Hruska KS.
    • Cancer Genet. 2022 Aug;266-267:86-89. doi: 10.1016/j.cancergen.2022.07.004. Epub 2022 Jul 28.
    • Mutation profiles in circulating cell-free DNA predict acquired resistance to Olaparib in high-grade serous ovarian carcinoma.
    • Hu D, Guo E, Yang B, Qin X, Fu Y, Fan J, Zhuang X, Yao Q, Lu F, Li W, Xiao R, Wu X, Yang X, Wang Z, Liu C, You L, Zang R, Zhou Q, Zhao W, Chen G, Sun C.
    • Cancer Sci. 2022 Aug;113(8):2849-2861. doi: 10.1111/cas.15456. Epub 2022 Jun 26.
    • Histological and Immunohistochemical Characteristics for Hereditary Breast Cancer Risk in a Cohort of Brazilian Women.
    • de Freitas RM, Guerra MR, Fayer VA, Campos AAL, Cintra JRD, Warren J, Ervilha RR, de Paula CD, Bustamante-Teixeira MT.
    • Rev Bras Ginecol Obstet. 2022 Aug;44(8):761-770. English. doi: 10.1055/s-0042-1743103. Epub 2022 Apr 25.
    • Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer.
    • Paracchini L, Mannarino L, Beltrame L, Landoni F, Fruscio R, Grassi T, Dalessandro ML, D'Incalci M, Marchini S.
    • Cancers (Basel). 2022 Jul 29;14(15):3697. doi: 10.3390/cancers14153697.
    • Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
    • Sabatier R, Garnier S, Guille A, Carbuccia N, Pakradouni J, Adelaide J, Provansal M, Cappiello M, Rousseau F, Chaffanet M, Birnbaum D, Mamessier E, Gonçalves A, Bertucci F.
    • Front Oncol. 2022 Jul 29;12:946257. doi: 10.3389/fonc.2022.946257.

    Identifier: NCT02342158: Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors (PERMED01). (ClinicalTrials.gov)

    • Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer.
    • Zografos E, Andrikopoulou A, Papatheodoridi AM, Kaparelou M, Bletsa G, Liontos M, Dimopoulos MA, Zagouri F.
    • Genes (Basel). 2022 Jul 29;13(8):1362. doi: 10.3390/genes13081362.
    • Live Cell Detection of Poly(ADP-Ribose) for Use in Genetic and Genotoxic Compound Screens.
    • Koczor CA, Haider AJ, Saville KM, Li J, Andrews JF, Beiser AV, Sobol RW.
    • Cancers (Basel). 2022 Jul 28;14(15):3676. doi: 10.3390/cancers14153676.
    • The Differential Metabolic Signature of Breast Cancer Cellular Response to Olaparib Treatment.
    • Berardi D, Hunter Y, van den Driest L, Farrell G, Rattray NJW, Rattray Z.
    • Cancers (Basel). 2022 Jul 27;14(15):3661. doi: 10.3390/cancers14153661.
    • High grade acinic cell carcinoma of the breast with clear cytoplasm mimics clear cell carcinoma in a BRCA1 mutation carrier: a case report and review of the literature on the molecular analysis.
    • Min L, Qiao H, Hongkai Z.
    • Histol Histopathol. 2022 Jul 27:18501. doi: 10.14670/HH-18-501. Epub ahead of print.
    • DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers.
    • Gull N, Jones MR, Peng PC, Coetzee SG, Silva TC, Plummer JT, Reyes ALP, Davis BD, Chen SS, Lawrenson K, Lester J, Walsh C, Rimel BJ, Li AJ, Cass I, Berg Y, Govindavari JB, Rutgers JKL, Berman BP, Karlan BY, Gayther SA.
    • J Exp Clin Cancer Res. 2022 Jul 27;41(1):232. doi: 10.1186/s13046-022-02440-z.
    • DNA nicks induce mutational signatures associated with BRCA1 deficiency.
    • Feng YL, Liu Q, Chen RD, Liu SC, Huang ZC, Liu KM, Yang XY, Xie AY.
    • Nat Commun. 2022 Jul 25;13(1):4285. doi: 10.1038/s41467-022-32011-x.
    • Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
    • de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC.
    • J Clin Oncol. 2022 Jul 20;40(21):2361-2374. doi: 10.1200/JCO.21.01536. Epub 2022 Mar 30.
    • Comprehensive Genomic Profiling in the Management of Ovarian Cancer-National Results from Croatia.
    • Cerina D, Matkovic V, Katic K, Belac Lovasic I, Šeparovic R, Canjko I, Bajic Ž, Vrdoljak E.
    • J Pers Med. 2022 Jul 19;12(7):1176. doi: 10.3390/jpm12071176.
    • Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2.
    • Wu S, Qi L, Chen H, Zhang K, He J, Guo X, Shen L, Zhou Y, Zhong X, Zheng S, Zhou J, Chen Y.
    • NPJ Breast Cancer. 2022 Jul 19;8(1):86. doi: 10.1038/s41523-022-00454-6.
    • Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jul 13.
    • Research news

    Original research:

    PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.

    • Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.
    • Long M, Liu H, Wu J, Wang S, Liao X, Liu Y, Hu T.
    • Comput Math Methods Med. 2022 Jul 9;2022:5508301. doi: 10.1155/2022/5508301.
    • Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer.
    • Moore G, Majumdar R, Powell SN, Khan AJ, Weinhold N, Yin S, Higginson DS.
    • Mol Cancer Res. 2022 Jul 6;20(7):1061-1070. doi: 10.1158/1541-7786.MCR-21-1012.
    • Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
    • Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, Swisher EM, Liu ET.
    • Sci Transl Med. 2022 Jul 6;14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926. Epub 2022 Jul 6.

    Research news: Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response. (Precision Oncology News)

    • Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers.
    • Kim SR, Tone A, Kim R, Cesari M, Clarke B, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE, Eiriksson L.
    • Int J Gynecol Cancer. 2022 Jul 4;32(7):891-898. doi: 10.1136/ijgc-2021-003082.
    • Evaluating Mismatch Repair Status to Screen Clinical Advanced Breast Carcinomas for Immunotherapy: Experience From a Large Academic Institution.
    • Arole V, Shafi S, Challa B, Parwani AV, Tozbikian G, Li Z.
    • Clin Breast Cancer. 2022 Jul;22(5):e680-e684. doi: 10.1016/j.clbc.2022.01.010. Epub 2022 Jan 22.
    • Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy.
    • Wang X, Hu N, Cui L, Si Y, Yue J, Zheng F, Kang Y, Yuan P.
    • Curr Cancer Drug Targets. 2022 [Jul];22(6):530-536. doi: 10.2174/1568009622666220214092207.
    • A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    • Shao C, Wan J, Lam FC, Tang H, Marley AR, Song Y, Miller C, Brown M, Han J, Adeboyeje G.
    • Environ Mol Mutagen. 2022 Jul;63(6):308-316. doi: 10.1002/em.22505. Epub 2022 Aug 30.
    • Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
    • Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J.
    • JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195.
    • TP53 variants in p53 signatures and the clonality of STICs in RRSO samples.
    • Akahane T, Masuda K, Hirasawa A, Kobayashi Y, Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, Aoki D.
    • J Gynecol Oncol. 2022 Jul;33(4):e50. doi: 10.3802/jgo.2022.33.e50. Epub 2022 Mar 21.
    • Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
    • Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP.
    • J Pathol. 2022 Jul;257(3):255-261. doi: 10.1002/path.5891. Epub 2022 Apr 18.
    • Review
    • Recombinant human chorionic gonadotropin induces signaling pathways towards cancer prevention in the breast of BRCA1/2 mutation carriers.
    • Su Y, Dang NM, Depypere H, Santucci-Pereira J, Gutiérrez-Díez PJ, Kanefsky J, Janssens JP, Russo J.
    • Eur J Cancer Prev. 2022 Jun 30. doi: 10.1097/CEJ.0000000000000763. Epub ahead of print.
    • Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance.
    • Uddin MH, Zhou JY, Pimentel J, Patrick SM, Kim S, Shekhar MP, Wu GS.
    • Front Oncol. 2022 Jun 29;12:908603. doi: 10.3389/fonc.2022.908603.
    • An Integrated Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide Study): Rationale, Study Design and Pilot Study.
    • Peremiquel-Trillas P, Paytubi S, Pelegrina B, Frias-Gomez J, Carmona Á, Martínez JM, de Francisco J, Benavente Y, Barahona M, Briansó F, Canet-Hermida J, Caño V, Vidal A, Zanca A, Baixeras N, Rodríguez A, Fernández-Gonzalez S, Dueñas N, Càrdenas L, Aytés Á, Bianchi I, Pavón MÀ, Reventós J, Capellà G, Gómez D, Diaz M, Ponce J, Brunet J, Matias-Guiu X, Bosch FX, de Sanjosé S, Alemany L, Pineda M, Marin F, Costas L.
    • J Pers Med. 2022 Jun 29;12(7):1074. doi: 10.3390/jpm12071074.
    • EARS2 significantly coexpresses with PALB2 in breast and pancreatic cancer.
    • Lehrer S, Rheinstein PH.
    • Cancer Treat Res Commun. 2022 [2022 Jun 28];32:100595. doi: 10.1016/j.ctarc.2022.100595. Epub 2022 Jun 28.
    • The impact of rare germline variants on human somatic mutation processes.
    • Vali-Pour M, Lehner B, Supek F.
    • Nat Commun. 2022 Jun 28;13(1):3724. doi: 10.1038/s41467-022-31483-1.

    Research news: Cancer Risk May Be Influenced by Rare Germline Variants. (Inside Precision Medicine)

    • Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes.
    • Ardeshna DR, Rangwani S, Cao T, Pawlik TM, Stanich PP, Krishna SG.
    • Biomedicines. 2022 Jun 22;10(7):1475. doi: 10.3390/biomedicines10071475.
    • A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
    • Iwasawa T, Kosaka T, Morita S, Mikami S, Nakamura K, Hongo H, Nishihara H, Oya M.
    • BMC Med Genomics. 2022 Jun 20;15(1):138. doi: 10.1186/s12920-022-01286-w.
    • The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.
    • Lin K, Baritaki S, Vivarelli S, Falzone L, Scalisi A, Libra M, Bonavida B.
    • Antioxidants (Basel). 2022 Jun 17;11(6):1195. doi: 10.3390/antiox11061195.
    • Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    • Darbeheshti F, Kadkhoda S, Keshavarz-Fathi M, Razi S, Bahramy A, Mansoori Y, Rezaei N.
    • BMC Cancer. 2022 Jun 17;22(1):668. doi: 10.1186/s12885-022-09761-4.
    • The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes.
    • Štancl P, Hamel N, Sigel KM, Foulkes WD, Karlic R, Polak P.
    • Front Genet. 2022 Jun 17;13:852159. doi: 10.3389/fgene.2022.852159.
    • The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer.
    • Kensler KH, Baichoo S, Pathania S, Rebbeck TR.
    • NPJ Precis Oncol. 2022 Jun 17;6(1):39. doi: 10.1038/s41698-022-00284-6.
    • Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
    • Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, Papaikonomou K, Jones L, Herzog C, Pashayan N, Simões BM, Clarke RB, Evans DG, Ghezelayagh TS, Ponandai-Srinivasan S, Boggavarapu NR, Lalitkumar PG, Howell SJ, Risques RA, Rådestad AF, Dubeau L, Gemzell-Danielsson K, Widschwendter M.
    • Genome Med. 2022 Jun 15;14(1):64. doi: 10.1186/s13073-022-01063-5.

    EudraCT number: 2009-009014-40: Pre-treatment with Mifepristone prior to Mirena insertion for optimizing bleeding pattern in pre-menopausal women. (EU Clinical Trials Register)

    Identifier: NCT01898312: BRCA1/2 and Effect of Mifepristone on the Breast. (ClinicalTrials.gov)

    EudraCT number: 2015-001587-19: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk. (EU Clinical Trials Register)

    • Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
    • Dehdashti F, Reimers MA, Shoghi KI, Chen DL, Luo J, Rogers B, Pachynski RK, Sreekumar S, Weimholt C, Zhou D.
    • Mol Imaging Biol. 2022 Jun 14. doi: 10.1007/s11307-022-01746-w. Epub ahead of print.
    • Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery.
    • Yi H, Li L, Huang J, Ma Z, Li H, Chen J, Zheng X, Chen J, He H, Song J.
    • Front Mol Biosci. 2022 Jun 13;9:906922. doi: 10.3389/fmolb.2022.906922.
    • Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).
    • Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL, Kirchner M, Goldschmid H, Pfarr N, Weichert W, Hübschmann D, Fröhling S, Sutter C, Schaaf CP, Schirmacher P, Endris V, Stenzinger A, Budczies J.
    • NPJ Precis Oncol. 2022 Jun 9;6(1):36. doi: 10.1038/s41698-022-00276-6.
    • Characterization of rare histological subtypes of ovarian cancer based on molecular profiling.
    • Takahashi N, Hatakeyama K, Nagashima T, Ohshima K, Urakami K, Yamaguchi K, Hirashima Y.
    • Cancer Med. 2022 Jun 8. doi: 10.1002/cam4.4927. Epub ahead of print.
    • Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation.
    • Kim JW, Kang HE, Choi J, Yun SG, Jung SP, Bae SY, You JY, Choi YJ, Kim YH, Park KH.
    • Cancer Res Treat. 2022 Jun 8. doi: 10.4143/crt.2021.1567. Epub ahead of print.
    • Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
    • Saito A, Tanioka M, Hirata M, Watanabe T, Odaka Y, Shimoi T, Sudo K, Noguchi E, Ishikawa M, Yonemori K.
    • Cancer Treat Res Commun. 2022 [Epub 2022 Jun 8];32:100587. doi: 10.1016/j.ctarc.2022.100587. Epub 2022 Jun 8.
    • A human breast atlas integrating single-cell proteomics and transcriptomics.
    • Gray GK, Li CM, Rosenbluth JM, Selfors LM, Girnius N, Lin JR, Schackmann RCJ, Goh WL, Moore K, Shapiro HK, Mei S, D'Andrea K, Nathanson KL, Sorger PK, Santagata S, Regev A, Garber JE, Dillon DA, Brugge JS.
    • Dev Cell. 2022 Jun 6;57(11):1400-1420.e7. doi: 10.1016/j.devcel.2022.05.003. Epub 2022 May 25.
    • Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study.
    • Colosini A, Bernardi S, Foroni C, Pasinetti N, Guerini AE, Russo D, Bresciani R, Tomasi C, Magrini SM, Bardoscia L, Triggiani L.
    • Biomedicines. 2022 Jun 4;10(6):1321. doi: 10.3390/biomedicines10061321.
    • Associations of Plasma Bioactive Adrenomedullin Levels with Cardiovascular Risk Factors in BRCA1/2 Mutation Carriers.
    • Lammert J, Basrai M, Struck J, Hartmann O, Engel C, Bischoff SC, Berling-Ernst A, Halle M, Kiechle M, Grill S.
    • Geburtshilfe Frauenheilkd. 2022 Jun 3;82(6):601-609. doi: 10.1055/a-1811-2164.

    Identifier: NCT02087592: Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers (LIBRE). (ClinicalTrials.gov)

    Identifier: NCT02516540: Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers (LIBRE-2). (ClinicalTrials.gov)

    • Are Mutation Carrier Patients Different from Non-Carrier Patients? Genetic, Pathology, and US Features of Patients with Breast Cancer.
    • Pintican RM, Chiorean A, Duma M, Feier D, Szep M, Eniu D, Goidescu I, Dudea S.
    • Cancers (Basel). 2022 Jun 2;14(11):2759. doi: 10.3390/cancers14112759.
    • Genetic Aspects of Mammographic Density Measures Associated with Breast Cancer Risk.
    • Li S, Nguyen TL, Nguyen-Dumont T, Dowty JG, Dite GS, Ye Z, Trinh HN, Evans CF, Tan M, Sung J, Jenkins MA, Giles GG, Hopper JL, Southey MC.
    • Cancers (Basel). 2022 Jun 2;14(11):2767. doi: 10.3390/cancers14112767.
    • BARD1 mystery: tumor suppressors are cancer susceptibility genes.
    • Hawsawi YM, Shams A, Theyab A, Abdali WA, Hussien NA, Alatwi HE, Alzahrani OR, Oyouni AAA, Babalghith AO, Alreshidi M.
    • BMC Cancer. 2022 Jun 1;22(1):599. doi: 10.1186/s12885-022-09567-4.
    • Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer.
    • Waks AG, Kim D, Jain E, Snow C, Kirkner GJ, Rosenberg SM, Oh C, Poorvu PD, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Warner E, Collins LC, Partridge AH, Wagle N.
    • Clin Cancer Res. 2022 Jun 1;28(11):2339-2348. doi: 10.1158/1078-0432.CCR-21-2572.

    Commentary:

    One Size Does Not Fit All: Breast Cancer in Young Women.

    • Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants.
    • Terrero G, Datta J, Dennison J, Sussman DA, Lohse I, Merchant NB, Hosein PJ.
    • JAMA Oncol. 2022 Jun 1;8(6):1-3. doi: 10.1001/jamaoncol.2022.0611.
    • Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers.
    • Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Phan NN, Hsu CY, Chiu JH, Tseng LM.
    • Ann Surg Oncol. 2022 Jun;29(6):3578-3590. doi: 10.1245/s10434-022-11347-0. Epub 2022 Feb 28.
    • PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.
    • Jones N, Gros A, Velasco V, Dapremont V, Brouste V, Gastaldello B, Debled M, Tunon de Lara C, Bonnet F, Barouk-Simonet E, Bubien V, Venat L, MacGrogan G, Longy M, Sevenet N.
    • Cancer Genet. 2022 Jun;264-265:8-15. doi: 10.1016/j.cancergen.2022.02.008. Epub 2022 Feb 25.
    • Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation.
    • Federico AD, Gelsomino F, De Biase D, Ardizzoni A.
    • Clin Lung Cancer. 2022 Jun;23(4):e283-e284. doi: 10.1016/j.cllc.2021.09.011. Epub 2021 Oct 10.
    • Letter, Case report

    Case report:

    The Common Thread: A Case of Synchronous Lung Cancers and a Germline CHEK2 Mutation.

    • Immunohistochemical Evaluation of BAP1 Expression in Breast Cancer with Known BRCA1 and BRCA2 Mutations and Comparison with Histopathological Features.
    • Çalim-Gürbüz B, Güvendir I, Ünal B, Erdogan-Durmus S, Topal CS, Agaoglu NB, Doganay HL, Kizilboga T, Zemheri IE.
    • Int J Surg Pathol. 2022 Jun;30(4):397-404. doi: 10.1177/10668969221085969. Epub 2022 Mar 9.
    • PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
    • Sokol ES, Jin DX, Fine A, Trabucco SE, Maund S, Frampton G, Molinero L, Antonarakis ES.
    • JCO Precis Oncol. 2022 Jun;6:e2100531. doi: 10.1200/PO.21.00531.

    Research news: Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients. (Precision Oncology News)

    • Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options.
    • Ozer M, Ranganathan M, Lecomte N, Schvartzman JM, Walch HS, Chatila WK, Hong J, Carlo MI, Walsh MF, Sheehan M, Mandelker D, Ceyhan-Birsoy O, Maio A, Kemel Y, Iacobuzio-Donahue CA, O'Reilly EM, Yu KH.
    • JCO Precis Oncol. 2022 Jun;6:e2100560. doi: 10.1200/PO.21.00560.
    • Case report
    • Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?
    • Keane F, Park W, O'Reilly EM.
    • JCO Precis Oncol. 2022 Jun;6:e2200141. doi: 10.1200/PO.22.00141.

    Letter, Reply:

    Reply to F. Keane et al.

    Original research:

    Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.

    • Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    • Meijer TG, Nguyen L, Van Hoeck A, Sieuwerts AM, Verkaik NS, Ladan MM, Ruigrok-Ritstier K, van Deurzen CHM, van de Werken HJG, Lips EH, Linn SC, Memari Y, Davies H, Nik-Zainal S, Kanaar R, Martens JWM, Cuppen E, Jager A, van Gent DC.
    • Oncogene. 2022 Jun;41(26):3498-3506. doi: 10.1038/s41388-022-02363-1. Epub 2022 Jun 3.
    • CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset.
    • Avesani G, Tran HE, Cammarata G, Botta F, Raimondi S, Russo L, Persiani S, Bonatti M, Tagliaferri T, Dolciami M, Celli V, Boldrini L, Lenkowicz J, Pricolo P, Tomao F, Rizzo SMR, Colombo N, Manganaro L, Fagotti A, Scambia G, Gui B, Manfredi R.
    • Cancers (Basel). 2022 May 31;14(11):2739. doi: 10.3390/cancers14112739.
    • The Pathogenic R3052W BRCA2 Variant Disrupts Homology-Directed Repair by Failing to Localize to the Nucleus.
    • Jimenez-Sainz J, Krysztofiak A, Garbarino J, Rogers F, Jensen RB.
    • Front Genet. 2022 May 30;13:884210. doi: 10.3389/fgene.2022.884210.
    • Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.
    • Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, Leone G, Xiang JZ, Wingate A, Tagawa S, Jayaram A, Linch M; PEACE Consortium, Jamal-Hanjani M, Swanton C, Rubin MA, Wyatt AW, Beltran H, Attard G, Demichelis F.
    • NAR Cancer. 2022 May 27;4(2):zcac016. doi: 10.1093/narcan/zcac016.
    • Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    • Chen T, Yu T, Zhuang S, Geng Y, Xue J, Wang J, Ai L, Chen B, Zhao Z, Li Y, Wang J, Liang H, Xu Y, Gu Y.
    • Br J Cancer. 2022 May 26. doi: 10.1038/s41416-022-01836-0. Epub ahead of print.
    • Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance.
    • Kyo S, Kanno K, Takakura M, Yamashita H, Ishikawa M, Ishibashi T, Sato S, Nakayama K.
    • Cancers (Basel). 2022 May 19;14(10):2504. doi: 10.3390/cancers14102504.
    • Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    • Wen H, Feng Z, Ma Y, Liu R, Ou Q, Guo Q, Shen Y, Wu X, Shao Y, Bao H, Wu X.
    • BMC Cancer. 2022 May 16;22(1):550. doi: 10.1186/s12885-022-09602-4.
    • Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer.
    • Lee JD, Ryu WJ, Han HJ, Kim TY, Kim MH, Sohn J.
    • Cancers (Basel). 2022 May 13;14(10):2405. doi: 10.3390/cancers14102405.
    • Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.
    • Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT.
    • NPJ Breast Cancer. 2022 May 10;8(1):64. doi: 10.1038/s41523-022-00427-9.
    • Low CRIM1 Levels Predict Poor Prognosis in Breast Cancer Patients.
    • Wen W, Jiang B, Cao X, Xie L, Zhang X, Li Y, He R.
    • Front Oncol. 2022 May 6;12:882328. doi: 10.3389/fonc.2022.882328.
    • Protocol for the Detection of Organoid-Initiating Cell Activity in Patient-Derived Single Fallopian Tube Epithelial Cells.
    • Feng L, Yang W, Zhao H, Bakkum-Gamez J, Sherman ME, Kannan N.
    • Methods Mol Biol. 2022 [First Online: 2022 May 5];2429:445-454. doi: 10.1007/978-1-0716-1979-7_30.
    • BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score.
    • Ergasti R, Marchetti C, Tudisco R, Iervolino A, Naldini A, Oliva R, Inzani F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 May 3;32(5):639-645. doi: 10.1136/ijgc-2021-003116.
    • Alterations in homologous recombination repair genes in prostate cancer brain metastases.
    • Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins SA, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing EJ, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya AO, Bubendorf L, Moch H, Thalmann G, Ng CKY, Gillessen S, Piscuoglio S, Rubin MA.
    • Nat Commun. 2022 May 3;13(1):2400. doi: 10.1038/s41467-022-30003-5.
    • Molecular phenotypes and clinical characterization of familial hereditary breast cancer among half and full sisters.
    • Xu Y, He J, Qian C, Yang C.
    • BMC Womens Health. 2022 May 2;22(1):145. doi: 10.1186/s12905-022-01732-y.
    • BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.
    • Abdallah R, Zhao S, Garinet S, Hormigos K, Le Corre D, Cros J, Perez Toralla K, Bats AS, Augustin J, Bachet JB, Taly V, Blons H, Taieb J, Laurent-Puig P.
    • Clin Res Hepatol Gastroenterol. 2022 May;46(5):101880. doi: 10.1016/j.clinre.2022.101880. Epub 2022 Feb 11.
    • A Review of MutSa and its Absence in Mismatch Repair Related Ovarian Carcinomas.
    • Hayes A, Jaman A, Johnson E, Rausch M.
    • FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.R4038.
    • Conference abstract. Review
    • Pregnancy Hormone Mediated Tumorigenesis in BRCA1 Defective Breast Cancers.
    • Krishnan N, Yadev I, Anandan J, Patra D, Rajan A, Srinivas P.
    • FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.0R373.
    • Conference abstract
    • Genetic variation of PD-1 L1 gene affects its expression and is related to clinical outcome in epithelial ovarian cancer.
    • Sun H, Li Y, Si W, Hua T, Chen J, Kang S.
    • Front Oncol. 2022 Apr 26;12:763134. doi: 10.3389/fonc.2022.763134.
    • Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    • Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M.
    • BMC Med. 2022 Apr 25;20(1):136. doi: 10.1186/s12916-022-02332-1.
    • Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    • Golesworthy B, Wang Y, Tanti A, Pacis A, Romero JM, Cuggia A, Domecq C, Bourdel G, Denroche RE, Jang GH, Grant RC, Borgida A, Grünwald BT, Dodd A, Wilson JM, Bourque G, O'Kane GM, Fischer SE, Kron CM, Fiset PO, Omeroglu A, Foulkes WD, Gallinger S, Guiot MC, Gao ZH, Zogopoulos G.
    • Front Oncol. 2022 Apr 25;12:860767. doi: 10.3389/fonc.2022.860767.
    • Pathogenic BRCA1 variants disrupt PLK1-regulation of mitotic spindle orientation.
    • He Z, Ghorayeb R, Tan S, Chen K, Lorentzian AC, Bottyan J, Aalam SMM, Pujana MA, Lange PF, Kannan N, Eaves CJ, Maxwell CA.
    • Nat Commun. 2022 Apr 22;13(1):2200. doi: 10.1038/s41467-022-29885-2.
    • Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients.
    • Hu L, Sun J, Li Z, Qu Z, Liu Y, Wan Q, Liu J, Ding X, Zang F, Zhang J, Yao L, Xu Y, Wang Y, Xie Y.
    • NPJ Breast Cancer. 2022 Apr 21;8(1):52. doi: 10.1038/s41523-022-00417-x.
    • Improving ovarian cancer treatment decision using a novel risk predictive tool.
    • Xu Z, Song J, Cao L, Rong Z, Zhang W, He J, Li K, Hou Y.
    • Aging (Albany NY). 2022 Apr 19;14(8):3464-3483. doi: 10.18632/aging.204023. Epub 2022 Apr 19.
    • Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    • Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, Villacampa G, Guzmán M, Rodríguez O, Grueso J, Jiménez J, Arenas EJ, Degasperi A, Dias JML, Forment JV, O'Connor MJ, Déas O, Cairo S, Zhou Y, Musolino A, Caldas C, Nik-Zainal S, Clarke RB, Nuciforo P, Díez O, Serres-Créixams X, Peg V, Espinosa-Bravo M, Macarulla T, Oaknin A, Mateo J, Arribas J, Dienstmann R, Bellet M, Oliveira M, Saura C, Gutiérrez-Enríquez S, Balmaña J, Serra V.
    • Cancer Res. 2022 Apr 15;82(8):1646-1657. doi: 10.1158/0008-5472.CAN-21-2409.
    • Male Breast Cancer: From Molecular Genetics to Clinical Management.
    • Pensabene M, Von Arx C, De Laurentiis M.
    • Cancers (Basel). 2022 Apr 15;14(8):2006. doi: 10.3390/cancers14082006.
    • Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants.
    • Alenezi WM, Fierheller CT, Revil T, Serruya C, Mes-Masson AM, Foulkes WD, Provencher D, El Haffaf Z, Ragoussis J, Tonin PN.
    • Genes (Basel). 2022 Apr 15;13(4):697. doi: 10.3390/genes13040697.
    • Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
    • Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Özgüroglu M, Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono J.
    • Clin Cancer Res. 2022 Apr 14;28(8):1518-1530. doi: 10.1158/1078-0432.CCR-21-3940.
    • A South African Indian population group dataset for breast cancer and BRCA1/2 variants.
    • Combrink HMVE, van der Merwe NC, Katarya R, de Wet K, Motloung MH.
    • Data Brief. 2022 Apr 14;42:108180. doi: 10.1016/j.dib.2022.108180.

    Original research:

    Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study.

    • Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation.
    • Park SS, Uzelac A, Kotsopoulos J.
    • Hered Cancer Clin Pract. 2022 Apr 13;20(1):14. doi: 10.1186/s13053-022-00223-3.
    • The Impact of BRCA Status on Therapy Choices.
    • Schapira L, Tung N.
    • Medscape. 2022 Apr 12.
    • Phylogenetic Analysis IDs Subset of De Novo Tumors Unrelated to Primary DCIS.
    • Ray T.
    • GenomeWeb. Disease Areas. Cancer. 2022 Apr 11.
    • Some Recurrent DCIS Breast Tumors are Actually New Lesions.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Apr 11.
    • Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.
    • Weber-Lassalle K, Ernst C, Reuss A, Möllenhoff K, Baumann K, Jackisch C, Hauke J, Dietrich D, Borde J, Park-Simon TW, Hanker L, Prieske K, Schmidt S, Weber-Lassalle N, Pohl-Rescigno E, Kommoss S, Marmé F, Heitz F, Stingl JC, Schmutzler RK, Harter P, Hahnen E.
    • J Natl Cancer Inst. 2022 Apr 11;114(4):565-570. doi: 10.1093/jnci/djab231.

    Commentary:

    Untangling the Relationship Between Clonal Hematopoiesis and Ovarian Cancer Therapies.

    • Fallopian Tube Originating Ovarian Cancer in a 53-Year-Old Postmenopausal Female With Hereditary Breast Cancer (BRCA) Genes: A Case Study.
    • Garrick I, Ahasan H, Jiang M, Musheyev Y, Ftiha F, Levada M.
    • Cureus. 2022 Apr 7;14(4):e23929. doi: 10.7759/cureus.23929.
    • Modification of BRCA1-associated breast cancer risk by HMMR overexpression.
    • Mateo F, He Z, Mei L, de Garibay GR, Herranz C, García N, Lorentzian A, Baiges A, Blommaert E, Gómez A, Mirallas O, Garrido-Utrilla A, Palomero L, Espín R, Extremera AI, Soler-Monsó MT, Petit A, Li R, Brunet J, Chen K, Tan S, Eaves CJ, McCloskey C, Hakem R, Khokha R, Lange PF, Lázaro C, Maxwell CA, Pujana MA.
    • Nat Commun. 2022 Apr 7;13(1):1895. doi: 10.1038/s41467-022-29335-z.
    • Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.
    • Garber HR, Raghavendra AS, Lehner M, Qiao W, Gutierrez-Barrera AM, Tripathy D, Arun B, Ibrahim NK.
    • NPJ Breast Cancer. 2022 Apr 7;8(1):46. doi: 10.1038/s41523-022-00407-z.
    • Identification and Somatic Characterization of the Germline PTEN Promoter Variant rs34149102 in a Family with Gastrointestinal and Breast Tumors.
    • Disciglio V, Sanese P, Fasano C, Lotesoriere C, Valentini AM, Forte G, Lepore Signorile M, De Marco K, Grossi V, Lolli I, Cariola F, Simone C.
    • Genes (Basel). 2022 Apr 5;13(4):644. doi: 10.3390/genes13040644.
    • Cancer Causative Mutations Occurring in Early Embryogenesis.
    • Pareja F, Ptashkin RN, Brown DN, Derakhshan F, Selenica P, da Silva EM, Gazzo AM, Da Cruz Paula A, Breen K, Shen R, Marra A, Zehir A, Benayed R, Berger MF, Ceyhan-Birsoy O, Jairam S, Sheehan M, Patel U, Kemel Y, Casanova-Murphy J, Schwartz CJ, Vahdatinia M, Comen E, Borsu L, Pei X, Riaz N, Abramson DH, Weigelt B, Walsh MF, Hadjantonakis AK, Ladanyi M, Offit K, Stadler ZK, Robson ME, Reis-Filho JS, Mandelker D.
    • Cancer Discov. 2022 Apr 1;12(4):949-957. doi: 10.1158/2159-8290.CD-21-1110.

    Commentary:

    Patchwork Cancer Predisposition.

    • Association of Genetic Ancestry and Molecular Signatures with Cancer Survival Disparities: A Pan-Cancer Analysis.
    • Lee KK, Rishishwar L, Ban D, Nagar SD, Mariño-Ramírez L, McDonald JF, Jordan IK.
    • Cancer Res. 2022 Apr 1;82(7):1222-1233. doi: 10.1158/0008-5472.CAN-21-2105.
    • Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
    • Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA.
    • Clin Cancer Res. 2022 Apr 1;28(7):1383-1390. doi: 10.1158/1078-0432.CCR-21-2080.
    • Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss of Heterozygosity Score.
    • Westphalen CB, Fine AD, André F, Ganesan S, Heinemann V, Rouleau E, Turnbull C, Garcia Palacios L, Lopez JA, Sokol ES, Mateo J.
    • Clin Cancer Res. 2022 Apr 1;28(7):1412-1421. doi: 10.1158/1078-0432.CCR-21-2096.
    • Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    • Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_351186.
    • Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    • Lee S, Park K, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Ahn HK, Park WY, Im SA, Park YH.
    • Breast. 2022 Apr;62:52-60. doi: 10.1016/j.breast.2022.01.014. Epub 2022 Jan 29.
    • Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.
    • Moore GM, Powell SN, Higginson DS, Khan AJ.
    • Breast Cancer Res Treat. 2022 Apr;192(3):649-653. doi: 10.1007/s10549-022-06529-z. Epub 2022 Jan 29.
    • Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.
    • Iyevleva AG, Aleksakhina SN, Sokolenko AP, Baskina SV, Venina AR, Anisimova EI, Bizin IV, Ivantsov AO, Belysheva YV, Chernyakova AP, Togo AV, Imyanitov EN.
    • Breast Cancer Res Treat. 2022 Apr;192(2):283-291. doi: 10.1007/s10549-022-06517-3. Epub 2022 Jan 12.
    • Immunotherapy for ovarian cancer.
    • Porter R, Matulonis UA.
    • Clin Adv Hematol Oncol. 2022 Apr;20(4):240-253.
    • Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
    • Lee S, Kim HY, Jung YJ, Jung CS, Im D, Kim JY, Lee SM, Oh SH.
    • Curr Probl Cancer. 2022 Apr;46(2):100843. doi: 10.1016/j.currproblcancer.2022.100843. Epub 2022 Feb 9.
    • The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
    • Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, Cormio G, Maiello E.
    • Int J Mol Sci. 2022 Mar 31;23(7):3871. doi: 10.3390/ijms23073871.
    • Habitat Analysis of Breast Cancer-Enhanced MRI Reflects BRCA1 Mutation Determined by Immunohistochemistry.
    • Du T, Zhao H.
    • Biomed Res Int. 2022 Mar 30;2022:9623173. doi: 10.1155/2022/9623173.
    • PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients' CTCs.
    • Sklias T, Vardas V, Pantazaka E, Christopoulou A, Georgoulias V, Kotsakis A, Vasilopoulos Y, Kallergi G.
    • Cancers (Basel). 2022 Mar 29;14(7):1731. doi: 10.3390/cancers14071731.
    • BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma.
    • Jin TY, Park KS, Nam SE, Yoo YB, Park WS, Yun IJ.
    • Int J Mol Sci. 2022 Mar 29;23(7):3754. doi: 10.3390/ijms23073754.
    • Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma.
    • Wu J, Raz Y, Recouvreux MS, Diniz MA, Lester J, Karlan BY, Walts AE, Gertych A, Orsulic S.
    • Front Oncol. 2022 Mar 21;12:853755. doi: 10.3389/fonc.2022.853755.
    • Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.
    • Li Y, Nie Y, Guo H, Guo H, Ha C, Li Y.
    • Front Oncol. 2022 Mar 18;12:847085. doi: 10.3389/fonc.2022.847085.
    • Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study.
    • Macrini S, Francesconi S, Caprera C, Lancia D, Corsi M, Gunnellini M, Rocchi A, Pireddu A, Marziani F, Mosillo C, Calandrella ML, Caserta C, Giannarelli D, Guida A, Ascani S, Bracarda S.
    • Cancers (Basel). 2022 Mar 17;14(6):1542. doi: 10.3390/cancers14061542.
    • Influence of cellular models and individual factor in the biological response to chest CT scan exams.
    • Devic C, Bodgi L, Sonzogni L, Pilleul F, Ribot H, Charry C, Le Moigne F, Paul D, Carbillet F, Munier M, Foray N.
    • Eur Radiol Exp. 2022 Mar 17;6(1):14. doi: 10.1186/s41747-022-00266-0.
    • Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by TP53 p.R337H Carriers.
    • Sandoval RL, Polidorio N, Leite ACR, Cartaxo M, Pisani JP, Quirino CV, Cezana L, Pereira NG, Pereira AAL, Rossi BM, Achatz MI.
    • Front Oncol. 2022 Mar 16;12:836937. doi: 10.3389/fonc.2022.836937.
    • BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling.
    • Bradbury M, Borràs E, Castellví J, Méndez O, Sánchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A, Sabidó E, Santamaria A.
    • Sci Rep. 2022 Mar 15;12(1):4445. doi: 10.1038/s41598-022-08461-0.
    • Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.
    • Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S.
    • NPJ Breast Cancer. 2022 Mar 4;8(1):28. doi: 10.1038/s41523-022-00395-0.
    • Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.
    • Breast Cancer Association Consortium, Mavaddat N, Dorling L, Carvalho S, Allen J, González-Neira A, Keeman R, Bolla MK, Dennis J, Wang Q, Ahearn TU, Andrulis IL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Briceno I, Brüning T, Camp NJ, Campbell A, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Christiansen H, Czene K, Dörk T, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, Geisler J, Giles GG, Guénel P, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Hartikainen JM, Hartman M, Hoppe R, Howell A, Jakubowska A, Jung A, Khusnutdinova EK, Kristensen VN, Li J, Lim SH, Lindblom A, Loizidou MA, Lophatananon A, Lubinski J, Madsen MJ, Mannermaa A, Manoochehri M, Margolin S, Mavroudis D, Milne RL, Mohd Taib NA, Morra A, Muir K, Obi N, Osorio A, Park-Simon TW, Peterlongo P, Radice P, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sim X, Southey MC, Thorne H, Tomlinson I, Torres D, Truong T, Yip CH, Spurdle AB, Vreeswijk MPG, Dunning AM, García-Closas M, Pharoah PDP, Kvist A, Muranen TA, Nevanlinna H, Teo SH, Devilee P, Schmidt MK, Easton DF.
    • JAMA Oncol. 2022 Mar 1;8(3):e216744. doi: 10.1001/jamaoncol.2021.6744. Epub 2022 Mar 17.

    Press: Breast Tumor Features Reflecting Germline Variants May Improve Risk Prediction Models. (Precision Oncology News)

    Research news: Variants of Nine Breast Cancer Genes Associated With Severe Disease. (Medscape)

    • Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers.
    • Sun S, Brazhnik K, Lee M, Maslov AY, Zhang Y, Huang Z, Klugman S, Park BH, Vijg J, Montagna C.
    • J Clin Invest. 2022 Mar 1;132(5):e148113. doi: 10.1172/JCI148113.
    • Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
    • Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, Yamamoto Y.
    • Breast Cancer. 2022 Mar;29(2):368-376. doi: 10.1007/s12282-021-01319-9. Epub 2022 Jan 5.
    • Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.
    • Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK.
    • Cancer Med. 2022 Mar;11(6):1474-1483. doi: 10.1002/cam4.4566. Epub 2022 Feb 6.
    • Next-generation sequencing of endoscopically obtained tissues from patients with all stages of pancreatic cancer.
    • Takano S, Fukasawa M, Shindo H, Takahashi E, Fukasawa Y, Kawakami S, Hayakawa H, Kuratomi N, Kadokura M, Yamaguchi T, Inoue T, Maekawa S, Enomoto N.
    • Cancer Sci. 2022 Mar;113(3):1069-1077. doi: 10.1111/cas.15249. Epub 2022 Jan 10.
    • Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    • Lin DI, Fine A, Danziger NA, Huang RSP, Mata DA, Decker B, Killian JK, Ramkissoon SH, Lechpammer M, Janovitz T, Ross JS, Sokol ES, Elvin JA.
    • Gynecol Oncol. 2022 Mar;164(3):558-565. doi: 10.1016/j.ygyno.2021.12.030. Epub 2022 Jan 5.
    • Computerized morphometry analysis of epithelial fimbriae nuclear symmetry in BRCA carriers may identify patients at risk for developing ovarian cancer.
    • Amit A, Sabo E, Petruseva A, Stroller L, Reiss A, Klorin G.
    • Microsc Res Tech. 2022 Mar;85(3):892-899. doi: 10.1002/jemt.23958. Epub 2021 Oct 9.
    • DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    • Zhu S, Zhang Z, Zhang H, Liu Z, Liu M, Liu Q, Zang L, Wang L, Ji J, Wu B, Sun L, Zhang Z, Cao H, Wang Y, Wang H, Shang Z, Niu Y.
    • Prostate. 2022 Mar;82(4):464-474. doi: 10.1002/pros.24292. Epub 2022 Jan 17.
    • A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.
    • Jagannathan G, White MJ, Xian RR, Emens LA, Cimino-Mathews A.
    • Surg Pathol Clin. 2022 Mar;15(1):105-120. doi: 10.1016/j.path.2021.11.007. Epub 2022 Jan 31.
    • Review
    • Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
    • Fumet JD, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, Truntzer C, Tredan O, Liebrich C, Lortholary A, Pissaloux D, Leary A, Pfisterer J, Eeckhoutte A, Hilpert F, Fabbro M, Caux C, Alexandre J, Houlier A, Sehouli J, Sohier E, Kimmig R, Dubois B, Spaeth D, Treilleux I, Frenel JS, Herwig U, Le Saux O, Bendriss-Vermare N, du Bois A.
    • Cancers (Basel). 2022 Feb 25;14(5):1189. doi: 10.3390/cancers14051189.
    • Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report.
    • Qian B, Leng W, Yan Z, Lu J, Chen S, Yi H, Jiang Z.
    • Front Oncol. 2022 Feb 25;12:778545. doi: 10.3389/fonc.2022.778545.
    • Variants of Nine Breast Cancer Genes Associated With Severe Disease.
    • Worcester S.
    • Medscape. 2022 Feb 25.

    Original research:

    Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.

    • PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.
    • Jones N, Gros A, Velasco V, Dapremont V, Brouste V, Gastaldello B, Debled M, de Lara CT, Bonnet F, Barouk-Simonet E, Bubien V, Venat L, MacGrogan G, Longy M, Sevenet N.
    • Cancer Genet. 2022 Feb 24. doi: 10.1016/j.cancergen.2022.02.008. Epub ahead of print.
    • Derivation, Comprehensive Analysis, and Assay Validation of a Pyroptosis-Related lncRNA Prognostic Signature in Patients With Ovarian Cancer.
    • Cao X, Zhang Q, Zhu Y, Huo X, Bao J, Su M.
    • Front Oncol. 2022 Feb 24;12:780950. doi: 10.3389/fonc.2022.780950.
    • Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants.
    • Freire MV, Martin M, Thissen R, Van Marcke C, Segers K, Sépulchre E, Leroi N, Lété C, Fasquelle C, Radermacher J, Gokburun Y, Collignon J, Sacré A, Josse C, Palmeira L, Bours V.
    • Front Oncol. 2022 Feb 24;12:835581. doi: 10.3389/fonc.2022.835581.
    • PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components.
    • O'Sullivan Coyne G, Karlovich C, Wilsker D, Voth AR, Parchment RE, Chen AP, Doroshow JH.
    • Onco Targets Ther. 2022 Feb 24;15:165-180. doi: 10.2147/OTT.S278092.
    • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.
    • Quesada S, Fabbro M, Solassol J.
    • Cancers (Basel). 2022 Feb 23;14(5):1132. doi: 10.3390/cancers14051132.
    • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.
    • Quesada S, Fabbro M, Solassol J.
    • Cancers (Basel). 2022 Feb 21;14(4):1098. doi: 10.3390/cancers14041098.
    • RNA Interference Induces BRCA1 Gene Methylation and Increases the Radiosensitivity of Breast Cancer Cells.
    • Shi Y, Huang R, Zhang Y, Feng Q, Pan X, Wang L.
    • Cancer Biother Radiopharm. 2022 Feb 18. doi: 10.1089/cbr.2021.0346. Epub ahead of print.
    • RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.
    • Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, Wang Z, Azuma H, Szallasi Z, Mouw KW, Zou L, Kibel AS, Jia L.
    • Sci Adv. 2022 Feb 18;8(7):eabl9794. doi: 10.1126/sciadv.abl9794. Epub 2022 Feb 18.
    • Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients.
    • Chen W, Xia W, Xue S, Huang H, Lin Q, Liu Y, Liu T, Zhang Y, Zhang P, Wang J, Yang Y, Dong B, Yu Z.
    • Front Oncol. 2022 Feb 17;12:746102. doi: 10.3389/fonc.2022.746102.
    • Co-Relation of Hormonal Profile and BRCA1 in Sporadic Breast Carcinoma: A Single Institutional Experience of 303 Patients.
    • Agarwal P, Khan F, Gupta S, Bhalla S, Thomas A, Anand A, Singh K, Sonkar AA.
    • Clin Pathol. 2022 Feb 14;15:2632010X221076379. doi: 10.1177/2632010X221076379.
    • Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
    • Poveda A, Lopez-Reig R, Oaknin A, Redondo A, Rubio MJ, Guerra E, Fariñas-Madrid L, Gallego A, Rodriguez-Freixinos V, Fernandez-Serra A, Juan O, Romero I, Lopez-Guerrero JA.
    • Cancers (Basel). 2022 Feb 12;14(4):915. doi: 10.3390/cancers14040915.
    • The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology.
    • Hirko KA, Rocque G, Reasor E, Taye A, Daly A, Cutress RI, Copson ER, Lee DW, Lee KH, Im SA, Park YH.
    • BMC Med. 2022 Feb 11;20(1):72. doi: 10.1186/s12916-022-02260-0.
    • Serous Tubal Intraepithelial Carcinoma in a Risk-reducing Salpingo-oophorectomy Specimen From a RAD51D Mutation Carrier: A Case Report.
    • Gregory-Davis KJ, Walker A, Colello LS, McKinnon W, Everett E, Chang MC.
    • Int J Gynecol Pathol. 2022 Feb 11. doi: 10.1097/PGP.0000000000000857. Epub ahead of print.
    • Case report
    • Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
    • Launonen IM, Lyytikäinen N, Casado J, Anttila EA, Szabó A, Haltia UM, Jacobson CA, Lin JR, Maliga Z, Howitt BE, Strickland KC, Santagata S, Elias K, D'Andrea AD, Konstantinopoulos PA, Sorger PK, Färkkilä A.
    • Nat Commun. 2022 Feb 11;13(1):835. doi: 10.1038/s41467-022-28389-3.
    • Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    • Wei G, Teng M, Rosa M, Wang X.
    • Breast Cancer Res. 2022 Feb 8;24(1):11. doi: 10.1186/s13058-022-01507-1.
    • Theranostic Interpolation of Genomic Instability in Breast Cancer.
    • Rasool R, Ullah I, Mubeen B, Alshehri S, Imam SS, Ghoneim MM, Alzarea SI, Al-Abbasi FA, Murtaza BN, Kazmi I, Nadeem MS.
    • Int J Mol Sci. 2022 Feb 7;23(3):1861. doi: 10.3390/ijms23031861.
    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.
    • Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics.
    • Yao Q, Liu Y, Zhang L, Dong L, Bao L, Bai Q, Cui Q, Xu J, Li M, Liu J, Chuai S, Ying J, Zhang Z, Zhou X.
    • Front Oncol. 2022 Feb 3;12:709645. doi: 10.3389/fonc.2022.709645.
    • Cell-type-specific epigenomic variations associated with BRCA1 mutation in pre-cancer human breast tissues.
    • Hsieh YP, Naler LB, Ma S, Lu C.
    • NAR Genom Bioinform. 2022 Feb 2;4(1):lqac006. doi: 10.1093/nargab/lqac006.
    • The DNA methylome of cervical cells can predict the presence of ovarian cancer.
    • Barrett JE, Jones A, Evans I, Reisel D, Herzog C, Chindera K, Kristiansen M, Leavy OC, Manchanda R, Bjørge L, Zikan M, Cibula D, Widschwendter M.
    • Nat Commun. 2022 Feb 1;13(1):448. doi: 10.1038/s41467-021-26615-y.

    Press: Methylation Signatures Within Cervical Cells Capture Ovarian, Breast Cancer Risk. (GenomeWeb)

    • The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples.
    • Barrett JE, Herzog C, Jones A, Leavy OC, Evans I, Knapp S, Reisel D, Nazarenko T, Kim YN, Franchi D, Ryan A, Franks J, Bjørge L, Zikan M, Cibula D, Harbeck N, Colombo N, Dudbridge F, Jones L, Sundström K, Dillner J, Rådestad AF, Gemzell-Danielsson K, Pashayan N, Widschwendter M.
    • Nat Commun. 2022 Feb 1;13(1):449. doi: 10.1038/s41467-021-27918-w.

    Press: Methylation Signatures Within Cervical Cells Capture Ovarian, Breast Cancer Risk. (GenomeWeb)

    • Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells.
    • Tadehara M, Kato T, Adachi K, Tamaki A, Kesen Y, Sakurai Y, Ichinoe M, Koizumi W, Murakumo Y.
    • Pancreas. 2022 Feb 1;51(2):183-189. doi: 10.1097/MPA.0000000000001975.
    • Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
    • Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW.
    • Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e2117754119. doi: 10.1073/pnas.2117754119.

    Commentary:

    Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.

    • Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
    • Guzmán-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, Warner E, Partridge AH, Collins LC.
    • Br J Cancer. 2022 Feb;126(2):302-309. doi: 10.1038/s41416-021-01597-2. Epub 2021 Oct 26.
    • PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.
    • Kraya AA, Maxwell KN, Eiva MA, Wubbenhorst B, Pluta J, Feldman M, Nayak A, Powell DJ Jr, Domchek SM, Vonderheide RH, Nathanson KL.
    • JCO Precis Oncol. 2022 Feb;6:e2100159. doi: 10.1200/PO.21.00159.
    • Identifying Transcripts with Tandem Duplications from RNA-Sequencing Data to Predict BRCA1-Type Primary Breast Cancer.
    • Qu S, Martens JWM, Hollestelle A, Smid M.
    • Cancers (Basel). 2022 Jan 31;14(3):753. doi: 10.3390/cancers14030753.
    • Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.
    • Pirš B, Škof E, Smrkolj V, Smrkolj Š.
    • Cancers (Basel). 2022 Jan 27;14(3):631. doi: 10.3390/cancers14030631.
    • Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.
    • Lundy J, McKay O, Croagh D, Ganju V.
    • JCO Precis Oncol. 2022 Jan [27];6:e2100437. doi: 10.1200/PO.21.00437.

    Letter, Commentary:

    Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?

    Letter, Reply:

    Reply to F. Keane et al.

    • Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy.
    • Lodewijk I, Bernardini A, Suárez-Cabrera C, Bernal E, Sánchez R, Garcia JL, Rojas K, Morales L, Wang S, Han X, Dueñas M, Paramio JM, Manso L.
    • NPJ Precis Oncol. 2022 Jan 27;6(1):7. doi: 10.1038/s41698-021-00247-3.
    • Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.
    • Cosgrove N, Varešlija D, Keelan S, Elangovan A, Atkinson JM, Cocchiglia S, Bane FT, Singh V, Furney S, Hu C, Carter JM, Hart SN, Yadav S, Goetz MP, Hill ADK, Oesterreich S, Lee AV, Couch FJ, Young LS.
    • Nat Commun. 2022 Jan 26;13(1):514. doi: 10.1038/s41467-022-27987-5.
    • What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.
    • Palicelli A, Croci S, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Zanelli M, Chaux A, Cañete-Portillo S, Bonasoni MP, Ascani S, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Gandhi J, Nicoli D, Farnetti E, Piana S, Tafuni A, Bonacini M.
    • Biomedicines. 2022 Jan 22;10(2):236. doi: 10.3390/biomedicines10020236.
    • The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis.
    • Andrikopoulou A, Chatzinikolaou S, Kyriopoulos I, Bletsa G, Kaparelou M, Liontos M, Dimopoulos MA, Zagouri F.
    • Front Oncol. 2022 Jan 21;11:797505. doi: 10.3389/fonc.2021.797505.
    • Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    • Kasuga A, Okamoto T, Udagawa S, Mori C, Mie T, Furukawa T, Yamada Y, Takeda T, Matsuyama M, Sasaki T, Ozaka M, Ueki A, Sasahira N.
    • Int J Mol Sci. 2022 Jan 21;23(3):1205. doi: 10.3390/ijms23031205.
    • Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes.
    • Custódio N, Savisaar R, Carvalho C, Bak-Gordon P, Ribeiro MI, Tavares J, Nunes PB, Peixoto A, Pinto C, Escudeiro C, Teixeira MR, Carmo-Fonseca M.
    • Biomedicines. 2022 Jan 18;10(2):199. doi: 10.3390/biomedicines10020199.
    • Clinical benefit with PARP inhibitor for pathogenic germline FANCA-mutated relapsed epithelial ovarian cancer: a case report.
    • Qian B, Lu J, Leng W, Yan Z, Chen S, Yi H, Jiang Z.
    • Front Oncol. 2022 Jan 18;10:778545. doi: 10.3389/fonc.2022.778545.
    • Long-term tumour dormancy in a BRCA1 heterozygote.
    • Amuzu S, Fu L, Demko N, Rivera B, Domecq C, de Kock L, Hamel N, Gilbert L, Polak P, Ragoussis J, Foulkes WD.
    • J Med Genet. 2022 Jan 17:jmedgenet-2021-108269. doi: 10.1136/jmedgenet-2021-108269. Epub ahead of print.
    • Case report
    • Value of the loss of heterozygosity to BRCA1 variant classification.
    • Santana Dos Santos E, Spurdle AB, Carraro DM, Briaux A, Southey M, Torrezan G, Petitalot A, Leman R, Lafitte P; kConFab Investigators, Meseure D, Driouch K, Side L, Brewer C, Beck S, Melville A, Callaway A, Revillion F, Folgueira MAAK, Parsons MT, Thorne H, Vincent-Salomon A, Stoppa-Lyonnet D, Bieche I, Caputo SM, Rouleau E.
    • NPJ Breast Cancer. 2022 Jan 17;8(1):9. doi: 10.1038/s41523-021-00361-2.
    • Integration of tumour sequencing and case-control data to assess pathogenicity of RAD51C missense variants in familial breast cancer.
    • Lim BWX, Li N, Rowley SM, Thompson ER, McInerny S, Zethoven M, Scott RJ, Devereux L, Sloan EK, James PA, Campbell IG.
    • NPJ Breast Cancer. 2022 Jan 17;8(1):10. doi: 10.1038/s41523-021-00373-y.
    • Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors.
    • Stopsack KH, Nandakumar S, Arora K, Nguyen B, Vasselman SE, Nweji B, McBride SM, Morris MJ, Rathkopf DE, Slovin SF, Danila DC, Autio KA, Scher HI, Mucci LA, Solit DB, Gönen M, Chen Y, Berger MF, Schultz N, Abida W, Kantoff PW.
    • Clin Cancer Res. 2022 Jan 15;28(2):318-326. doi: 10.1158/1078-0432.CCR-21-2577. Epub 2021 Oct 19.
    • Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
    • Schwartz CJ, da Silva EM, Marra A, Gazzo AM, Selenica P, Rai VK, Mandelker D, Pareja F, Misyura M, D'Alfonso TM, Brogi E, Drullinsky P, Razavi P, Robson ME, Drago JZ, Wen HY, Zhang L, Weigelt B, Shia J, Reis-Filho JS, Zhang H.
    • Clin Cancer Res. 2022 Jan 15;28(2):404-413. doi: 10.1158/1078-0432.CCR-21-2027. Epub 2021 Oct 19.
    • CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival.
    • Minguillón J, Ramírez MJ, Rovirosa L, Bustamante-Madrid P, Camps-Fajol C, Ruiz de Garibay G, Shimelis H, Montanuy H, Pujol R, Hernandez G, Bogliolo M, Castillo P, Soucy P, Martrat G, Gómez A, Cuadras D, García MJ, Gayarre J, Cimba, Lázaro C, Benítez J, Couch FJ, Pujana MA, Surrallés J.
    • Cancers (Basel). 2022 Jan 12;14(2):353. doi: 10.3390/cancers14020353.
    • Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.
    • Liu H, Zhang Z, Chen L, Pang J, Wu H, Liang Z.
    • Front Oncol. 2022 Jan 12;11:798173. doi: 10.3389/fonc.2021.798173.
    • Construction and Validation of a Prognostic Risk Model for Triple Negative Breast Cancer Based on Autophagy-Related Genes.
    • Jia R, Yan C, Liu Q.
    • Front Oncol. 2022 Jan 10;10:829045. doi: 10.3389/fonc.2022.829045.
    • Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    • Zong H, Zhang J, Xu Z, Pan JN, Wang R, Han J, Jiang M, Ren R, Zang L, Wang H, Cao WM.
    • J Cancer. 2022 Jan 9;13(4):1119-1129. doi: 10.7150/jca.65650.
    • Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report.
    • Zhuang J, Zhang S, Qiu X, Fu Y, Ai S, Zhao T, Yang Y, Guo H.
    • Front Oncol. 2022 Jan 5;11:777318. doi: 10.3389/fonc.2021.777318.
    • Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    • Lai Z, Brosnan M, Sokol ES, Xie M, Dry JR, Harrington EA, Barrett JC, Hodgson D.
    • BMC Cancer. 2022 Jan 3;22(1):13. doi: 10.1186/s12885-021-09082-y.
    • Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response.
    • Kang HG, Hwangbo H, Kim MJ, Kim S, Lee EJ, Park MJ, Kim JW, Kim BG, Cho EH, Chang S, Lee JY, Choi JK.
    • Cancer Res. 2022 Jan 1;82(1):142-154. doi: 10.1158/0008-5472.CAN-21-2023. Epub 2021 Oct 28.
    • Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    • Guffanti F, Alvisi MF, Anastasia A, Ricci F, Chiappa M, Llop-Guevara A, Serra V, Fruscio R, Degasperi A, Nik-Zainal S, Bani MR, Lupia M, Giavazzi R, Rulli E, Damia G.
    • Br J Cancer. 2022 Jan;126(1):120-128. doi: 10.1038/s41416-021-01609-1. Epub 2021 Nov 3.
    • Tubal histopathological abnormalities in BRCA1/2 mutation carriers undergoing prophylactic salpingo-oophorectomy: a case-control study.
    • Sina F, Cassani C, Comerio C, De Ponti E, Zanellini F, Delle Marchette M, Roversi G, Jaconi M, Arbustini E, Urtis M, Dell'Oro C, Zambetti B, Paniga C, Acampora E, Negri S, Lazzarin S, Cesari S, Spinillo A, Kotsopoulos J, Fruscio R.
    • Int J Gynecol Cancer. 2022 Jan;32(1):41-47. doi: 10.1136/ijgc-2021-003153. Epub 2021 Nov 29.
    • Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma.
    • Klapp V, Galluzzi L.
    • Trends Cancer. 2022 Jan;8(1):1-3. doi: 10.1016/j.trecan.2021.11.006. Epub 2021 Nov 25.
    • Research news

    Original research:

    Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.

    • CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.
    • Manganaro L, Celli V, Viggiani V, Berardelli E, Granato T, Tartaglione S, Farina A, Catalano C, Angeloni A, Anastasi E.
    • Tumour Biol. 2022;44(1):171-185. doi: 10.3233/TUB-211557.
    • Evidence for Diverse Prognosis in High-Grade Serous Ovarian Carcinoma: Solid, Pseudoendometrioid, and Transitional-Like; So-Called "SET Morphology" and Progesterone Receptor Status.
    • Uner H, Demir M, Goksuluk D, Kars A, Uner M, Usubutun A.
    • Turk Patoloji Derg. 2022;38(3):240-250. English. doi: 10.5146/tjpath.2022.01571.
    • Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.
    • Yucer N, Ahdoot R, Workman MJ, Laperle AH, Recouvreux MS, Kurowski K, Naboulsi DJ, Liang V, Qu Y, Plummer JT, Gayther SA, Orsulic S, Karlan BY, Svendsen CN.
    • Cell Rep. 2021 Dec 28;37(13):110146. doi: 10.1016/j.celrep.2021.110146.

    Research news: Researchers Create Organoids that Model BRCA-Positive Ovarian Cancer. (Clinical OMICs)

    • BRCA2 Haploinsufficiency in Telomere Maintenance.
    • Gunnarsdottir SR, Bjarnason H, Thorvaldsdottir B, Paland F, Steinarsdottir M, Eyfjörd JE, Bödvarsdottir SK.
    • Genes (Basel). 2021 Dec 28;13(1):83. doi: 10.3390/genes13010083.
    • BRCA1 and Metastasis: Outcome of Defective DNA Repair.
    • Krishnan R, Patel PS, Hakem R.
    • Cancers (Basel). 2021 Dec 27;14(1):108. doi: 10.3390/cancers14010108.
    • Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.
    • Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV.
    • Cancers (Basel). 2021 Dec 23;14(1):44. doi: 10.3390/cancers14010044.
    • BRCA role changes with association: tissue-specific impact on the prognosis.
    • Gupta B, Somasundaram K.
    • Oncotarget. 2021 Dec 21;12(26):2541-2542. doi: 10.18632/oncotarget.28149.

    Original research:

    Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients.

    • Invasive Breast Carcinoma: Rare Clinical Presentation in a Male Patient.
    • Hanna M, Solly M.
    • Cureus. 2021 Dec 20;13(12):e20547. doi: 10.7759/cureus.20547.
    • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.
    • Zhang M, Ma SC, Tan JL, Wang J, Bai X, Dong ZY, Zhang QX.
    • Front Oncol. 2021 Dec 16;11:772604. doi: 10.3389/fonc.2021.772604.
    • Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
    • Noh JJ, Kim MK, Choi MC, Lee JW, Park H, Jung SG, Joo WD, Song SH, Lee C.
    • Cancer Res Treat. 2021 Dec 13. doi: 10.4143/crt.2021.828. Epub ahead of print.
    • Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
    • De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS.
    • JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789.
    • Inference of tissue relative proportions of the breast epithelial cell types luminal progenitor, basal, and luminal mature.
    • Sci Rep. 2021 Dec 8;11(1):23702. doi: 10.1038/s41598-021-03161-7.
    • A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.
    • Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL, Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN.
    • Genome Med. 2021 Dec 3;13(1):186. doi: 10.1186/s13073-021-00998-5.
    • Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    • Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, Suehnholz SP, Chakravarty D, Yu KH, Varghese AM, Zervoudakis A, Li J, Ku GY, Park JS, Shcherba M, Harding JJ, Goldberg Z, Abou-Alfa GK, Salo-Mullen EE, Stadler ZK, Iacobuzio-Donahue CA, O'Reilly EM.
    • Cancer. 2021 Dec 1;127(23):4393-4402. doi: 10.1002/cncr.33812. Epub 2021 Aug 5.
    • Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial.
    • Schouten PC, Richters L, Vis DJ, Kommoss S, van Dijk E, Ernst C, Kluin RJC, Marmé F, Lips EH, Schmidt S, Scheerman E, Prieske K, van Deurzen CHM, Burges A, Ewing-Graham PC, Dietrich D, Jager A, de Gregorio N, Hauke J, du Bois A, Nederlof PM, Wessels LF, Hahnen E, Harter P, Linn SC, Schmutzler RK.
    • Clin Cancer Res. 2021 Dec 1;27(23):6559-6569. doi: 10.1158/1078-0432.CCR-21-1673. Epub 2021 Sep 30.
    • Prolonged recombinant pregnancy hormone use for breast cancer prevention in BRCA1 And 2 mutation carriers.
    • Depypere H, Su Y, Dang N, Poppe B, Stanczyk FZ, Janssens J, Russo J.
    • Eur J Cancer Prev. 2021 Dec 1;31(Suppl 1):S3-S4. doi: 10.1097/01.cej.0000816644.52776.6e. Epub 2021 Dec 30.
    • An Update on the effect of Recombinant Human Chorionic Gonadotropin in Breast Cancer Prevention.
    • Russo J.
    • Eur J Cancer Prev. 2021 Dec 1;31(Suppl 1):S4-S5. doi: 10.1097/01.cej.0000816656.58097.71. Epub 2021 Dec 30.
    • Genetic heterogeneity during breast cancer progression in young patients.
    • Hagio K, Hatanaka KC, Amano T, Matsuno Y, Hatanaka Y, Yamashita H.
    • Breast. 2021 Dec;60:206-213. doi: 10.1016/j.breast.2021.10.011. Epub 2021 Oct 28.
    • Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.
    • Neirich L, Yahiaoui-Doktor M, Lammert J, Basrai M, Seethaler B, Berling-Ernst A, Ramser J, Quante AS, Schmidt T, Niederberger U, Rhiem K, Schmutzler R, Engel C, Bischoff SC, Halle M, Kiechle M, Grill S.
    • Breast Cancer Res Treat. 2021 Dec;190(3):463-475. doi: 10.1007/s10549-021-06400-7. Epub 2021 Sep 27.
    • Prognostic difficulties of men with breast cancer.
    • Fentiman IS.
    • Breast J. 2021 Dec;27(12):877-882. doi: 10.1111/tbj.14297. Epub 2021 Oct 15.
    • Review
    • Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
    • Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P, Rodriguez-Canales J, Angell HK, Ng FSL, Waring PM, Hodgson D, Ledermann JA, Weberpals JI, Dean E, Harrington EA, Barrett JC, Pierce AJ, Leo E, Jones GN.
    • Br J Cancer. 2021 Dec;125(12):1666-1676. doi: 10.1038/s41416-021-01560-1. Epub 2021 Oct 18.
    • Diagnostic histologique et moléculaire des cancers de l'ovaire - recommandations pour la pratique clinique Saint-Paul 2021: Histological and molecular diagnosis of ovarian.
    • Genestie C, Gladieff L, Frère-Belda ML, Lortholary A, Vaur D, Treilleux I, Lyonnet DS.
    • Bull Cancer. 2021 Dec;108(9S1):S33-S38. doi: 10.1016/S0007-4551(21)00585-3.
    • Guideline
    • Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
    • Sakach E, O'Regan R, Meisel J, Li X.
    • Clin Breast Cancer. 2021 Dec;21(6):509-520. doi: 10.1016/j.clbc.2021.09.003. Epub 2021 Sep 17.
    • Review
    • Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
    • Aldea M, Lam L, Orillard E, Llacer Perez C, Saint-Ghislain M, Gravis G, Fléchon A, Roubaud G, Barthelemy P, Ricci F, Priou F, Neviere Z, Beaufils M, Laguerre B, Hardy AC, Helissey C, Ratta R, Borchiellini D, Pobel C, Joly F, Castro E, Thiery-Vuillemin A, Baciarello G, Fizazi K.
    • Eur J Cancer. 2021 Dec;159:87-97. doi: 10.1016/j.ejca.2021.09.029. Epub 2021 Nov 2.
    • Somatic mosaics in hereditary tumor predisposition syndromes.
    • Steinke-Lange V, de Putter R, Holinski-Feder E, Claes KB.
    • Eur J Med Genet. 2021 Dec;64(12):104360. doi: 10.1016/j.ejmg.2021.104360. Epub 2021 Oct 13.
    • Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    • Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O'Malley DM, Leary A, Welch S, Provencher D, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA.
    • Gynecol Oncol. 2021 Dec;163(3):490-497. doi: 10.1016/j.ygyno.2021.08.030. Epub 2021 Sep 30.
    • Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    • Azzalini E, Barbazza R, Stanta G, Giorda G, Bortot L, Bartoletti M, Puglisi F, Canzonieri V, Bonin S.
    • Gynecol Oncol. 2021 Dec;163(3):498-505. doi: 10.1016/j.ygyno.2021.09.012. Epub 2021 Oct 1.
    • Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    • Hodgson DR, Brown JS, Dearden SP, Lai Z, Elks CE, Milenkova T, Dougherty BA, Lanchbury JS, Perry M, Timms KM, Harrington EA, Barrett JC, Leary A, Pujade-Lauraine E.
    • Gynecol Oncol. 2021 Dec;163(3):563-568. doi: 10.1016/j.ygyno.2021.10.002. Epub 2021 Nov 4.
    • BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
    • Elazezy M, Prieske K, Kluwe L, Oliveira-Ferrer L, Peine S, Müller V, Woelber L, Schmalfeldt B, Pantel K, Joosse SA.
    • Mol Oncol. 2021 Dec;15(12):3615-3625. doi: 10.1002/1878-0261.13108. Epub 2021 Oct 12.
    • Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
    • Klotz DM, Link T, Wimberger P, Kuhlmann JD.
    • Mol Oncol. 2021 Dec;15(12):3626-3638. doi: 10.1002/1878-0261.12949. Epub 2021 Apr 2.
    • Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.
    • Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, Hoen DR, Mandal R, Setton J, Wu W, Shah R, Qeriqi B, Chang Q, Kendall S, Braunstein L, Weigelt B, Carrillo Albornoz PB, Morris LGT, Mandelker DL, Reis-Filho JS, de Stanchina E, Powell SN, Chan TA, Riaz N.
    • Nat Cancer. 2021 Dec;1(12):1188-1203. doi: 10.1038/s43018-020-00139-8. Epub 2020 Nov 16.

    Research news: Cancer Patients With BRCA1/2 Mutations Respond Differently to Immunotherapy, Study Shows. (Precision Oncology News; subscription required)

    • Epigenetic Dysregulation of KCNK9 Imprinting and Triple-Negative Breast Cancer.
    • Skaar DA, Dietze EC, Alva-Ornelas JA, Ann D, Schones DE, Hyslop T, Sistrunk C, Zalles C, Ambrose A, Kennedy K, Idassi O, Miranda Carboni G, Gould MN, Jirtle RL, Seewaldt VL.
    • Cancers (Basel). 2021 Nov 30;13(23):6031. doi: 10.3390/cancers13236031.
    • Prediction of BRCA gene mutation status in epithelial ovarian cancer by radiomics models based on 2D and 3D CT images
    • Mingzhu L, Yaqiong G, Mengru L, Wei W.
    • BMC Med Imaging. 2021 Nov 26;21(1):180. doi: 10.1186/s12880-021-00711-3.
    • Exonic sequencing and MLH3 gene expression analysis of breast cancer patients.
    • Khailany RA, Ozaslan M.
    • Cell Mol Biol (Noisy-le-grand). 2021 Nov 25;67(3):35-43. doi: 10.14715/cmb/2021.67.3.5.
    • GSA: an independent development algorithm for calling copy number and detecting homologous recombination deficiency (HRD) from target capture sequencing.
    • Chen D, Shao M, Meng P, Wang C, Li Q, Cai Y, Song C, Wang X, Shi T.
    • BMC Bioinformatics. 2021 Nov 23;22(1):562. doi: 10.1186/s12859-021-04487-9.
    • Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies.
    • Paracchini L, Mannarino L, Craparotta I, Romualdi C, Fruscio R, Grassi T, Fotia V, Caratti G, Perego P, Calura E, Clivio L, D'Incalci M, Beltrame L, Marchini S.
    • Oncotarget. 2016 Jul 9;12(24):2404-2417. doi: 10.18632/oncotarget.10505. eCollection 2021 Nov 23.
    • Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer.
    • Su R, Liu Y, Wu X, Xiang J, Xi X.
    • Front Mol Biosci. 2021 Nov 19;8:762741. doi: 10.3389/fmolb.2021.762741.
    • Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
    • Lieb V, Abdulrahman A, Weigelt K, Hauch S, Gombert M, Guzman J, Bellut L, Goebell PJ, Stöhr R, Hartmann A, Wullich B, Taubert H, Wach S.
    • Cells. 2021 Nov 18;10(11):3223. doi: 10.3390/cells10113223.
    • Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing.
    • Jalloul N, Gomy I, Stokes S, Gusev A, Johnson BE, Lindeman NI, Macconaill L, Ganesan S, Garber JE, Khiabanian H.
    • JCO Precis Oncol. 2021 Nov 17;5:PO.21.00279. doi: 10.1200/PO.21.00279.

    Letter, Commentary:

    Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing-A Quality Assurance Strategy.

    Letter, Reply:

    Reply to T. Ménard.

    • Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
    • Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE Jr, Loibl S, Stover DG.
    • NPJ Breast Cancer. 2021 Nov 11;7(1):142. doi: 10.1038/s41523-021-00349-y.
    • VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
    • Bizzaro F, Fuso Nerini I, Taylor MA, Anastasia A, Russo M, Damia G, Guffanti F, Guana F, Ostano P, Minoli L, Hattersley MM, Arnold S, Ramos-Montoya A, Williamson SC, Galbiati A, Urosevic J, Leo E, Cavallaro U, Ghilardi C, Barry ST, Bani MR, Giavazzi R.
    • J Hematol Oncol. 2021 Nov 6;14(1):186. doi: 10.1186/s13045-021-01196-x.
    • Genomic Features of Radiation-Associated Muscle-Invasive Bladder Cancer.
    • Muralidhar V, Carvalho F, Preston M, Curran C, Freeman D, Sonpavde G, Kibel A, Van Allen EM, Mossanen M, Mouw KW.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S13-S14. doi: 10.1016/j.ijrobp.2021.07.062.
    • Examining the Prevalence of Homologous Recombination Repair Defects in ER+ Breast Cancers.
    • Moore GM, Powell SN, Higginson DS, Khan AJ.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S35-S36. doi: 10.1016/j.ijrobp.2021.07.106.
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.
    • Satyananda V, Oshi M, Endo I, Takabe K.
    • Ann Surg Oncol. 2021 Nov;28(12):7356-7365. doi: 10.1245/s10434-021-10063-5. Epub 2021 May 8.

    Commentary:

    ASO Author Reflections: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.

    Commentary:

    ASO Visual Abstract: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.

    • Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
    • Jørgensen N, Hviid TVF, Nielsen LB, Sønderstrup IMH, Eriksen JO, Ejlertsen B, Gerdes AM, Kruse TA, Thomassen M, Jensen MB, Lænkholm AV.
    • Br J Cancer. 2021 Nov;125(10):1388-1398. doi: 10.1038/s41416-021-01514-7. Epub 2021 Aug 7.
    • Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
    • Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS.
    • Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27.
    • Detection of hypermethylation BRCA1/2 gene promoter in breast tumours among Moroccan women.
    • Saif I, Bouziyane A, Benhessou M, Karroumi ME, Ennaji MM.
    • Mol Biol Rep. 2021 Nov;48(11):7147-7152. doi: 10.1007/s11033-021-06705-2. Epub 2021 Sep 30.
    • The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    • Tao M, Wu X.
    • J Exp Clin Cancer Res. 2021 Oct 26;40(1):338. doi: 10.1186/s13046-021-02139-7.
    • Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.
    • Sun H, Zeng J, Miao Z, Lei KC, Huang C, Hu L, Su SM, Chan UI, Miao K, Zhang X, Zhang A, Guo S, Chen S, Meng Y, Deng M, Hao W, Lei H, Lin Y, Yang Z, Tang D, Wong KH, Zhang XD, Xu X, Deng CX.
    • Theranostics. 2021 Oct 25;11(20):9967-9987. doi: 10.7150/thno.63995.
    • Genetic polymorphisms and promoter methylation of miR-9-3 in the modulation of breast cancer risk in a Chinese population.
    • Pan G, Luo Z, Tang R.
    • Clin Breast Cancer. 2021 Oct 23:S1526-8209(21)00299-8. doi: 10.1016/j.clbc.2021.10.010. Epub ahead of print.
    • Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics.
    • Huang X, Wang X, Qian H, Jin X, Jiang G.
    • Evid Based Complement Alternat Med. 2021 Oct 22;2021:5314016. doi: 10.1155/2021/5314016.
    • Detection of BRCA1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian Cancer.
    • Li L, Chen F, Lin A, Wang D, Shi Y, Chen G.
    • Comput Math Methods Med. 2021 Oct 21;2021:4854282. doi: 10.1155/2021/4854282.
    • Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report.
    • McFarland TR, Tandar CE, Agarwal N, Swami U.
    • Cancer Treat Res Commun. 2021;29:100480. doi: 10.1016/j.ctarc.2021.100480. Epub 2021 Oct 20.
    • Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing.
    • Wessman S, Fuentes BB, Törngren T, Kvist A, Kokaraki G, Menkens H, Hjerpe E, Hugo Y, Petta TB, Borg Å, Carlson JW.
    • Cancers (Basel). 2021 Oct 19;13(20):5240. doi: 10.3390/cancers13205240.
    • Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
    • Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI.
    • NPJ Precis Oncol. 2021 Oct 19;5(1):92. doi: 10.1038/s41698-021-00232-w.
    • Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and BRCA1/2 Mutation-Type-Specific Critical Regulation in Breast Cancer.
    • Li Y, Dong W, Zhang P, Zhang T, Ma L, Qu M, Ma X, Zhou X, He Q.
    • Front Cell Dev Biol. 2021 Oct 18;9:750897. doi: 10.3389/fcell.2021.750897.
    • Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
    • Coulson-Gilmer C, Morgan RD, Nelson L, Barnes BM, Tighe A, Wardenaar R, Spierings DCJ, Schlecht H, Burghel GJ, Foijer F, Desai S, McGrail JC, Taylor SS.
    • J Exp Clin Cancer Res. 2021 Oct 16;40(1):323. doi: 10.1186/s13046-021-02124-0.
    • Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
    • Sztupinszki Z, Diossy M, Börcsök J, Prosz A, Cornelius N, Kjeldsen MK, Mirza MR, Szallasi Z.
    • Clin Cancer Res. 2021 Oct 15;27(20):5681-5687. doi: 10.1158/1078-0432.CCR-21-0981. Epub 2021 Aug 11.
    • Molecular and Clinical Significance of Stanniocalcin-1 Expression in Breast Cancer Through Promotion of Homologous Recombination-Mediated DNA Damage Repair.
    • Hou J, Cheng J, Dai Z, Wei N, Chen H, Wang S, Dai M, Li L, Wang H, Ni Q.
    • Front Cell Dev Biol. 2021 Oct 15;9:731086. doi: 10.3389/fcell.2021.731086.
    • Prognostic Prediction of BRCA Mutations by 18F-FDG PET/CT SUVmax in Breast Cancer.
    • Özdemir S, Silan F, Akgün MY, Araci N, Çirpan I, Koç Öztürk F, Özdemir Ö.
    • Mol Imaging Radionucl Ther. 2021 Oct 15;30(3):158-168. doi: 10.4274/mirt.galenos.2021.82584.
    • Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination.
    • Setton J, Selenica P, Mukherjee S, Shah R, Pecorari I, McMillan B, Pei IX, Kemel Y, Ceyhan-Birsoy O, Sheehan M, Tkachuk K, Brown DN, Zhang L, Cadoo K, Powell S, Weigelt B, Robson M, Riaz N, Offit K, Reis-Filho JS, Mandelker D.
    • NPJ Breast Cancer. 2021 Oct 11;7(1):135. doi: 10.1038/s41523-021-00339-0.
    • PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer.
    • Hsu WJ, Chen CH, Chang YC, Cheng CH, TsaI YH, Lin CW.
    • J Pers Med. 2021 Oct 8;11(10):1009. doi: 10.3390/jpm11101009.
    • Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation.
    • Meng F, Lu L, Tan Y, Duan Q, Lu H.
    • Front Oncol. 2021 Oct 4;11:757965. doi: 10.3389/fonc.2021.757965.
    • CRISPR screens guide the way for PARP and ATR inhibitors biomarker discovery.
    • Schleicher EM, Moldovan GL.
    • FEBS J. 2021 Oct 3. doi: 10.1111/febs.16217. Epub ahead of print.
    • Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy.
    • Batra A, Tang PA, Cheung WY.
    • Am J Clin Oncol. 2021 Oct 1;44(10):519-525. doi: 10.1097/COC.0000000000000856.
    • Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
    • Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C.
    • Acta Pharm Sin B. 2021 Oct;11(10):2983-2994. doi: 10.1016/j.apsb.2021.01.003. Epub 2021 Jan 6.
    • Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study.
    • Denis-Laroque L, Drouet Y, Plotton I, Chopin N, Bonadona V, Lornage J, Salle B, Lasset C, Rousset-Jablonski C.
    • Breast. 2021 Oct;59:239-247. doi: 10.1016/j.breast.2021.07.010. Epub 2021 Jul 12.
    • Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
    • Zavarikina TM, Khokhlova SV, Tyulyandina AS, Khabas GN, Asaturova AV, Nosova YV, Brenner PK, Kapralova MA, Khodirev DS, Stenina MB.
    • Bull Exp Biol Med. 2021 Oct;171(6):755-759. doi: 10.1007/s10517-021-05310-4. Epub 2021 Oct 28.
    • BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis.
    • Pan JN, Lei L, Ye WW, Wang XJ, Cao WM.
    • J Breast Cancer. 2021 Oct;24(5):474-480. doi: 10.4048/jbc.2021.24.e39. Epub 2021 Sep 7.
    • Identification of metabolism-associated molecular subtype in ovarian cancer.
    • Liu X, Wu A, Wang X, Liu Y, Xu Y, Liu G, Liu L.
    • J Cell Mol Med. 2021 Oct;25(20):9617-9626. doi: 10.1111/jcmm.16907. Epub 2021 Sep 15.
    • Assessment of mismatch repair deficiency in ovarian cancer.
    • Crosbie EJ, Ryan NAJ, McVey RJ, Lalloo F, Bowers N, Green K, Woodward ER, Clancy T, Bolton J, Wallace AJ, McMahon RF, Evans DG.
    • J Med Genet. 2021 Oct;58(10):687-691. doi: 10.1136/jmedgenet-2020-107270. Epub 2020 Sep 11.
    • Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients.
    • Barbosa A, Pinto P, Peixoto A, Guerra J, Pinheiro M, Santos C, Pinto C, Escudeiro C, Bartosch C, Santos R, Brandão A, Silva J, Teixeira MR.
    • Front Oncol. 2021 Sep 30;11:754094. doi: 10.3389/fonc.2021.754094.
    • Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.
    • Venetis K, Fusco N, Sajjadi E.
    • Front Oncol. 2021 Sep 29;11:735476. doi: 10.3389/fonc.2021.735476.

    Original research:

    Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.

    • Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients.
    • Leaf S, Carlsen L, El-Deiry WS.
    • Oncotarget. 2021 Sep 28;12(20):1992-2005. doi: 10.18632/oncotarget.28082.

    •• Commentary:

    BRCA role changes with association: tissue-specific impact on the prognosis.

    •• Commentary:

    Redefining and expanding the sphere of influence of BRCA in breast and colorectal cancers and beyond.

    • Pathogenic genetic variants from highly connected cancer susceptibility genes confer the loss of structural stability.
    • Reza MN, Ferdous N, Emon MTH, Islam MS, Mohiuddin AKM, Hossain MU.
    • Sci Rep. 2021 Sep 28;11(1):19264. doi: 10.1038/s41598-021-98547-y.
    • Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis.
    • Gasparri ML, Di Micco R, Zuber V, Taghavi K, Bianchini G, Bellaminutti S, Meani F, Graffeo R, Candiani M, Mueller MD, Papadia A, Gentilini OD.
    • Breast. 2021 Sep 27;60:155-162. doi: 10.1016/j.breast.2021.09.006. Epub ahead of print.
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • Novel mechanisms in alcohol neurodevelopmental disorders via BRCA1 depletion and BRCA1-dependent NADPH oxidase regulation.
    • Drake DM, Wells PG.
    • Redox Biol. 2021 Sep 23;48:102148. doi: 10.1016/j.redox.2021.102148. Epub ahead of print.
    • Determinants of Homologous Recombination Deficiency in Pancreatic Cancer.
    • Wattenberg MM, Reiss KA.
    • Cancers (Basel). 2021 Sep 21;13(18):4716. doi: 10.3390/cancers13184716.
    • Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    • Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, Andújar-Sánchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J.
    • Mol Cell. 2021 Sep 18:S1097-2765(21)00739-5. doi: 10.1016/j.molcel.2021.09.005. Epub ahead of print.
    • Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
    • Kaur HB, Vidotto T, Mendes AA, Salles DC, Isaacs WB, Antonarakis ES, Lotan TL.
    • Cancer Immunol Immunother. 2021 Sep 17. doi: 10.1007/s00262-021-03050-y. Epub ahead of print.
    • Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells.
    • Chirshev E, Suzuki T, Wang H, Nguyen A, Hojo N, Sanderman L, Mirshahidi S, Ioffe YJ, Unternaehrer JJ.
    • Cancers (Basel). 2021 Sep 15;13(18):4617. doi: 10.3390/cancers13184617.
    • Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
    • Saravi S, Alizzi Z, Tosi S, Hall M, Karteris E.
    • Cells. 2021 Sep 15;10(9):2434. doi: 10.3390/cells10092434.
    • Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.
    • Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S.
    • Clin Cancer Res. 2021 Sep 15:clincanres.2328.2021. doi: 10.1158/1078-0432.CCR-21-2328. Epub ahead of print.
    • miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer.
    • Wang W, Zhang W, Wu J, Zhou Z, Ma J.
    • Clin Exp Med. 2021 Sep 14. doi: 10.1007/s10238-021-00757-1. Epub ahead of print.
    • Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    • Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB.
    • Clin Cancer Res. 2021 Sep 13:clincanres.1656.2021. doi: 10.1158/1078-0432.CCR-21-1656. Epub ahead of print.
    • Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer.
    • Huang KL, Liu YL, Hsu YY, Kuo WL.
    • Healthcare (Basel). 2021 Sep 13;9(9):1203. doi: 10.3390/healthcare9091203.
    • Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
    • Qing T, Wang X, Jun T, Ding L, Pusztai L, Huang KL.
    • Cancers (Basel). 2021 Sep 12;13(18):4572. doi: 10.3390/cancers13184572.
    • Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.
    • Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S.
    • Int J Mol Sci. 2021 Sep 10;22(18):9783. doi: 10.3390/ijms22189783.
    • Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression.
    • Fores-Martos J, Cervera-Vidal R, Sierra-Roca J, Lozano-Asencio C, Fedele V, Cornelissen S, Edvarsen H, Tadeo-Cervera I, Eroles P, Lluch A, Tabares-Seisdedos R, Falcó A, Van't Veer LJ, Schmidt M, Quigley DA, Børresen-Dale AL, Kristensen VN, Balmain A, Climent J.
    • NPJ Breast Cancer. 2021 Sep 10;7(1):118. doi: 10.1038/s41523-021-00329-2.
    • Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium.
    • Iacovelli R, Astore S, Ciccarese C, Cannella MA, Bove P, Iacovelli V, Tortora G.
    • Expert Rev Anticancer Ther. 2021 Sep 9:1-4. doi: 10.1080/14737140.2021.1976148. Epub ahead of print.
    • Conference report
    • Clinical consequences of BRCA2 hypomorphism.
    • Castells-Roca L, Gutiérrez-Enríquez S, Bonache S, Bogliolo M, Carrasco E, Aza-Carmona M, Montalban G, Muñoz-Subirana N, Pujol R, Cruz C, Llop-Guevara A, Ramírez MJ, Saura C, Lasa A, Serra V, Diez O, Balmaña J, Surrallés J.
    • NPJ Breast Cancer. 2021 Sep 9;7(1):117. doi: 10.1038/s41523-021-00322-9.
    • Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance.
    • Zelli V, Silvestri V, Valentini V, Bucalo A, Rizzolo P, Zanna I, Bianchi S, Coppa A, Giannini G, Cortesi L, Calistri D, Tibiletti MG, Fox SB, Fab K, Palli D, Ottini L.
    • Cancers (Basel). 2021 Sep 8;13(18):4515. doi: 10.3390/cancers13184515.
    • REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.
    • Taglialatela A, Leuzzi G, Sannino V, Cuella-Martin R, Huang JW, Wu-Baer F, Baer R, Costanzo V, Ciccia A.
    • Mol Cell. 2021 Sep 7:S1097-2765(21)00683-3. doi: 10.1016/j.molcel.2021.08.016. Epub ahead of print.
    • Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    • Hodgson D, Lai Z, Dearden S, Barrett JC, Harrington EA, Timms K, Lanchbury J, Wu W, Allen A, Senkus E, Domchek SM, Robson M.
    • Ann Oncol. 2021 Sep 6:S0923-7534(21)04458-6. doi: 10.1016/j.annonc.2021.08.2154. Epub ahead of print.
    • Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers.
    • Tommasi C, Pellegrino B, Boggiani D, Sikokis A, Michiara M, Uliana V, Bortesi B, Bonatti F, Mozzoni P, Pinelli S, Squadrilli A, Viani MV, Cassi D, Maglietta G, Meleti M, Musolino A.
    • Front Oncol. 2021 Sep 6;11:700853. doi: 10.3389/fonc.2021.700853.
    • Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types.
    • van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW.
    • Clin Cancer Res. 2021 Sep 2:clincanres.1104.2021. doi: 10.1158/1078-0432.CCR-21-1104. Epub ahead of print.
    • Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants.
    • Villy MC, Masliah-Planchon J, Melaabi S, Trabelsi Grati O, Girard E, Bataillon G, Vincent-Salomon A, Le Gall J, Golmard L, Stoppa-Lyonnet D, Bieche I, Colas C.
    • Gynecol Oncol Rep. 2021 Sep 2;37:100855. doi: 10.1016/j.gore.2021.100855.
    • Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
    • Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK.
    • J Cancer Res Clin Oncol. 2021 Sep 2. doi: 10.1007/s00432-021-03778-1. Epub ahead of print.
    • Ultrasound Imaging Morphology is Associated with Biological Behavior in Invasive Ductal Carcinoma of the Breast.
    • Vijayaraghavan GR, Kona M, Maheswaran A, Kandil DH, Toke MK, Vedantham S.
    • J Clin Imaging Sci. 2021 Sep 2;11:48. doi: 10.25259/JCIS_60_2021.
    • The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells.
    • Simoneau A, Xiong R, Zou L.
    • Genes Dev. 2021 Sep 1;35(17-18):1271-1289. doi: 10.1101/gad.348479.121. Epub 2021 Aug 12.
    • COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases.
    • Faermann R, Nissan N, Halshtok-Neiman O, Shalmon A, Gotlieb M, Yagil Y, Samoocha D, Friedman E, Sklair-Levy M.
    • Acad Radiol. 2021 Sep;28(9):1191-1197. doi: 10.1016/j.acra.2021.06.003. Epub 2021 Jun 10.

    Commentary:

    Managing the Risk of Delayed Breast Cancer Screening Versus COVID-19 Vaccination Associated Axillary Lymphadenopathy.

    • Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
    • Lai J, Tong C, Chien JR.
    • Anticancer Res. 2021 Sep;41(9):4417-4422. doi: 10.21873/anticanres.15248.
    • Case report
    • Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    • Rasmussen M, Lim K, Rambech E, Andersen MH, Svane IM, Andersen O, Jensen LH, Nilbert M, Therkildsen C.
    • Gynecol Oncol. 2021 Sep;162(3):686-693. doi: 10.1016/j.ygyno.2021.07.001. Epub 2021 Jul 16.
    • The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    • Kim SR, Malcolmson J, Li X, Bernardini MQ, Hogen L, May T.
    • Gynecol Oncol. 2021 Sep;162(3):702-706. doi: 10.1016/j.ygyno.2021.07.010. Epub 2021 Jul 10.
    • Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.
    • Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B.
    • JAMA Oncol. 2021 Jun 4 [2021 Sept];7(9):1–5 [1378-1382]. doi: 10.1001/jamaoncol.2021.2350. Epub ahead of print.
    • Evidence for accelerated aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutations.
    • Shalabi SF, Miyano M, Sayaman RW, Lopez JC, Jokela TA, Todhunter ME, Hinz S, Garbe JC, Stampfer MR, Kessenbrock K, Seewaldt VE, LaBarge MA.
    • Nat Aging. 2021 Sep;1(9):838-849. doi: 10.1038/s43587-021-00104-9. Epub 2021 Sep 14.
    • Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
    • Mani C, Tripathi K, Chaudhary S, Somasagara RR, Rocconi RP, Crasto C, Reedy M, Athar M, Palle K.
    • Neoplasia. 2021 Sep;23(9):1002-1015. doi: 10.1016/j.neo.2021.06.010. Epub 2021 Aug 8.
    • Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.
    • Hesterberg AB, Gordetsky JB, Hurley PJ.
    • Urology. 2021 Sep;155:47-54. doi: 10.1016/j.urology.2021.05.028. Epub 2021 May 28.
    • Review
    • Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
    • Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou S, Llop-Guevara A, Phan Z, Yong A, Wilkinson A, Sergio CM, Ferraro D, Etemadmoghadam D, Bowtell DD; kConFab Investigators, Serra V, Waring P, Lim E, Caldon CE.
    • NPJ Breast Cancer. 2021 Aug 31;7(1):111. doi: 10.1038/s41523-021-00312-x.
    • Male breast cancer: an update.
    • Fox S, Speirs V, Shaaban AM.
    • Virchows Arch. 2021 Aug 30. doi: 10.1007/s00428-021-03190-7. Epub ahead of print.
    • Review
    • Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality.
    • Benfatto S, Serçin Ö, Dejure FR, Abdollahi A, Zenke FT, Mardin BR.
    • Mol Cancer. 2021 Aug 28;20(1):111. doi: 10.1186/s12943-021-01405-8.
    • Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma.
    • Pan H, Cheng H, Wang H, Ge W, Yuan M, Jiang S, Wan X, Dong Y, Liu Z, Zhao R, Fang Y, Lou F, Cao S, Han W.
    • Cancer Sci. 2021 Aug 27. doi: 10.1111/cas.15119. Epub ahead of print.
    • Thyroid Hormone Receptor Beta as Tumor Suppressor: Untapped Potential in Treatment and Diagnostics in Solid Tumors.
    • Davidson CD, Gillis NE, Carr FE.
    • Cancers (Basel). 2021 Aug 24;13(17):4254. doi: 10.3390/cancers13174254.
    • The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer.
    • Lan H, Yuan J, Zeng D, Liu C, Guo X, Yong J, Zeng X, Xiao S.
    • Front Genet. 2021 Aug 20;12:693259. doi: 10.3389/fgene.2021.693259.
    • Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
    • Gong Y, Nagarathinam R, Arisi MF, Gerratana L, Winn JS, Slifker M, Pei J, Cai KQ, Hasse Z, Obeid E, Noriega J, Sebastiano C, Ross E, Alpaugh K, Cristofanilli M, Fernandez SV.
    • Int J Mol Sci. 2021 Aug 19;22(16):8924. doi: 10.3390/ijms22168924.
    • High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
    • Zhu L, Pan JN, Qian Z, Ye WW, Wang XJ, Cao WM.
    • Breast Cancer. 2021 Aug 17. doi: 10.1007/s12282-021-01286-1. Epub ahead of print.
    • Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    • Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, Kaneyasu T, Mori S, Mandai M, Matsumura N.
    • JCO Precis Oncol. 2021 Aug 11;5:PO.21.00141. doi: 10.1200/PO.21.00141.
    • A review on the relationship between anti-mullerian hormone and fertility in treating young breast cancer patients.
    • Song Y, Liu H.
    • BMC Womens Health. 2021 Aug 10;21(1):295. doi: 10.1186/s12905-021-01420-3.
    • The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.
    • Gianni P, Matenoglou E, Geropoulos G, Agrawal N, Adnani H, Zafeiropoulos S, Miyara SJ, Guevara S, Mumford JM, Molmenti EP, Giannis D.
    • Clin Breast Cancer. 2021 Aug 10:S1526-8209(21)00238-X. doi: 10.1016/j.clbc.2021.08.001. Epub ahead of print.
    • Review
    • Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome.
    • Dong Q, Liu M, Chen B, Zhao Z, Chen T, Wang C, Zhuang S, Li Y, Wang Y, Ai L, Liu Y, Liang H, Qi L, Gu Y.
    • Comput Struct Biotechnol J. 2021 Aug 10;19:4435-4446. doi: 10.1016/j.csbj.2021.08.007.
    • Guardians of the Genome: BRCA2 and Its Partners.
    • Le HP, Heyer WD, Liu J.
    • Genes (Basel). 2021 Aug 10;12(8):1229. doi: 10.3390/genes12081229.
    • Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity.
    • Ketola K, Kaljunen H, Taavitsainen S, Kaarijärvi R, Järvelä E, Rodriguez Martin B, Haase K, Woodcock DJ, Tubio J, Wedge DC, Nykter M, Bova GS.
    • Cancer Res. 2021 Aug 4:canres.0371.2021. doi: 10.1158/0008-5472.CAN-21-0371. Epub ahead of print.
    • Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer.
    • Kuo KK, Hsiao PJ, Chang WT, Chuang SC, Yang YH, Wuputra K, Ku CC, Pan JB, Li CP, Kato K, Liu CJ, Wu DC, Yokoyama KK.
    • Cancers (Basel). 2021 Aug 3;13(15):3920. doi: 10.3390/cancers13153920.
    • BRCA2 deficiency reveals that oxidative stress impairs RNaseH1 function to cripple mitochondrial DNA maintenance.
    • Renaudin X, Lee M, Shehata M, Surmann EM, Venkitaraman AR.
    • Cell Rep. 2021 Aug 3;36(5):109478. doi: 10.1016/j.celrep.2021.109478.
    • DNA methylation and breast cancer-associated variants.
    • Ho PJ, Dorajoo R, Ivankovic I, Ong SS, Khng AJ, Tan BK, Tan VKM, Lim SH, Tan EY, Tan SM, Tan QT, Yan Z, Ngeow J, Sim Y, Chan P, Chuan JCJ, Chan CW, Tang SW, Hartman M, Li J.
    • Breast Cancer Res Treat. 2021 Aug;188(3):713-727. doi: 10.1007/s10549-021-06185-9. Epub 2021 Mar 26.
    • Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
    • Boilève A, Lavaud P, Caron O.
    • Eur Urol Oncol. 2021 Aug;4(4):674-675. doi: 10.1016/j.euo.2021.06.004. Epub 2021 Jun 19.
    • Letter, Comment

    Review:

    Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.

    • Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas.
    • Gondo N, Sakai Y, Zhang Z, Hato Y, Kuzushima K, Phimsen S, Kawashima Y, Kuroda M, Suzuki M, Okada S, Iwata H, Toyama T, Rezano A, Kuwahara K.
    • Lab Invest. 2021 Aug;101(8):1048-1059. doi: 10.1038/s41374-021-00613-6. Epub 2021 May 24.

    •• Original research:

    Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas.

    • MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells.
    • Zeng X, Jiang S, Ruan S, Guo Z, Guo J, Liu M, Ye C, Dong J.
    • Mol Med Rep. 2021 Aug;24(2):548. doi: 10.3892/mmr.2021.12187. Epub 2021 Jun 3.
    • Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer.
    • Paik HJ, Jung YJ, Kim DI, Lee S, Jung CS, Kang SK, Kim JJ, Oh SY, Joo JH, Kim HY.
    • Oncology. 2021 [Aug];99(8):499-506. doi: 10.1159/000515790. Epub 2021 Jun 7.
    • Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma.
    • Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Eftekhariyan Ghamsari MR, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Cancer Study AO, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL.
    • Cancer Res. 2021 Jul 28:canres.0774.2021. doi: 10.1158/0008-5472.CAN-21-0774. Epub ahead of print.
    • Assistance by Routine CT Features Combined With 3D Texture Analysis in the Diagnosis of BRCA Gene Mutation Status in Advanced Epithelial Ovarian Cancer.
    • Li MR, Liu MZ, Ge YQ, Zhou Y, Wei W.
    • Front Oncol. 2021 Jul 26;11:696780. doi: 10.3389/fonc.2021.696780.
    • Rapid progression of metastatic pancreatic adenocarcinoma during platinum-based therapy in a patient harboring a pathogenic BRCA2 germline variant.
    • Sorscher S, Ramkissoon S.
    • Oncologist. 2021 Jul 26. doi: 10.1002/onco.13912. Epub ahead of print.
    • Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    • Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.
    • Breast Cancer. 2021 Jul 24. doi: 10.1007/s12282-021-01276-3. Epub ahead of print.
    • Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.
    • Imyanitov E, Sokolenko A.
    • World J Clin Oncol. 2021 Jul 24;12(7):544-556. doi: 10.5306/wjco.v12.i7.544.
    • Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
    • Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES.
    • JCO Precis Oncol. 2021 Jul 22;5:PO.21.00070. doi: 10.1200/PO.21.00070.
    • Increased gene expression variability in BRCA1-associated and basal-like breast tumours.
    • Wiggins GAR, Black MA, Dunbier A, Morley-Bunker AE; kConFab Investigators, Pearson JF, Walker LC.
    • Breast Cancer Res Treat. 2021 Jul 21. doi: 10.1007/s10549-021-06328-y. Epub ahead of print.
    • Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
    • Zhang G, Zhang J, Zhu Y, Liu H, Shi Y, Mi K, Li M, Zhao Q, Huang Z, Huang J.
    • Exp Cell Res. 2021 Jul 21:112742. doi: 10.1016/j.yexcr.2021.112742. Epub ahead of print.
    • Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
    • Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, Fahr N, Desbuisson M, Grimm A, Zhang H, Chong C, Dagher J, Chee S, Tsianou T, Dorier J, Stevenson BJ, Iseli C, Ronet C, Bobisse S, Genolet R, Walton J, Bassani-Sternberg M, Kandalaft LE, Ren B, McNeish I, Swisher E, Harari A, Delorenzi M, Ciriello G, Irving M, Rusakiewicz S, Foukas PG, Martinon F, Dangaj Laniti D, Coukos G.
    • Cell Rep. 2021 Jul 20;36(3):109412. doi: 10.1016/j.celrep.2021.109412.

    Research news:

    Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma.

    • Prediction of BRCA Gene Mutation in Breast Cancer Based on Deep Learning and Histopathology Images.
    • Wang X, Zou C, Zhang Y, Li X, Wang C, Ke F, Chen J, Wang W, Wang D, Xu X, Xie L, Zhang Y.
    • Front Genet. 2021 Jul 20;12:661109. doi: 10.3389/fgene.2021.661109.
    • Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    • Sohn MH, Kim SI, Shin JY, Kim HS, Chung HH, Kim JW, Lee M, Seo JS.
    • Genes (Basel). 2021 Jul 20;12(7):1103. doi: 10.3390/genes12071103.
    • Germline and Somatic mutations in postmenopausal breast cancer patients.
    • Nagy TR, Maistro S, Encinas G, Katayama MLH, Pereira GFL, Gaburo-Júnior N, Franco LAM, Gouvêa ACRC, Diz MDPE, Leite LAS, Folgueira MAAK.
    • Clinics (Sao Paulo). 2021 Jul 16;76:e2837. doi: 10.6061/clinics/2021/e2837.
    • Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    • Zeng H, Chen L, Zhang M, Luo Y, Ma X.
    • Gynecol Oncol. 2021 Jul 15:S0090-8258(21)00577-1. doi: 10.1016/j.ygyno.2021.07.015. Epub ahead of print.
    • Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.
    • Berkel C, Cacan E.
    • Biochem Biophys Res Commun. 2021 Jul 14;570:74-81. doi: 10.1016/j.bbrc.2021.07.004. Epub ahead of print.
    • The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
    • Shui L, Li X, Peng Y, Tian J, Li S, He D, Li A, Tian B, Li M, Gao H, An N, Yi C, Cao D.
    • J Transl Med. 2021 Jul 12;19(1):301. doi: 10.1186/s12967-021-02972-6.
    • Dose-dependent effects of aerobic exercise on clinically relevant biomarkers among healthy women at high genetic risk for breast cancer: A secondary analysis of a randomized controlled study.
    • Ehret CJ, Zhou S, Tchou JC, Schmitz KH, Sturgeon KM.
    • Cancer Rep (Hoboken). 2021 Jul 9:e1497. doi: 10.1002/cnr2.1497. Epub ahead of print.
    • Interactions of BRCA1-mutated Breast Cancer Cell Lines with Adipose-derived Stromal Cells (ADSCs).
    • Plangger A, Haslik W, Rath B, Neumayer C, Hamilton G.
    • J Mammary Gland Biol Neoplasia. 2021 Jul 6. doi: 10.1007/s10911-021-09493-4. Epub ahead of print.
    • Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies.
    • Cunnea P, Fotopoulou C, Ploski J, Trillsch F, Mahner S, Kessler M.
    • Cancers (Basel). 2021 Jul 3;13(13):3349. doi: 10.3390/cancers13133349.
    • Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging.
    • Krug KB, Burke CJ, Weiss K, Baltzer PAT, Rhiem K, Maintz D, Schlamann M, Hellmich M.
    • Eur Radiol. 2021 Jul 3. doi: 10.1007/s00330-021-08069-4. Epub ahead of print.
    • Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer.
    • Dameri M, Ferrando L, Cirmena G, Vernieri C, Pruneri G, Ballestrero A, Zoppoli G.
    • Int J Mol Sci. 2021 Jul 1;22(13):7154. doi: 10.3390/ijms22137154.
    • Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer.
    • Ma D, Chen SY, Ren JX, Pei YC, Jiang CW, Zhao S, Xiao Y, Xu XE, Liu GY, Hu X, Liang XZ, Yu KD, Li DQ, Jiang YZ, Shao ZM.
    • J Natl Cancer Inst. 2021 Jul 1;113(7):884-892. doi: 10.1093/jnci/djaa175. Erratum in: J Natl Cancer Inst. 2021 Aug 17.
    • Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer.
    • Gonda K, Horita S, Maejima Y, Takenoshita S, Shimomura K.
    • Sci Prog. 2021 Jul-Sep;104(3):368504211039590. doi: 10.1177/00368504211039590.
    • DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations.
    • Yang M, Fan Y, Wu ZY, Gu J, Feng Z, Zhang Q, Han S, Zhang Z, Li X, Hsueh YC, Ni Y, Li X, Li J, Hu M, Li W, Gao H, Yang C, Zhang C, Zhang L, Zhu T, Cheng M, Ji F, Xu J, Cui H, Tan G, Zhang MQ, Liang C, Liu Z, Song YQ, Niu G, Wang K.
    • EBioMedicine. 2021 Jul;69:103446. doi: 10.1016/j.ebiom.2021.103446. Epub 2021 Jun 19.
    • BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
    • Royfman R, Whiteley E, Noe O, Morand S, Creeden J, Stanbery L, Hamouda D, Nemunaitis J.
    • Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.
    • Review
    • Ovarian metastasis from breast cancer mimicking a primary ovarian neoplasm: A case report.
    • Akizawa Y, Kanno T, Horibe Y, Shimizu Y, Noguchi E, Yamamoto T, Okamoto T, Nagashima Y, Tabata T.
    • Mol Clin Oncol. 2021 Jul;15(1):135. doi: 10.3892/mco.2021.2297. Epub 2021 May 17. PMID: 34055350; PMCID: PMC8145603.
    • Defizienz der homologen Rekombinationsreparatur als prädiktiver Marker : Grundlagen und Nachweis [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
    • Pfarr N, Merkelbach-Bruse S.
    • Pathologe. 2021 Jul;42(4):391-398. German. doi: 10.1007/s00292-021-00950-9. Epub 2021 Jun 21.
    • Review, Article in German
    • Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
    • Kim SH, Kang CM.
    • Ann Hepatobiliary Pancreat Surg. 2021 Jun 30;25(Suppl 1):S149. doi: 10.14701/ahbps.BP-PP-1-2.
    • Circulating tumor DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    • Zhao J, Sun G, Zhu S, Dai J, Chen J, Zhang M, Ni Y, Zhang H, Shen P, Zhao X, Zhang B, Pan X, Nie L, Yin X, Liang J, Zhang X, Wang Z, Zhu X, Liao B, Liu Z, Armstrong CM, Gao AC, Huang H, Chen N, Zeng H.
    • BJU Int. 2021 Jun 29. doi: 10.1111/bju.15530. Epub ahead of print.
    • RASSF1A Suppression as a Potential Regulator of Mechano-Pathobiology Associated with Mammographic Density in BRCA Mutation Carriers.
    • Reye G, Huang X, Britt KL, Meinert C, Blick T, Xu Y, Momot KI, Lloyd T, Northey JJ, Thompson EW, Hugo HJ.
    • Cancers (Basel). 2021 Jun 29;13(13):3251. doi: 10.3390/cancers13133251.
    • Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    • Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Jonkers J, Johnson N, Turchi JJ, Rothenberg E, Cantor SB.
    • Mol Cell. 2021 Jun 26:S1097-2765(21)00458-5. doi: 10.1016/j.molcel.2021.06.011. Epub ahead of print.
    • BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer.
    • Pilyugin M, Ratajska M, Stukan M, Concin N, Zeillinger R, Irminger-Finger I.
    • Genes (Basel). 2021 Jun 25;12(7):969. doi: 10.3390/genes12070969.
    • Assessing Genetic Variants in Matched Biocompartments From Patients With Serous Ovarian Cancer.
    • Sanders BE, Ku L, Walker P, Bitler BG.
    • Technol Cancer Res Treat. 2021 Jan-Dec [First Published June 25, 2021.];20:15330338211027917. doi: 10.1177/15330338211027917.
    • A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
    • Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ.
    • Clin Cancer Res. 2021 Jun 24:clincanres.0121.2021. doi: 10.1158/1078-0432.CCR-21-0121. Epub ahead of print.
    • Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
    • Liao Y, Badmann S, Kaltofen T, Mayr D, Schmoeckel E, Deuster E, Mannewitz M, Landgrebe S, Kolben T, Hester A, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B.
    • Biomedicines. 2021 Jun 22;9(7):706. doi: 10.3390/biomedicines9070706.
    • Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.
    • Uddin MH, Li Y, Khan HY, Muqbil I, Aboukameel A, Sexton RE, Reddy S, Landesman Y, Kashyap T, Azmi AS, Heath EI.
    • Int J Mol Sci. 2021 Jun 22;22(13):6676. doi: 10.3390/ijms22136676.
    • Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    • Darelius A, Kristjansdottir B, Dahm-Kähler P, Strandell A.
    • Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714. Epub ahead of print.
    • Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer.
    • Chappell K, Manna K, Washam CL, Graw S, Alkam D, Thompson MD, Zafar MK, Hazeslip L, Randolph C, Gies A, Bird JT, Byrd AK, Miah S, Byrum SD.
    • Mol Omics. 2021 Jun 18. doi: 10.1039/d1mo00117e. Epub ahead of print.
    • Breast specific molecular clocks comprised of ELF5 expression and promoter methylation identify individuals susceptible to cancer initiation.
    • Miyano M, Sayaman RW, Shalabi SF, Senapati P, Lopez JC, Angarola BL, Hinz S, Zirbes A, Anczukow O, Yee LD, Sedrak MS, Stampfer MR, Seewaldt VL, LaBarge MA.
    • Cancer Prev Res (Phila). 2021 Jun 17:canprevres.CAPR-20-0635-A.2020. doi: 10.1158/1940-6207.CAPR-20-0635. Epub ahead of print.
    • Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis.
    • Shen J, Liu T, Bei Q, Xu S.
    • Front Oncol. 2021 Jun 17;11:685065. doi: 10.3389/fonc.2021.685065.
    • Relevance of Platinum-Free Interval and BRCA Reversion Mutations for Veliparib Monotherapy After Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
    • Puhalla SL, Diéras V, Arun BK, Kaufman B, Wildiers H, Han HS, Ayoub JP, Stearns V, Yuan Y, Helsten T, Riley-Gillis B, Murphy E, Kundu MG, Wu M, Maag D, Ratajczak CK, Ramathal CY, Friedlander M.
    • Clin Cancer Res. 2021 Jun 15:clincanres.0748.2021. doi: 10.1158/1078-0432.CCR-21-0748. Epub ahead of print.
    • Association between Predicted Effects of TP53 Missense Variants on Protein Conformation and Their Phenotypic Presentation as Li-Fraumeni Syndrome or Hereditary Breast Cancer.
    • Liu Y, Axell O, van Leeuwen T, Konrat R, Kharaziha P, Larsson C, Wright APH, Bajalica-Lagercrantz S.
    • Int J Mol Sci. 2021 Jun 14;22(12):6345. doi: 10.3390/ijms22126345.
    • Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?
    • Orhan E, Velazquez C, Tabet I, Sardet C, Theillet C.
    • Cancers (Basel). 2021 Jun 11;13(12):2930. doi: 10.3390/cancers13122930.
    • Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer.
    • Woodward ER, van Veen EM, Forde C, Harkness EF, Byers HJ, Ellingford JM, Burghel GJ, Schlech H, Bowers NL, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ, Gareth Evans D.
    • Genet Med. 2021 Jun 10. doi: 10.1038/s41436-021-01234-6. Epub ahead of print.
    • PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.
    • Li X, Fang T, Xu S, Jin P, Zhou D, Wang Z, Li H, Yang Z, Chen G, Zheng X, Xia Y, Wei X, Zhang Z, Yang X, Wang Y, Gao Q.
    • NPJ Precis Oncol. 2021 Jun 9;5(1):49. doi: 10.1038/s41698-021-00189-w.
    • Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
    • Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA.
    • Ann Oncol. 2021 Jun 8:S0923-7534(21)02047-0. doi: 10.1016/j.annonc.2021.06.002. Epub ahead of print.
    • RAD51D Aberrant Splicing in Breast Cancer: Identification of Splicing Regulatory Elements and Minigene-Based Evaluation of 53 DNA Variants.
    • Bueno-Martínez E, Sanoguera-Miralles L, Valenzuela-Palomo A, Lorca V, Gómez-Sanz A, Carvalho S, Allen J, Infante M, Pérez-Segura P, Lázaro C, Easton DF, Devilee P, Vreeswijk MPG, de la Hoya M, Velasco EA.
    • Cancers (Basel). 2021 Jun 7;13(11):2845. doi: 10.3390/cancers13112845.
    • Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations.
    • Kim KH, Kim HS, Kim SS, Shim HS, Yang AJ, Lee JJB, Yoon HI, Ahn JB, Chang JS.
    • Cancer Res Treat. 2021 Jun 4. doi: 10.4143/crt.2020.1247. Epub ahead of print.
    • Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
    • Sokolenko AP, Gorodnova TV, Bizin IV, Kuligina ES, Kotiv KB, Romanko AA, Ermachenkova TI, Ivantsov AO, Preobrazhenskaya EV, Sokolova TN, Broyde RV, Imyanitov EN.
    • Cancer Chemother Pharmacol. 2021 Jun 2. doi: 10.1007/s00280-021-04301-6. Epub ahead of print.
    • Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer.
    • Graf RP, Eskander R, Brueggeman L, Stupack DG.
    • JAMA Netw Open. 2021 Jun 1;4(6):e2114162. doi: 10.1001/jamanetworkopen.2021.14162. Erratum in: JAMA Netw Open. 2021 Aug 2;4(8):e2125709.
    • BRCA1-BRCT Mutations Alter the Subcellular Localization of BRCA1 In Vitro.
    • Drikos I, Boutou E, Kastritis PL, Vorgias CE.
    • Anticancer Res. 2021 Jun;41(6):2953-2962. doi: 10.21873/anticanres.15077.
    • The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer.
    • Coletta AM, Agha NH, Baker FL, Niemiro GM, Mylabathula PL, Brewster AM, Bevers TB, Fuentes-Mattei E, Basen-Engquist K, Gilchrist SC, Simpson RJ.
    • Breast Cancer Res Treat. 2021 Jun;187(2):407-416. doi: 10.1007/s10549-021-06111-z. Epub 2021 Feb 8.

    Identifier: NCT02923401: High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer. (ClinicalTrials.gov)

    • Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
    • Zhong Q, Xiong Y, Ling C, Qian Y, Zhao X, Yang H.
    • Exp Biol Med (Maywood). 2021 Jun;246(11):1297-1306. doi: 10.1177/1535370221994077.
    • Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    • Zhang X, Devins K, Ko EM, Reyes MC, Simpkins F, Drapkin R, Schwartz LE, Yoon JY.
    • Gynecol Oncol. 2021 Jun;161(3):762-768. doi: 10.1016/j.ygyno.2021.03.019. Epub 2021 Mar 24.
    • DNA methylation variations in familial female and male breast cancer.
    • Abeni E, Grossi I, Marchina E, Coniglio A, Incardona P, Cavalli P, Zorzi F, Chiodera PL, Paties CT, Crosatti M, De Petro G, Salvi A.
    • Oncol Lett. 2021 Jun;21(6):468. doi: 10.3892/ol.2021.12729. Epub 2021 Apr 12.
    • Micronuclei and upper body cancers (head, neck, breast cancers) a systematic review and meta-analysis.
    • Bolognesi C, Bruzzone M, Ceppi M, Marcon F.
    • Mutat Res. 2021 Jan-Jun;787:108358. doi: 10.1016/j.mrrev.2020.108358. Epub 2020 Nov 28.
    • Detecting Variants in the NBN Gene While Testing for Hereditary Breast Cancer: What to Do Next?
    • Zuntini R, Bonora E, Pradella LM, Amato LB, Vidone M, De Fanti S, Catucci I, Cortesi L, Medici V, Ferrari S, Gasparre G, Peterlongo P, Sazzini M, Turchetti D.
    • Int J Mol Sci. 2021 May 29;22(11):5832. doi: 10.3390/ijms22115832.
    • Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
    • Jiang X, Hu X, Gu Y, Li Y, Jin M, Zhao H, Gao R, Huang Z, Lu J.
    • Pathol Res Pract. 2021 May 29;224:153507. doi: 10.1016/j.prp.2021.153507. Epub ahead of print.
    • Breast cancer type 1 and neurodegeneration: consequences of deficient DNA repair.
    • Leung E, Hazrati LN.
    • Brain Commun. 2021 May 27;3(2):fcab117. doi: 10.1093/braincomms/fcab117.
    • Pathology of Breast Cancer Metastasis and A View of Metastasis to The Brain.
    • Sakibuzzaman M, Mahmud S, Afroze T, Fathma S, Zakia UB, Afroz S, Zafar F, Hossain M, Barua A, Akter S, Chowdhury HI, Ahsan E, Eshan SH, Fariza TT.
    • Int J Neurosci. 2021 May 27:1-18. doi: 10.1080/00207454.2021.1935929. Epub ahead of print.
    • Review
    • NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer.
    • Marchetti C, D'Indinosante M, Bottoni C, Di Ilio C, Di Berardino S, Costantini B, Minucci A, Vertechy L, Scambia G, Fagotti A.
    • Sci Rep. 2021 May 27;11(1):11125. doi: 10.1038/s41598-021-90361-w.
    • Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity.
    • Phung TN, Webster TH, Lenkiewicz E, Malasi S, Andreozzi M, McCullough AE, Anderson KS, Pockaj BA, Wilson MA, Barrett MT.
    • Sci Rep. 2021 May 19;11(1):10571. doi: 10.1038/s41598-021-90170-1.
    • Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and Ovarian).
    • Evrard C, Alexandre J.
    • Cancers (Basel). 2021 May 18;13(10):2434. doi: 10.3390/cancers13102434.
    • Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers.
    • Hu L, Su L, Cheng H, Mo C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Zhang J, Xie Y.
    • Cancer Res. 2021 May 15;81(10):2600-2611. doi: 10.1158/0008-5472.CAN-20-2123. Epub 2021 Mar 16.
    • Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 May 15;81(10):2774-2787. doi: 10.1158/0008-5472.CAN-20-2912. Epub 2021 Jan 29.
    • MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer.
    • Bååth M, Jönsson JM, Westbom Fremer S, Martín de la Fuente L, Tran L, Malander S, Kannisto P, Måsbäck A, Honeth G, Hedenfalk I.
    • Genes (Basel). 2021 May 14;12(5):742. doi: 10.3390/genes12050742.
    • Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
    • Dong B, Fan L, Yang B, Chen W, Li Y, Wu K, Zhang F, Dong H, Cheng H, Pan J, Zhu Y, Chi C, Dong L, Sha J, Li L, Yao X, Xue W.
    • J Natl Compr Canc Netw. 2021 May 14;19(8):905-914. doi: 10.6004/jnccn.2020.7663.
    • The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis.
    • Gráf A, Enyedi MZ, Pintér L, Kriston-Pál É, Jaksa G, Bálind Á, Ezer É, Horváth P, Sükösd F, Kiss E, Haracska L.
    • Cancers (Basel). 2021 May 13;13(10):2354. doi: 10.3390/cancers13102354.
    • Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects.
    • Li N, Zethoven M, McInerny S, Devereux L, Huang YK, Thio N, Cheasley D, Gutiérrez-Enríquez S, Moles-Fernández A, Diez O, Nguyen-Dumont T, Southey MC, Hopper JL, Simard J, Dumont M, Soucy P, Meindl A, Schmutzler R, Schmidt MK, Adank MA, Andrulis IL, Hahnen E, Engel C, Lesueur F, Girard E, Neuhausen SL, Ziv E, Allen J, Easton DF, Scott RJ, Gorringe KL, James PA, Campbell IG.
    • NPJ Breast Cancer. 2021 May 12;7(1):52. doi: 10.1038/s41523-021-00255-3.
    • Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers.
    • Ahn HS, Ho JY, Yu J, Yeom J, Lee S, Hur SY, Jung Y, Kim K, Choi YJ.
    • Cancers (Basel). 2021 May 11;13(10):2300. doi: 10.3390/cancers13102300.
    • C/EBPß promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    • Tan J, Zheng X, Li M, Ye F, Song C, Xu C, Zhang X, Li W, Wang Y, Zeng S, Li H, Chen G, Huang X, Ma D, Liu D, Gao Q.
    • Oncogene. 2021 May 8. doi: 10.1038/s41388-021-01788-4. Epub ahead of print.
    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
    • A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast.
    • Pal B, Chen Y, Vaillant F, Capaldo BD, Joyce R, Song X, Bryant VL, Penington JS, Di Stefano L, Tubau Ribera N, Wilcox S, Mann GB; kConFab, Papenfuss AT, Lindeman GJ, Smyth GK, Visvader JE.
    • EMBO J. 2021 May 5:e107333. doi: 10.15252/embj.2020107333. Epub ahead of print.
    • Lynch Syndrome in Thai Endometrial Cancer Patients.
    • Manchana T, Ariyasriwatana C, Triratanachat S, Phowthongkum P.
    • Asian Pac J Cancer Prev. 2021 May 1;22(5):1477-1483. doi: 10.31557/APJCP.2021.22.5.1477.
    • Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers.
    • Depypere H, Su Y, Dang N, Poppe B, Stanczyk F, Janssens J, Russo J.
    • Eur J Cancer Prev. 2021 May 1;30(3):195-203. doi: 10.1097/CEJ.0000000000000664.
    • The diverse metabolic heterogeneity of stem cells in a BRCA+/-breast cancer population.
    • Gramatiuk SM, Bagmut IY, Sheremet MI, Maksymyuk VV, Tarabanchuk VV, Moroz PV.
    • J Med Life. 2021 May-Jun;14(3):331-336. doi: 10.25122/jml-2020-0105.
    • [Germline and Somatic Mutations in Archived Breast Cancer Specimens of Different Subtypes].
    • Abramov IS, Korneva YS, Shisterova OA, Ikonnikova AY, Emelyanova MA, Lisitsa TS, Krasnov GS, Nasedkina TV.
    • Mol Biol (Mosk). 2021 May-Jun;55(3):412-421. Russian. doi: 10.31857/S0026898421030022.
    • [Article in Russian]
    • Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    • Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Andrews Wright N, Rath P, Torchia J, Fortuna A, Jones GN, Roudier MP, Bernard L, Lo B, Torti D, Leon A, Marsh K, Hodgson D, Duciaume M, Howat WJ, Lukashchuk N, Lazic SE, Whelan D, Sekhon HS.
    • Cancer Med. 2021 May;10(9):3045-3058. doi: 10.1002/cam4.3831. Epub 2021 Apr 3.
    • Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    • Filippova OT, Selenica P, Pareja F, Vahdatinia M, Zhu Y, Pei X, Riaz N, Long Roche K, Chi DS, Abu-Rustum NR, Ellenson LH, Reis-Filho JS, Zamarin D, Weigelt B.
    • Gynecol Oncol. 2021 May;161(2):545-552. doi: 10.1016/j.ygyno.2021.02.028. Epub 2021 Mar 3.
    • Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series.
    • Kasherman L, Garg S, Tchrakian N, Clarke B, Karakasis K, Kim RH, Stockley TL, Dhani N, Oza AM, Lheureux S.
    • Gynecol Oncol Rep. 2021 Feb 12;36:100729. doi: 10.1016/j.gore.2021.100729. eCollection 2021 May.
    • Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer.
    • Yuan Y, Xiao WW, Xie WH, Li RZ, Gao YH.
    • BMC Cancer. 2021 Apr 30;21(1):479. doi: 10.1186/s12885-021-08234-4.
    • Genomic Correlates of DNA Damage in Breast Cancer Subtypes.
    • Cabañas Morafraile E, Pérez-Peña J, Fuentes-Antrás J, Manzano A, Pérez-Segura P, Pandiella A, Galán-Moya EM, Ocaña A.
    • Cancers (Basel). 2021 Apr 27;13(9):2117. doi: 10.3390/cancers13092117.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 24;13(9):2057. doi: 10.3390/cancers13092057.
    • Functional Genomic Analyses of the 21q22.3 Locus Identifying Functional Variants and Candidate Gene YBEY for Breast Cancer Risk.
    • Shidal C, Shu X, Wu J, Wang J, Huang S, Long J, Bauer JA, Ping J, Guo X, Zheng W, Shu XO, Cai Q.
    • Cancers (Basel). 2021 Apr 23;13(9):2037. doi: 10.3390/cancers13092037.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 23;13(9):2042. doi: 10.3390/cancers13092042.
    • Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.
    • Otsuka I.
    • Int J Mol Sci. 2021 Apr 23;22(9):4409. doi: 10.3390/ijms22094409.
    • Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.
    • Turan V, Lambertini M, Lee DY, Wang E, Clatot F, Karlan BY, Demeestere I, Bang H, Oktay K.
    • J Clin Oncol. 2021 Apr 23:JCO2002880. doi: 10.1200/JCO.20.02880. Epub ahead of print.
    • Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses.
    • Ng PS, Pan JW, Ahmad Zabidi MM, Rajadurai P, Yip CH, Reuda OM, Dunning AM, Antoniou AC, Easton DF, Caldas C, Chin SF, Teo SH.
    • NPJ Breast Cancer. 2021 Apr 23;7(1):46. doi: 10.1038/s41523-021-00254-4.
    • Comments on "Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns".
    • Brane A, Behring M, Halilova KI, Norian L.
    • Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33605. Epub ahead of print.
    • Letter, Commentary

    Original research:

    Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns.

    • Age-related activity of Poly (ADP-ribose) polymerase (PARP) in men with localized prostate cancer.
    • Deniz M, Zengerling F, Gundelach T, Moreno-Villanueva M, Bürkle A, Janni W, Bolenz C, Kostezka S, Marienfeld R, Benckendorff J, Friedl TWP, Wiesmüller L, Rall-Scharpf M.
    • Mech Ageing Dev. 2021 Apr 19:111494. doi: 10.1016/j.mad.2021.111494. Epub ahead of print.
    • DNA damage response and repair in pancreatic cancer development and therapy.
    • Rahnamay Farnood P, Danesh Pazhooh R, Asemi Z, Yousefi B.
    • DNA Repair (Amst). 2021 Apr 15;103:103116. doi: 10.1016/j.dnarep.2021.103116. Epub ahead of print.
    • Review
    • What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors.
    • De Leo A, Santini D, Ceccarelli C, Santandrea G, Palicelli A, Acquaviva G, Chiarucci F, Rosini F, Ravegnini G, Pession A, Turchetti D, Zamagni C, Perrone AM, De Iaco P, Tallini G, de Biase D.
    • Diagnostics (Basel). 2021 Apr 14;11(4):697. doi: 10.3390/diagnostics11040697.
    • A new interaction between BRCA2 and DDX5 promotes the repair of DNA breaks at transcribed chromatin.
    • Gómez-González B, Sessa G, Carreira A, Aguilera A.
    • Mol Cell Oncol. 2021 Apr 14;8(3):1910474. doi: 10.1080/23723556.2021.1910474.
    • Commentary
    • Current update on the molecular genetics and management of hereditary ovarian cancers: a primer for radiologists.
    • Itani M, Lalwani N, Ganeshan D, Zulfiqar M, Siegel C.
    • Abdom Radiol (NY). 2021 Apr 13. doi: 10.1007/s00261-020-02911-x. Epub ahead of print.
    • Review
    • Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.
    • Guo T, Dong X, Xie S, Zhang L, Zeng P, Zhang L.
    • Cancer Manag Res. 2021 Apr 8;13:3081-3100. doi: 10.2147/CMAR.S292992.
    • Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.
    • Takahashi K, Takenaka M, Okamoto A, Bowtell DDL, Kohno T.
    • Cancers (Basel). 2021 Apr 7;13(8):1769. doi: 10.3390/cancers13081769.
    • Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence.
    • Penkert J, Märtens A, Seifert M, Auber B, Derlin K, Hille-Betz U, Hörmann P, Klopp N, Prokein J, Schlicker L, Wacker F, Wallaschek H, Schlegelberger B, Hiller K, Ripperger T, Illig T.
    • Front Oncol. 2021 Apr 7;11:627217. doi: 10.3389/fonc.2021.627217.
    • Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer.
    • Zeng B, Huang P, Du P, Sun X, Huang X, Fang X, Li L.
    • Front Oncol. 2021 Apr 6;11:637431. doi: 10.3389/fonc.2021.637431.
    • The dystonia gene THAP1 controls DNA double-strand break repair choice.
    • Shinoda K, Zong D, Callen E, Wu W, Dumitrache LC, Belinky F, Chari R, Wong N, Ishikawa M, Stanlie A, Multhaupt-Buell T, Sharma N, Ozelius L, Ehrlich M, McKinnon PJ, Nussenzweig A.
    • Mol Cell. 2021 Apr 6:S1097-2765(21)00229-X. doi: 10.1016/j.molcel.2021.03.034. Epub ahead of print.
    • Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
    • Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K.
    • Cancers (Basel). 2021 Apr 1;13(7):1656. doi: 10.3390/cancers13071656.
    • Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation?
    • Fresa A, Sica S.
    • Hered Cancer Clin Pract. 2021 Apr 1;19(1):22. doi: 10.1186/s13053-021-00179-w.
    • Clinico-radio-pathological Features and Biological Behavior of Breast Cancer in Young Indian Women: A Prospective Study.
    • Sudhir R, Sannapareddy K, Potlapalli A, Penmetsa V.
    • Indian J Radiol Imaging. 2021 Apr;31(2):323-332. doi: 10.1055/s-0041-1734342. Epub 2021 Jul 30.
    • Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival.
    • Earl J, Barreto E, Castillo ME, Fuentes R, Rodríguez-Garrote M, Ferreiro R, Reguera P, Muñoz G, Garcia-Seisdedos D, López JV, Sainz B Jr, Malats N, Carrato A.
    • Cancers (Basel). 2021 Mar 31;13(7):1612. doi: 10.3390/cancers13071612. Erratum in: Cancers (Basel). 2021 Jul 22;13(15):3687.
    • Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients.
    • Barakeh DH, Aljelaify R, Bashawri Y, Almutairi A, Alqubaishi F, Alnamnakani M, Almubarak L, Al Naeem A, Almushawah F, Alrashed M, Abedalthagafi M.
    • Oncotarget. 2021 Mar 30;12(7):686-697. doi: 10.18632/oncotarget.27909.
    • Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair.
    • Chaudhry SR, Lopes J, Levin NK, Kalpage H, Tainsky MA.
    • Cell Death Discov. 2021 Mar 29;7(1):62. doi: 10.1038/s41420-021-00442-y.
    • Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer.
    • Zhou C, Porter N, Borges M, Gauthier C, Ferguson L, Huang B, Nanda N, He J, Laheru D, Hruban RH, Goggins M, Klein AP, Roberts NJ.
    • Pancreatology. 2021 Mar 28:S1424-3903(21)00109-5. doi: 10.1016/j.pan.2021.03.015. Epub ahead of print.
    • Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey.
    • Özdemir K, Gürkan H, Demir S, Atli E, Özen Y, Sezer A, Tunçbilek N, Çicin I.
    • Balkan J Med Genet. 2021 Mar 23;23(2):49-58. doi: 10.2478/bjmg-2020-0016. eCollection 2020 Nov.
    • SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
    • Pang JB, Castles B, Byrne DJ, Button P, Hendry S, Lakhani SR, Sivasubramaniam V, Cooper WA, Armes J, Millar EKA, Raymond W, Roberts-Thomson S, Kumar B, Burr M, Selinger C, Harvey K, Chan C, Beith J, Clouston D, O'Toole SA, Fox SB; kConFab.
    • Am J Surg Pathol. 2021 Mar 22. doi: 10.1097/PAS.0000000000001701. Epub ahead of print.
    • The Role of Exosomes in Breast Cancer Diagnosis.
    • Piombino C, Mastrolia I, Omarini C, Candini O, Dominici M, Piacentini F, Toss A.
    • Biomedicines. 2021 Mar 18;9(3):312. doi: 10.3390/biomedicines9030312.
    • Serum Selenium Level Predicts 10-Year Survival after Breast Cancer.
    • Szwiec M, Marciniak W, Derkacz R, Huzarski T, Gronwald J, Cybulski C, Debniak T, Jakubowska A, Lener M, Falco M, Kladny J, Baszuk P, Duszynski J, Kotsopoulos J, Narod SA, Lubinski J.
    • Nutrients. 2021 Mar 16;13(3):953. doi: 10.3390/nu13030953.
    • E2F1 copy number variations in germline and breast cancer: a retrospective study of 222 Italian women.
    • Rocca MS, Benna C, Goldin E, Di Nisio A, De Toni L, Cosci I, Marchet A, Nitti D, Foresta C.
    • Mol Med. 2021 Mar 10;27(1):26. doi: 10.1186/s10020-021-00287-2.
    • Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.
    • Ren XY, Song Y, Wang J, Chen LY, Pang JY, Zhou LR, Shen SJ, Cao X, Wang YX, Shao MM, Liang ZY, Sun Q, Wu HW.
    • Front Oncol. 2021 Mar 4;11:570623. doi: 10.3389/fonc.2021.570623.

    Commentary:

    Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.

    • Replication Gaps Underlie BRCA Deficiency and Therapy Response.
    • Panzarino NJ, Krais JJ, Cong K, Peng M, Mosqueda M, Nayak SU, Bond SM, Calvo JA, Doshi MB, Bere M, Ou J, Deng B, Zhu LJ, Johnson N, Cantor SB.
    • Cancer Res. 2021 Mar 1;81(5):1388-1397. doi: 10.1158/0008-5472.CAN-20-1602. Epub 2020 Nov 12.

    Commentary:

    Which Holds the Key to BRCAness: Inability to Repair the Break, Protect the Fork, or Prevent the Gap?

    • Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations.
    • Iyengar NM, Zhou XK, Mendieta H, El-Hely O, Giri DD, Winston L, Falcone DJ, Wang H, Meng L, Ha T, Pollak M, Morrow M, Dannenberg AJ.
    • NPJ Breast Cancer. 2021 Mar 1;7(1):18. doi: 10.1038/s41523-021-00226-8.
    • Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients.
    • Ji G, Yao Q, Bao L, Zhang J, Bai Q, Zhu X, Tu X, Bi R, Zhou X.
    • Ann Transl Med. 2021 Mar;9(6):453. doi: 10.21037/atm-20-6827.
    • Variant in BCAR4 gene correlated with the breast cancer susceptibility and mRNA expression of lncRNA BCAR4 in Chinese Han population.
    • Peng R, Cao J, Guo Q, Sun Q, Xu L, Xie X, Song C.
    • Breast Cancer. 2021 Mar;28(2):424-433. doi: 10.1007/s12282-020-01174-0. Epub 2020 Oct 28.
    • LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
    • Chen L, Hou J, Zeng X, Guo Q, Deng M, Kloeber JA, Tu X, Zhao F, Wu Z, Huang J, Luo K, Kim W, Lou Z.
    • Clin Transl Med. 2021 Mar;11(3):e341. doi: 10.1002/ctm2.341.
    • Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    • Boerner T, Walch HS, Nguyen B, Iasonos A, Zhou QC, Schultz N, Chui MH, Grisham RN, Tew WP, O'Cearbhaill RE, Aghajanian C, Zivanovic O, Abu-Rustum NR, Gardner GJ, Sonoda Y, Chi DS, Long Roche K.
    • Gynecol Oncol. 2021 Mar;160(3):696-703. doi: 10.1016/j.ygyno.2020.12.022. Epub 2020 Dec 30.
    • Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    • Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, Garcia RL, Lee M, Katz R, Leslie KK, Risques RA, Swisher EM.
    • Gynecol Oncol. 2021 Mar;160(3):786-792. doi: 10.1016/j.ygyno.2020.12.007. Epub 2020 Dec 26.
    • Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients.
    • Lu HY, Tai YJ, Chen YL, Chiang YC, Hsu HC, Cheng WF.
    • J Gynecol Oncol. 2021 Mar;32(2):e18. doi: 10.3802/jgo.2021.32.e18. Epub 2020 Dec 3.
    • Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
    • Morizono A, Tanabe M, Ikemura M, Sasaki T, Ushiku T, Seto Y.
    • J Hum Genet. 2021 Feb 27. doi: 10.1038/s10038-021-00911-3. Epub ahead of print.
    • Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
    • How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS.
    • Cancers (Basel). 2021 Feb 24;13(5):946. doi: 10.3390/cancers13050946.
    • Lifestyle, behavioral, and dietary risk factors in relation to mammographic breast density in women at high risk for breast cancer.
    • Ahern TP, Sprague BL, Farina NH, Tsai E, Cuke M, Kontos D, Wood ME.
    • Cancer Epidemiol Biomarkers Prev. 2021 Feb 22:cebp.1567.2020. doi: 10.1158/1055-9965.EPI-20-1567. Epub ahead of print.
    • Longitudinal and multi-tissue molecular diagnostics track somatic BRCA2 reversion mutations that correct the open reading frame of germline alteration upon clinical relapse.
    • Sorrells S, McKinnon KE, McBratney A, Sumey C.
    • NPJ Genom Med. 2021 Feb 22;6(1):17. doi: 10.1038/s41525-021-00181-0.
    • Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
    • Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E.
    • Eur J Cancer. 2021 Feb 21;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub ahead of print.
    • BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
    • Salwa A, Ferraresi A, Chinthakindi M, Vallino L, Vidoni C, Dhanasekaran DN, Isidoro C.
    • Biomedicines. 2021 Feb 18;9(2):207. doi: 10.3390/biomedicines9020207.
    • Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns.
    • Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Borg Å, Vallon-Christersson J, Hall P, Czene K.
    • Int J Cancer. 2021 Feb 15;148(4):884-894. doi: 10.1002/ijc.33270. Epub 2020 Sep 5.

    Letter, Commentary:

    Comments on "Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns".

    • Clinicopathological Correlates of ?d T Cell Infiltration in Triple-Negative Breast Cancer.
    • Boissière-Michot F, Chabab G, Mollevi C, Guiu S, Lopez-Crapez E, Ramos J, Bonnefoy N, Lafont V, Jacot W.
    • Cancers (Basel). 2021 Feb 12;13(4):765. doi: 10.3390/cancers13040765.
    • The Rare Diagnosis of Synchronous Breast and Colonic Cancers: A Case Report and Review of Literature.
    • Asaad A, Barron M, Rasheed N, Idaewor P, Saad Abdalla Al-Zawi A.
    • Cureus. 2021 Feb 12;13(2):e13314. doi: 10.7759/cureus.13314.
    • Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
    • Chen MK.
    • FEBS J. 2021 Feb 11. doi: 10.1111/febs.15730. Epub ahead of print.
    • Commentary
    • Molecular analyses of triple-negative breast cancer in the young and elderly.
    • Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Campos AB, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Staaf J.
    • Breast Cancer Res. 2021 Feb 10;23(1):20. doi: 10.1186/s13058-021-01392-0.
    • Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
    • Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons A, Loehr A, Venstrom JM, Oxnard GR.
    • Clin Cancer Res. 2021 Feb 8. doi: 10.1158/1078-0432.CCR-20-4805. Epub ahead of print.

    Commentary, Review:

    Liquid Biopsy: It's the Bloody Truth!

    • Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers.
    • Grill S, Yahiaoui-Doktor M, Basrai M, Struck J, Schulte J, Berling-Ernst A, Engel C, Ullrich M, Lammert J, Bischoff SC, Schmidt T, Niederberger U, Chronas D, Rhiem K, Schmutzler R, Halle M, Kiechle M.
    • Breast Cancer Res Treat. 2021 Feb 4. doi: 10.1007/s10549-020-06070-x. Epub ahead of print.
    • RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.
    • Patel PS, Abraham KJ, Guturi KKN, Halaby MJ, Khan Z, Palomero L, Ho B, Duan S, St-Germain J, Algouneh A, Mateo F, El Ghamrasni S, Barbour H, Barnes DR, Beesley J, Sanchez O, Berman HK, Brown GW, Affar EB, Chenevix-Trench G, Antoniou AC, Arrowsmith CH, Raught B, Pujana MA, Mekhail K, Hakem A, Hakem R.
    • J Clin Invest. 2021 Feb 1;131(3):e140105. doi: 10.1172/JCI140105.
    • Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    • Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Duc AN, Chui SY, Husain A, Winer EP, Adams S, Schmid P.
    • J Natl Cancer Inst. 2021 Feb 1:djab004. doi: 10.1093/jnci/djab004. Epub ahead of print.
    • Insufficient evidence of endocervical origin in germline BRCA1 and MSH2-associated tumors.
    • Kertowidjojo E, Park KJ, Hodgson A.
    • Tumori. 2021 Feb 1:300891621991674. doi: 10.1177/0300891621991674. Epub ahead of print.
    • Letter
    • Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort.
    • Tsibulak I, Wieser V, Welponer H, Leitner K, Hackl H, Marth C, Fiegl H, Zeimet AG.
    • Acta Oncol. 2021 Feb;60(2):187-190. doi: 10.1080/0284186X.2020.1841288. Epub 2020 Nov 4.
    • A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
    • Huang L, Lang GT, Liu Q, Shi JX, Shao ZM, Cao AY.
    • Ann Transl Med. 2021 Feb;9(4):301. doi: 10.21037/atm-20-4852.
    • Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    • Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, Olmos D.
    • Br J Cancer. 2021 Feb;124(3):552-563. doi: 10.1038/s41416-020-01114-x. Epub 2020 Oct 27.
    • Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
    • Di Leone A, Fragomeni SM, Scardina L, Ionta L, Mulè A, Magno S, Terribile D, Masetti R, Franceschini G.
    • Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):1910-1915. doi: 10.26355/eurrev_202102_25087.
    • Genetically predicted circulating protein biomarkers and ovarian cancer risk.
    • Considine DPC, Jia G, Shu X, Schildkraut JM, Pharoah PDP, Zheng W, Kar SP; Ovarian Cancer Association Consortium.
    • Gynecol Oncol. 2021 Feb;160(2):506-513. doi: 10.1016/j.ygyno.2020.11.016. Epub 2020 Nov 25.
    • BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography.
    • Sobecki JN, Dryer KA, Mahajan AM, Spencer RJ.
    • Gynecol Oncol Rep. 2020 Dec 25;35:100690. doi: 10.1016/j.gore.2020.100690. eCollection 2021 Feb.
    • Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 Jan 29:canres.2912.2020. doi: 10.1158/0008-5472.CAN-20-2912. Epub ahead of print.
    • Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    • Golan T, O'Kane GM, Denroche RE, Raitses-Gurevich M, Grant RC, Holter S, Wang Y, Zhang A, Jang GH, Stossel C, Atias D, Halperin S, Berger R, Glick Y, Patrick Park JY, Cuggia A, Williamson L, Wong HL, Schaeffer DF, Renouf DJ, Borgida A, Dodd A, Wilson JM, Fischer SE, Notta F, Knox JJ, Zogopoulos G, Gallinger S.
    • Gastroenterology. 2021 Jan 29:S0016-5085(21)00326-7. doi: 10.1053/j.gastro.2021.01.220. Epub ahead of print.
    • Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers.
    • Arakelyan A, Melkonyan A, Hakobyan S, Boyarskih U, Simonyan A, Nersisyan L, Nikoghosyan M, Filipenko M, Binder H.
    • Int J Mol Sci. 2021 Jan 28;22(3):1266. doi: 10.3390/ijms22031266.
    • Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer.
    • Elkholi IE, Di Iorio M, Fahiminiya S, Arcand SL, Han H, Nogué C, Behl S, Hamel N, Giroux S, de Ladurantaye M, Aleynikova O, Gotlieb WH, Côté JF, Rousseau F, Tonin PN, Provencher D, MesMasson AM, Akbari MR, Rivera B, Foulkes WD.
    • Sci Rep. 2021 Jan 28;11(1):2409. doi: 10.1038/s41598-021-81106-w.
    • iPSC-Derived Hereditary Breast Cancer Model Reveals the BRCA1-Deleted Tumor Niche as a New Culprit in Disease Progression.
    • Portier L, Desterke C, Chaker D, Oudrhiri N, Asgarova A, Dkhissi F, Turhan AG, Bennaceur-Griscelli A, Griscelli F.
    • Int J Mol Sci. 2021 Jan 27;22(3):1227. doi: 10.3390/ijms22031227.
    • CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
    • Heinze K, Rengsberger M, Gajda M, Jansen L, Osmers L, Oliveira-Ferrer L, Schmalfeldt B, Dürst M, Häfner N, Runnebaum IB.
    • Clin Epigenetics. 2021 Jan 22;13(1):15. doi: 10.1186/s13148-021-01006-8.
    • PDGFRß is an essential therapeutic target for BRCA1-deficient mammary tumors.
    • Bai F, Liu S, Liu X, Hollern DP, Scott A, Wang C, Zhang L, Fan C, Fu L, Perou CM, Zhu WG, Pei XH.
    • Breast Cancer Res. 2021 Jan 21;23(1):10. doi: 10.1186/s13058-021-01387-x.
    • The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
    • Molnár S, Vida B, Beke L, Méhes G, Póka R.
    • Diagnostics (Basel). 2021 Jan 19;11(1):E144. doi: 10.3390/diagnostics11010144.
    • Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing.
    • Liu PF, Zhuo ZL, Xie F, Wang S, Zhao XT.
    • Clin Chim Acta. 2021 Jan 18:S0009-8981(21)00019-X. doi: 10.1016/j.cca.2021.01.010. Epub ahead of print.
    • Homologous recombination deficiency: how genomic signatures are generated.
    • Setton J, Reis-Filho JS, Powell SN.
    • Curr Opin Genet Dev. 2021 Jan 18;66:93-100. doi: 10.1016/j.gde.2021.01.002. Epub ahead of print.
    • Review
    • Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    • Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES.
    • Mod Pathol. 2021 Jan 18. doi: 10.1038/s41379-020-00731-4. Epub ahead of print.
    • A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients.
    • Zhang Y, Shi X, Zhang J, Chen X, Zhang P, Liu A, Zhu T.
    • Sci Rep. 2021 Jan 11;11(1):387. doi: 10.1038/s41598-020-79694-0.
    • Pathogenicity Assessment of Variants for Breast Cancer Susceptibility Genes Based on BRCAness of Tumor Sample.
    • Yoshida R, Hagio T, Kaneyasu T, Gotoh O, Osako T, Tanaka N, Amino S, Yaguchi N, Nakashima E, Kitagawa D, Ueno T, Ohno S, Nakajima T, Nakamura S, Miki Y, Hirota T, Takahashi S, Matsuura M, Noda T, Mori S.
    • Cancer Sci. 2021 Jan 9. doi: 10.1111/cas.14803. Epub ahead of print.
    • Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.
    • Jung Y, Hur S, Liu J, Lee S, Kang BS, Kim M, Choi YJ.
    • J Gynecol Oncol. 2021 Jan 7. doi: 10.3802/jgo.2021.32.e23. Epub ahead of print.

    Editorial, Research review:

    Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.

    • Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    • Moustafa D, Elwahed MRA, Elsaid HH, Parvin JD.
    • PLoS One. 2021 Jan 7;16(1):e0235025. doi: 10.1371/journal.pone.0235025.
    • Reduced translation efficiency due to novel splicing variants in 5' untranslated region and identification of novel cis-regulatory elements in canine and human BRCA2.
    • Yoshikawa Y, Kozuma H, Morimatsu M, Sugawara K, Orino K.
    • BMC Mol Cell Biol. 2021 Jan 6;22(1):2. doi: 10.1186/s12860-020-00336-4.
    • [Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
    • Tsunoda Y, Sasaki A, Sakamoto N, Haruyama Y, Nashimoto M, Koshida Y, Fukuma E.
    • Gan To Kagaku Ryoho. 2021 Jan;48(1):53-56.
    • [Article in Japanese]
    • Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.
    • Natoli M, Gallon J, Lu H, Amgheib A, Pinato DJ, Mauri FA, Marafioti T, Akarca AU, Ullmo I, Ip J, Aboagye EO, Brown R, Karadimitris A, Ghaem-Maghami S.
    • J Immunother Cancer. 2021 Jan;9(1):e001519. doi: 10.1136/jitc-2020-001519.
    • Relationship between MUTYH, OGG1 and BRCA1 mutations and mRNA expression in breast and ovarian cancer predisposition.
    • Moscatello C, Di Nicola M, Veschi S, Di Gregorio P, Cianchetti E, Stuppia L, Battista P, Cama A, Curia MC, Aceto GM.
    • Mol Clin Oncol. 2021 Jan;14(1):15. doi: 10.3892/mco.2020.2177. Epub 2020 Nov 26.
    • PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    • Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R.
    • Mol Med Rep. 2021 Jan;23(1):75. doi: 10.3892/mmr.2020.11713. Epub 2020 Nov 25.
    • Case report
    • DNA Methylation in Ovarian Cancer Susceptibility.
    • Reid BM, Fridley BL.
    • Cancers (Basel). 2020 Dec 31;13(1):108. doi: 10.3390/cancers13010108.
    • Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
    • Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I.
    • J Natl Cancer Inst. 2020 Dec 29:djaa193. doi: 10.1093/jnci/djaa193. Epub ahead of print.
    • Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
    • Hodan R, Kingham K, Cotter K, Folkins AK, Kurian AW, Ford JM, Longacre T.
    • Cancer Med. 2020 Dec 25. doi: 10.1002/cam4.3688. Epub ahead of print.
    • The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.
    • Du ZH, Xia Y, Yang Q, Gao S.
    • Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983289. doi: 10.1177/1533033820983289. [First Published December 24, 2020.]
    • BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    • Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, Sessa F, Tibiletti MG.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9708. doi: 10.3390/ijms21249708.
    • A Mediterranean Dietary Intervention in Female Carriers of BRCA Mutations: Results from an Italian Prospective Randomized Controlled Trial.
    • Bruno E, Oliverio A, Paradiso AV, Daniele A, Tommasi S, Tufaro A, Terribile DA, Magno S, Filippone A, Venturelli E, Morelli D, Baldassari I, Cravana ML, Manoukian S, Pasanisi P.
    • Cancers (Basel). 2020 Dec 11;12(12):3732. doi: 10.3390/cancers12123732.
    • Non-invasive Technology Advances in Cancer-A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers.
    • Openshaw MR, McVeigh TP.
    • Front Digit Health. 2020 Dec 11;2:573010. doi: 10.3389/fdgth.2020.573010.
    • Gilead's Trodelvy Benefits TNBC Patients Regardless of Trop-2 Expression, BRCA1/2 Status.
    • Hopkins C.
    • Precision Oncology News. 2020 Dec 11.
    • Conference news
    • Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Grandal B, Evrevin C, Laas E, Jardin I, Rozette S, Laot L, Dumas E, Coussy F, Pierga JY, Brain E, Saule C, Stoppa-Lyonnet D, Frank S, Sénéchal C, Lae M, De Croze D, Bataillon G, Guerin J, Reyal F, Hamy AS.
    • Cancers (Basel). 2020 Dec 8;12(12):3681. doi: 10.3390/cancers12123681.
    • Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
    • Watt GP, Sung J, Morris EA, Buys SS, Bradbury AR, Brooks JD, Conant EF, Weinstein SP, Kontos D, Woods M, Colonna SV, Liang X, Stein MA, Pike MC, Bernstein JL.
    • Breast Cancer Res. 2020 Dec 7;22(1):138. doi: 10.1186/s13058-020-01375-7. PMID: 33287857.
    • Differential immunomodulatory Effect of PARP Inhibition in BRCA1 deficient and competent tumor cells.
    • Alvarado-Cruz I, Mahmoud M, Khan M, Zhao S, Oeck S, Meas R, Clairmont K, Quintana V, Zhu Y, Porciuncula A, Wyatt H, Ma S, Shyr Y, Kong Y, LoRusso PM, Laverty D, Nagel ZD, Schalper KA, Krauthammer M, Sweasy JB.
    • Biochem Pharmacol. 2020 Dec 4:114359. doi: 10.1016/j.bcp.2020.114359. Epub ahead of print.
    • Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study.
    • Kang S, Yu YL, Cho SY, Park SY.
    • Eur J Cancer. 2020 Dec;141:185-192. doi: 10.1016/j.ejca.2020.09.036. Epub 2020 Nov 6.
    • Homologous recombination deficiency real-time clinical assays, ready or not?
    • Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A.
    • Gynecol Oncol. 2020 Dec;159(3):877-886. doi: 10.1016/j.ygyno.2020.08.035. Epub 2020 Sep 20.
    • Review
    • Genome-wide methylation profiles in monozygotic twins with discordance for ovarian carcinoma.
    • Erdogan OS, Tuncer SB, Kilic S, Odemis DA, Turkcan GK, Celik B, Avsar M, Yazici H.
    • Oncol Lett. 2020 Dec;20(6):357. doi: 10.3892/ol.2020.12221. Epub 2020 Oct 14.
    • Gastric Cancer in BRCA1 Germline Mutation Carriers: Results of Endoscopic Screening and Molecular Analysis of Tumor Tissues.
    • Avanesyan AA, Sokolenko AP, Ivantsov AO, Kleshchev MA, Maydin MA, Bizin IV, Raskin GA, Shelekhova KV, Gorodnova TV, Bessonov AA, Anisimova EI, Volynshchikova OA, Romanko AA, Ni VI, Broyde RV, Tkachenko OB, Whitehead AJ, Scherbakov AM, Imyanitov EN.
    • Pathobiology. 2020 [Dec];87(6):367-374. doi: 10.1159/000511323. Epub 2020 Nov 6.
    • The significance of ovarian fibrosis.
    • Landry DA, Vaishnav HT, Vanderhyden BC.
    • Oncotarget. 2020 Nov 24;11(47):4366-4370. doi: 10.18632/oncotarget.27822.
    • Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.
    • Wei Y, Ou T, Lu Y, Wu G, Long Y, Pan X, Yao D.
    • PeerJ. 2020 Nov 24;8:e10414. doi: 10.7717/peerj.10414.
    • Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    • Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE.
    • Ann Oncol. 2020 Nov 23:S0923-7534(20)43164-3. doi: 10.1016/j.annonc.2020.11.009. Epub ahead of print.
    • Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
    • Turashvili G, Lazaro C, Ying S, Charames G, Wong A, Hamilton K, Yee D, Agro E, Chang M, Pollett A, Lerner-Ellis J.
    • Cancers (Basel). 2020 Nov 21;12(11):3468. doi: 10.3390/cancers12113468.
    • Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic.
    • Rojas-Jiménez E, Mejía-Gómez JC, Díaz-Velásquez C, Quezada-Urban R, Martínez Gregorio H, Vallejo-Lecuona F, de la Cruz-Montoya A, Porras Reyes FI, Pérez-Sánchez VM, Maldonado-Martínez HA, Robles-Estrada M, Bargalló-Rocha E, Cabrera-Galeana P, Ramos-Ramírez M, Chirino YI, Alonso Herrera L, Terrazas LI, Oliver J, Frecha C, Perdomo S, Vaca-Paniagua F.
    • Genes (Basel). 2020 Nov 19;11(11):E1367. doi: 10.3390/genes11111367.
    • Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.
    • Principe DR, Narbutis M, Koch R, Rana A.
    • Sci Rep. 2020 Nov 19;10(1):20223. doi: 10.1038/s41598-020-76975-6.
    • Beware Liquid Biopsies to Guide PARP Blockade.
    • [No author given]
    • Cancer Discov. 2020 Nov 18. doi: 10.1158/2159-8290.CD-NB2020-105. Epub ahead of print.
    • Research news
    • MSK Study Suggests Germline Tests May Miss Mosaic Cancer Risk Mutations in Some Patients.
    • GenomeWeb. Technology. 2020 Nov 18.
    • Conference news
    • Glucose Concentration in Cell Culture Medium Influences the BRCA1-Mediated Regulation of the Lipogenic Action of IGF-I in Breast Cancer Cells.
    • Koobotse MO, Schmidt D, Holly JMP, Perks CM.
    • Int J Mol Sci. 2020 Nov 17;21(22):E8674. doi: 10.3390/ijms21228674.
    • Association between vitamin D and ovarian cancer development in BRCA1 mutation carriers.
    • Pejovic T, Joshi S, Campbell S, Thisted S, Xu F, Xu J.
    • Oncotarget. 2020 Nov 10;11(45):4104-4114. doi: 10.18632/oncotarget.27803.
    • Pan-cancer landscape of homologous recombination deficiency.
    • Nguyen L, W M Martens J, Van Hoeck A, Cuppen E.
    • Nat Commun. 2020 Nov 4;11(1):5584. doi: 10.1038/s41467-020-19406-4.
    • BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
    • Krais JJ, Johnson N.
    • Cancer Res. 2020 Nov 1;80(21):4601-4609. doi: 10.1158/0008-5472.CAN-20-1830. Epub 2020 Aug 3.
    • Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.
    • Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, Korn WM, Lenz HJ, Wolf D, Feistritzer C, Spizzo G.
    • ESMO Open. 2020 Nov;5(6):e000942. doi: 10.1136/esmoopen-2020-000942.
    • Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
    • Gilson C, Ingleby F, Gilbert DC, Parry MA, Atako NB, Ali A, Hoyle A, Clarke NW, Gannon M, Wanstall C, Brawley C, Mason MD, Malik Z, Simmons A, Loehr A, Parry-Jones A, Eeles R, Kote-Jarai Z, James ND, Amos C, Parmar MKB, Langley RE, Sydes MR, Attard G, Chowdhury S; STAMPEDE Investigators.
    • JCO Precis Oncol. 2020 Nov;4:882-897. doi: 10.1200/PO.19.00388.
    • RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status.
    • Sinha A, Saleh A, Endersby R, Yuan SH, Chokshi CR, Brown KR, Kuzio B, Kauppinen T, Singh SK, Baker SJ, McKinnon PJ, Katyal S.
    • Cancers (Basel). 2020 Oct 29;12(11):3178. doi: 10.3390/cancers12113178.
    • BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women.
    • Sniadecki M, Brzezinski M, Darecka K, Klasa-Mazurkiewicz D, Poniewierza P, Krzeszowiec M, Kmiec N, Wydra D.
    • Genes (Basel). 2020 Oct 24;11(11):1251. doi: 10.3390/genes11111251.
    • Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
    • Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, Casanova C, Cormio G, Bologna A, Orditura M, Zavallone L, Attademo L, Gallà V, Franzese E, Pigozzi E, Loizzi V, Giorda G, Giardina D, Cioffi R, De Giorgi U.
    • Sci Rep. 2020 Oct 23;10(1):18190. doi: 10.1038/s41598-020-75316-x.
    • Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort.
    • Monson KR, Goldberg M, Wu HC, Santella RM, Chung WK, Terry MB.
    • Breast Cancer Res. 2020 Oct 22;22(1):109. doi: 10.1186/s13058-020-01352-0.
    • Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
    • Song L, Tang Z, Peng C, Yang Y, Guo C, Wang D, Guo L, Chen J, Liu C.
    • BMC Cancer. 2020 Oct 21;20(1):1020. doi: 10.1186/s12885-020-07524-7.
    • Lessons learned from setting up a prospective, longitudinal, multicenter study with women at high risk for breast cancer.
    • Patuleia SIS, Hagenaars SC, Moelans CB, Ausems MGEM, van Gils CH, Tollenaar RAEM, Van Diest PJ, Mesker WE, van der Wall E.
    • Cancer Epidemiol Biomarkers Prev. 2020 Oct 20:cebp.0770.2020. doi: 10.1158/1055-9965.EPI-20-0770. Epub ahead of print.
    • Review
    • Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
    • Kim SR, Tone A, Kim R, Cesari M, Clarke B, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.
    • Int J Gynecol Cancer. 2020 Oct 20:ijgc-2020-001927. doi: 10.1136/ijgc-2020-001927. Epub ahead of print.
    • Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours.
    • Wiggins GAR, Walker LC, Pearson JF.
    • Cancers (Basel). 2020 Oct 16;12(10):3015. doi: 10.3390/cancers12103015.
    • Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
    • Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, Shiraishi Y, Chiba K, Kataoka Y, Torii M, Yoshibayashi H, Yamagami K, Okamura R, Moriguchi Y, Kato H, Tsuyuki S, Yamauchi A, Suwa H, Inamoto T, Miyano S, Ogawa S, Toi M.
    • Commun Biol. 2020 Oct 16;3(1):578. doi: 10.1038/s42003-020-01301-9.
    • Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case.
    • Izawa M, Kosaka T, Nakamura K, Oba J, Hishida T, Hongo H, Mikami S, Nishihara H, Oya M.
    • IJU Case Rep. 2020 Oct 15;4(1):14-17. doi: 10.1002/iju5.12224.
    • The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    • De Palma FDE, Monaco VD, Pol JG, Kremer M, D'Argenio V, Stoll G, Montanaro D, Uszczynska-Ratajczak B, Klein CC, Vlasova A, Botti G, D'Aiuto M, Baldi A, Guigó R, Kroemer G, Maiuri MC, Salvatore F.
    • Pharmacol Res. 2020 Oct 14:105249. doi: 10.1016/j.phrs.2020.105249. Epub ahead of print.
    • Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study).
    • Nero C, Ciccarone F, Boldrini L, Lenkowicz J, Paris I, Capoluongo ED, Testa AC, Fagotti A, Valentini V, Scambia G.
    • Sci Rep. 2020 Oct 5;10(1):16511. doi: 10.1038/s41598-020-73505-2.
    • Using Co-segregation and Loss of Heterozygosity Analysis to Define the Pathogenicity of Unclassified Variants in Hereditary Breast Cancer Patients.
    • Grasel RS, Felicio PS, de Paula AE, Campacci N, Garcia FAO, de Andrade ES, Evangelista AF, Fernandes GC, Sabato CDS, De Marchi P, Souza CP, de Paula CAA, Torrezan GT, Galvão HCR, Carraro DM, Palmero EI.
    • Front Oncol. 2020 Oct 2;10:571330. doi: 10.3389/fonc.2020.571330.
    • Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.
    • Sadeghi F, Asgari M, Matloubi M, Ranjbar M, Karkhaneh Yousefi N, Azari T, Zaki-Dizaji M.
    • Biol Proced Online. 2020 Oct 1;22:23. doi: 10.1186/s12575-020-00133-5.
    • Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    • Lentz SE, Powell CB, Haque R, Armstrong MA, Anderson M, Liu Y, Jiang W, Chillemi G, Shaw S, Alvarado MM, Kushi LH, Skates SJ.
    • Gynecol Oncol. 2020 Oct 1:S0090-8258(20)33914-7. doi: 10.1016/j.ygyno.2020.09.021. Epub ahead of print.
    • Clinical assays for assessment of homologous recombination DNA repair deficiency.
    • Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF.
    • Gynecol Oncol. 2020 Oct 1:S0090-8258(20)33922-6. doi: 10.1016/j.ygyno.2020.09.029. Epub ahead of print.
    • Review
    • Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    • Kim SH, Ahn S, Suh KJ, Kim YJ, Park SY, Kang E, Kim EK, Kim IA, Chae S, Choi M, Kim JH.
    • Breast Cancer Res Treat. 2020 Oct;183(3):697-704. doi: 10.1007/s10549-020-05811-2. Epub 2020 Jul 26.
    • Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    • Bodily WR, Shirts BH, Walsh T, Gulsuner S, King MC, Parker A, Roosan M, Piccolo SR.
    • PLoS One. 2020 Sep 30;15(9):e0239197. doi: 10.1371/journal.pone.0239197.
    • Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
    • Rieckhoff J, Meyer F, Classen S, Zielinski A, Riepen B, Wikman H, Petersen C, Rothkamm K, Borgmann K, Parplys AC.
    • Cancers (Basel). 2020 Sep 29;12(10):2809. doi: 10.3390/cancers12102809.
    • Pathology of Hereditary Breast and Ovarian Cancer.
    • Hodgson A, Turashvili G.
    • Front Oncol. 2020 Sep 29;10:531790. doi: 10.3389/fonc.2020.531790.
    • Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor.
    • Liu J, Adhav R, Miao K, Su SM, Mo L, Chan UI, Zhang X, Xu J, Li J, Shu X, Zeng J, Zhang X, Lyu X, Pardeshi L, Tan K, Sun H, Wong KH, Deng C, Xu X.
    • Nat Commun. 2020 Sep 25;11(1):4875. doi: 10.1038/s41467-020-18637-9.
    • A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy.
    • Pan Y, Jia LP, Liu Y, Han Y, Li Q, Zou Q, Zhang Z, Huang J, Deng Q.
    • J Ovarian Res. 2020 Sep 19;13(1):112. doi: 10.1186/s13048-020-00712-w.
    • Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast.
    • Bodelon C, Oh H, Derkach A, Sampson JN, Sprague BL, Vacek P, Weaver DL, Fan S, Palakal M, Papathomas D, Xiang J, Patel DA, Linville L, Clare SE, Visscher DW, Mies C, Hewitt SM, Brinton LA, Storniolo AMV, He C, Chanock SJ, Garcia-Closas M, Gierach GL, Figueroa JD.
    • NPJ Breast Cancer. 2020 Sep 7;6:41. doi: 10.1038/s41523-020-00184-7. eCollection 2020.
    • Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.
    • Yadav G, Vashisht M, Yadav V, Shyam R.
    • Int J Prev Med. 2020 Sep 3;11:135. doi: 10.4103/ijpvm.IJPVM_75_19.
    • Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.
    • Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R.
    • Mol Oncol. 2020 Sep 3. doi: 10.1002/1878-0261.12791. Epub ahead of print.
    • Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    • Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Ferguson NL, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen MB, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom PJ, Alexander B, Brown C, Pusztai L, Ross JS, Ramkissoon SH.
    • Oncologist. 2020 Sep 1. doi: 10.1634/theoncologist.2020-0449. Epub ahead of print.
    • XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells.
    • Eckelmann BJ, Bacolla A, Wang H, Ye Z, Guerrero EN, Jiang W, El-Zein R, Hegde ML, Tomkinson AE, Tainer JA, Mitra S.
    • NAR Cancer. 2020 Sep;2(3):zcaa013. doi: 10.1093/narcan/zcaa013. Epub 2020 Aug 1.
    • Defining the mutation signatures of DNA polymerase [theta] in cancer genomes.
    • Hwang T, Reh S, Dunbayev Y, Zhong Y, Takata Y, Shen J, McBride KM, Murnane JP, Bhak J, Lee S, Wood RD, Takata KI.
    • NAR Cancer. 2020 Sep;2(3):zcaa017. doi: 10.1093/narcan/zcaa017. Epub 2020 Aug 27.
    • Male Breast Cancer in Togo: Imaging and Clinicopathological Findings.
    • Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G.
    • Int J Breast Cancer. 2020 Aug 31;2020:3056067. doi: 10.1155/2020/3056067.
    • Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers.
    • Hu ZY, Liu L, Xie N, Lu J, Liu Z, Tang Y, Wang Y, Yang J, Ouyang Q.
    • Front Genet. 2020 Aug 27;11:829. doi: 10.3389/fgene.2020.00829.
    • miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
    • Tuncer SB, Erdogan OS, Erciyas SK, Saral MA, Celik B, Odemis DA, Turkcan GK, Yazici H.
    • J Ovarian Res. 2020 Aug 27;13(1):99. doi: 10.1186/s13048-020-00706-8.
    • BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target.
    • Morand S, Stanbery L, Walter A, Rocconi RP, Nemunaitis J.
    • JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077. doi: 10.1093/jncics/pkaa077.
    • Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
    • Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J.
    • EJC Suppl. 2020 Aug 22;15:1-15. doi: 10.1016/j.ejcsup.2020.02.001.
    • Breast-Specific Epigenetic Regulation of DeltaNp73 and Its Role in DNA-Damage-Response of BRCA1-Mutated Human Mammary Epithelial Cells.
    • Avraham A, Feldman S, Cho SS, Kol A, Heler L, Riklin-Nahmias E, Sella A, Karni T, Allweis TM, Sukumar S, Evron E.
    • Cancers (Basel). 2020 Aug 21;12(9):E2367. doi: 10.3390/cancers12092367.
    • Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors.
    • Saotome K, Chiyoda T, Aimono E, Nakamura K, Tanishima S, Nohara S, Okada C, Hayashi H, Kuroda Y, Nomura H, Susumu N, Iwata T, Yamagami W, Kataoka F, Nishihara H, Aoki D.
    • Cancer Med. 2020 Aug 19. doi: 10.1002/cam4.3383. Epub ahead of print.
    • Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors.
    • Pasculli B, Barbano R, Fontana A, Biagini T, Di Viesti MP, Rendina M, Valori VM, Morritti M, Bravaccini S, Ravaioli S, Maiello E, Graziano P, Murgo R, Copetti M, Mazza T, Fazio VM, Esteller M, Parrella P.
    • Front Oncol. 2020 Aug 12;10:1415. doi: 10.3389/fonc.2020.01415.
    • Cytologic studies of in vivo fallopian tube specimens in patients undergoing salpingo-oophorectomy.
    • Pramanik S, Yang E, Wu W.
    • Cytojournal. 2020 Aug 10;17:19. doi: 10.25259/CytoJournal_7_2020.
    • BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic literature review.
    • Merlino L, Chiné A, Galli C, Piccioni MG.
    • Minerva Ginecol. 2020 Aug 3. doi: 10.23736/S0026-4784.20.04624-9. Epub ahead of print.
    • Review
    • Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    • Lertkhachonsuk AA, Suprasert P, Manchana T, Kittisiam T, Kantathavorn N, Chansoon T, Khunamornpong S, Pohthipornthawat N, Tangjitgamol S, Luasiripanthu T, Teerapakpinyo C, Shuangshot S, Iemwimangsa N, Chantratita W.
    • Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2381-2388. doi: 10.31557/APJCP.2020.21.8.2381.
    • Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
    • Arif T, Anwar N.
    • Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2395-2401. doi: 10.31557/APJCP.2020.21.8.2395.
    • PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer.
    • Zhang M, Zhang J.
    • Biosci Rep. 2020 Jul 30:BSR20201648. doi: 10.1042/BSR20201648. Epub ahead of print.
    • Breast MRI texture analysis for prediction of BRCA-associated genetic risk.
    • Vasileiou G, Costa MJ, Long C, Wetzler IR, Hoyer J, Kraus C, Popp B, Emons J, Wunderle M, Wenkel E, Uder M, Beckmann MW, Jud SM, Fasching PA, Cavallaro A, Reis A, Hammon M.
    • BMC Med Imaging. 2020 Jul 29;20(1):86. doi: 10.1186/s12880-020-00483-2.
    • Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
    • Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J.
    • Nat Commun. 2020 Jul 27;11(1):3747. doi: 10.1038/s41467-020-17537-2.
    • Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
    • Min A, Kim K, Jeong K, Choi S, Kim S, Suh KJ, Lee KH, Kim S, Im SA.
    • Sci Rep. 2020 Jul 27;10(1):12506. doi: 10.1038/s41598-020-68176-y.
    • BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    • Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM.
    • Breast Cancer Res. 2020 Jul 25;22(1):79. doi: 10.1186/s13058-020-01313-7.
    • Prophylactic Bilateral Salpingo-oophorectomy in BRCA2 Mutation with Incidental Finding of Serous Tubal Intraepithelial Carcinoma (STIC) and Subsequent Diagnosis of Primary Peritoneal Carcinoma (PPC): A Case Report and Review of Current Literature.
    • Palaiologos K, Ellaboudy A, Abdullah M, Karan S, Saha A.
    • Cureus. 2020 Jul 20;12(7):e9301. doi: 10.7759/cureus.9301.
    • Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer.
    • Boyarskikh UA, Gulyaeva LF, Avdalyan AM, Kechin AA, Khrapov EA, Lazareva DG, Kushlinskii NE, Melkonyan A, Arakelyan A, Filipenko ML.
    • Front Oncol. 2020 Jul 16;10:1103. doi: 10.3389/fonc.2020.01103.
    • The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer.
    • Dion L, Carton I, Jaillard S, Nyangoh Timoh K, Henno S, Sardain H, Foucher F, Levêque J, de la Motte Rouge T, Brousse S, Lavoué V.
    • J Clin Med. 2020 Jul 15;9(7):E2239. doi: 10.3390/jcm9072239.
    • Calibration of pathogenicity due to variant-induced leaky splicing defects by using BRCA2 exon 3 as a model system.
    • Tubeuf H, Caputo SM, Sullivan T, Rondeaux J, Krieger S, Caux-Moncoutier V, Hauchard J, Castelain G, Fiévet A, Meulemans L, Révillion F, Léone M, Boutry-Kryza N, Delnatte C, Guillaud-Bataille M, Cleveland L, Reid S, Southon E, Soukarieh O, Drouet A, Di Giacomo D, Vezain M, Bonnet-Dorion F, Bourdon V, Larbre H, Muller D, Pujol P, Vaz F, Audebert-Bellanger S, Colas C, Venat-Bouvet L, Solano AR, Stoppa-Lyonnet D, Houdayer C, Frebourg T, Gaildrat P, Sharan SK, Martins A.
    • Cancer Res. 2020 Jul 8:canres.0895.2020. doi: 10.1158/0008-5472.CAN-20-0895. Epub ahead of print.
    • Histopathologic features of breast cancer in Li-Fraumeni syndrome.
    • Kuba MG, Lester SC, Bowman T, Stokes SM, Taneja KL, Garber JE, Dillon DA.
    • Mod Pathol. 2020 Jul 7. doi: 10.1038/s41379-020-0610-4. Epub ahead of print.
    • Current status of breast cancer screening in high-risk women in Japan.
    • Tozaki M, Nakamura S.
    • Breast Cancer. 2020 Jul 6. doi: 10.1007/s12282-020-01103-1. Epub ahead of print.
    • Review
    • Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
    • Varanda AB, Martins-Logrado A, Ferreira MG, Fior R.
    • Cancers (Basel). 2020 Jul 2;12(7):E1769. doi: 10.3390/cancers12071769.
    • Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    • Luo S, Zhang Y, Yang Y, Zhu S, Liu W, Zhu J, Liang X, Jiang Z, Sun S, Hou X, Xiao Y, Li X.
    • Gynecol Oncol. 2020 Jul;158(1):66-76. doi: 10.1016/j.ygyno.2020.04.695. Epub 2020 May 8.
    • BReast CAncer susceptibility gene 2 deficiency exacerbates oxidized LDL-induced DNA damage and endothelial apoptosis.
    • Singh S, Nguyen H, Michels D, Bazinet H, Matkar PN, Liu Z, Esene L, Adam M, Bugyei-Twum A, Mebrahtu E, Joseph J, Ehsan M, Chen HH, Qadura M, Singh KK.
    • Physiol Rep. 2020 Jul;8(13):e14481. doi: 10.14814/phy2.14481.
    • Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
    • Tao Z, Li T, Feng Z, Liu C, Shao Y, Zhu M, Gong C, Wang B, Cao J, Wang L, Du Y, Lizaso A, Li B, Zhang J, Hu X.
    • Front Oncol. 2020 Jun 30;10:1023. doi: 10.3389/fonc.2020.01023.
    • NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
    • Miao K, Lei JH, Valecha MV, Zhang A, Xu J, Wang L, Lyu X, Chen S, Miao Z, Zhang X, Su SM, Shao F, Rajendran BK, Bao J, Zeng J, Sun H, Chen P, Tan K, Chen Q, Wong KH, Xu X, Deng CX.
    • Nat Commun. 2020 Jun 26;11(1):3256. doi: 10.1038/s41467-020-16936-9.
    • Roles of Chk2/CHEK2 in guarding against environmentally-induced DNA damage and replication-stress.
    • Mustofa MK, Tanoue Y, Tateishi C, Vaziri C, Tateishi S.
    • Environ Mol Mutagen. 2020 Jun 24. doi: 10.1002/em.22397. Epub ahead of print.
    • Review
    • Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer.
    • Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, Wander SA, Spring LM, Moy B, Shannon KM, Younger J, Lanman RB, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A.
    • Clin Cancer Res. 2020 Jun 22:clincanres.0638.2020. doi: 10.1158/1078-0432.CCR-20-0638. Epub ahead of print.
    • Immune Cell Associations with Cancer Risk.
    • Palomero L, Galván-Femenía I, de Cid R, Espín R, Barnes DR, Cimba, Blommaert E, Gil-Gil M, Falo C, Stradella A, Ouchi D, Roso-Llorach A, Violan C, Peña-Chilet M, Dopazo J, Extremera AI, García-Valero M, Herranz C, Mateo F, Mereu E, Beesley J, Chenevix-Trench G, Roux C, Mak T, Brunet J, Hakem R, Gorrini C, Antoniou AC, Lázaro C, Pujana MA.
    • iScience. 2020 Jun 20;23(7):101296. doi: 10.1016/j.isci.2020.101296. Epub ahead of print.
    • Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer.
    • Park S, Lee E, Park S, Lee S, Nam SJ, Kim SW, Lee JE, Yu JH, Kim JY, Ahn JS, Im YH, Park WY, Park K, Park YH.
    • Mol Cancer Res. 2020 Jun 17:molcanres.1108.2019. doi: 10.1158/1541-7786.MCR-19-1108. Epub ahead of print.
    • BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer.
    • Liu YL, Selenica P, Zhou Q, Iasonos A, Callahan M, Feit NZ, Boland J, Vazquez-Garcia I, Mandelker D, Zehir A, Burger RA, Powell DJ Jr, Friedman C, Cadoo K, Grisham R, Konner JA, O'Cearbhaill RE, Aghajanian C, Reis-Filho JS, Weigelt B, Zamarin D.
    • JCO Precis Oncol. 2020 Jun 16;4:PO.20.00069. doi: 10.1200/PO.20.00069.
    • Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
    • Baker LA, Holliday H, Roden D, Krisp C, Wu SZ, Junankar S, Serandour AA, Mohammed H, Nair R, Sankaranarayanan G, Law AMK, McFarland A, Simpson PT, Lakhani S, Dodson E, Selinger C, Anderson L, Samimi G, Hacker NF, Lim E, Ormandy CJ, Naylor MJ, Simpson K, Nikolic I, O'Toole S, Kaplan W, Cowley MJ, Carroll JS, Molloy M, Swarbrick A.
    • Breast Cancer Res. 2020 Jun 11;22(1):63. doi: 10.1186/s13058-020-01306-6.
    • Beneficial Molecular Adaptations In BRCA-Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study.
    • Bizjak DA, Schulz SVW, Schumann U, Otto S, Kirsten J, Ebner F, Leinert E, Huober J, Janni W, Steinacker JM.
    • Cancers (Basel). 2020 Jun 10;12(6):E1526. doi: 10.3390/cancers12061526.
    • The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study.
    • Grandi G, Del Savio MC, Sammarini M, Cortesi L, Toss A, Piombino C, Facchinetti F.
    • Eur J Cancer Prev. 2020 Jun 8. doi: 10.1097/CEJ.0000000000000606. Epub ahead of print.
    • Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
    • Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N.
    • NPJ Breast Cancer. 2020 Jun 5;6(1):19. doi: 10.1038/s41523-020-0160-4.
    • Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
    • Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N.
    • NPJ Breast Cancer. 2020 Jun 5;6(1):19. doi: 10.1038/s41523-020-0160-4.
  1. f
    • Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
    • Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N.
    • NPJ Breast Cancer. 2020 Jun 5;6:19. doi: 10.1038/s41523-020-0160-4.
    • Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    • Watanabe T, Honda T, Totsuka H, Yoshida M, Tanioka M, Shiraishi K, Shimada Y, Arai E, Ushiama M, Tamura K, Yoshida T, Kanai Y, Kohno T.
    • Breast Cancer Res Treat. 2020 Jun 3. doi: 10.1007/s10549-020-05716-0. Epub ahead of print.
    • Identifying Patients With Pancreatic Cancer Likely to Respond.
    • Harrison P.
    • Medscape. 2020 Jun 2.

    Original research:

    Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.

    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • Ancestry-specific predisposing germline variants in cancer.
    • Oak N, Cherniack AD, Mashl RJ; TCGA Analysis Network, Hirsch FR, Ding L, Beroukhim R, Gümüs ZH, Plon SE, Huang KL.
    • Genome Med. 2020 May 29;12(1):51. doi: 10.1186/s13073-020-00744-3.
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    • Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC.
    • Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7.
    • Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer.
    • Alhopuro P, Vainionpää R, Anttonen AK, Aittomäki K, Nevanlinna H, Pöyhönen M.
    • Fam Cancer. 2020 May 28. doi: 10.1007/s10689-020-00186-1. Epub ahead of print.
    • BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients.
    • Manchana T, Tantbirojn P, Pohthipornthawat N.
    • Gynecol Oncol Rep. 2020 May 27;33:100582. doi: 10.1016/j.gore.2020.100582.
    • Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
    • Horimoto Y, Thinzar Hlaing M, Saeki H, Kitano S, Nakai K, Sasaki R, Kurisaki-Arakawa A, Arakawa A, Otsuji N, Matsuoka S, Tokuda E, Arai M, Saito M.
    • Cancer Sci. 2020 May 24. doi: 10.1111/cas.14500. Epub ahead of print.
    • Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
    • Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, Balachandran V, McIntyre CA, El Dika I, Khalil DN, Harding JJ, Ghalehsari N, McKinnell Z, Chalasani SB, Makarov V, Selenica P, Pei X, Lecomte N, Kelsen DP, Abou-Alfa GK, Robson ME, Zhang L, Berger MF, Schultz N, Chan TA, Powell SN, Reis-Filho JS, Iacobuzio-Donahue CA, Riaz N, O'Reilly EM.
    • Clin Cancer Res. 2020 May 22. doi: 10.1158/1078-0432.CCR-20-0418. Epub ahead of print.
    • BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis.
    • Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, Swisher EM, Bernards SS, O'Riain C, O'Toole S, O'Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT.
    • J Natl Cancer Inst. 2020 May 15:djaa070. doi: 10.1093/jnci/djaa070. Epub ahead of print.
    • Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    • Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M.
    • J Pathol Clin Res. 2020 May 11. doi: 10.1002/cjp2.168. Epub ahead of print.
    • The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy.
    • Jacob SL, Kiedrowski LA, Chae YK.
    • Heliyon. 2020 May 8;6(5):e03841. doi: 10.1016/j.heliyon.2020.e03841.
    • Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability.
    • Zarrizi R, Higgs MR, Voßgröne K, Rossing M, Bertelsen B, Bose M, Kousholt AN, Rösner HI, Ejlertsen B, Stewart GS, Nielsen FC, Sørensen C.
    • J Clin Invest. 2020 May 7. pii: 127521. doi: 10.1172/JCI127521. [Epub ahead of print]
    • PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-Ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    • Chen H, Molberg K, Strickland AL, Castrillon DH, Carrick K, Jiang Q, Niu S, Rivera-Colon G, Gwin K, Hinson S, Lea J, Miller DS, Zheng W, Lucas E.
    • Am J Surg Pathol. 2020 May 6. doi: 10.1097/PAS.0000000000001503. [Epub ahead of print]
    • The Role of Circulating Adiponectin and SNP276G>T at ADIPOQ Gene in BRCA-mutant Women.
    • Daniele A, Paradiso AV, Divella R, Digennaro M, Patruno M, Tommasi S, Pilato B, Tufaro A, Barone M, Minoia C, Colangelo D, Savino E, Casamassima P, Bruno E, Oliverio A, Pasanisi P.
    • Cancer Genomics Proteomics. 2020 May-Jun;17(3):301-307. doi: 10.21873/cgp.20190.
    • Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
    • Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K.
    • J Immunother Cancer. 2020 May;8(1):e000375. doi: 10.1136/jitc-2019-000375.
    • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
    • Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH.
    • JCO Precis Oncol. 2020;4:442-465. doi: 10.1200/po.19.00345. Epub 2020 Apr 30.
    • Mucinous Histology, BRCA1/2 Mutations, and Elevated Tumor Mutational Burden in Colorectal Cancer.
    • Harpaz N, Gatt YE, Granit RZ, Fruchtman H, Hubert A, Grinshpun A.
    • J Oncol. 2020 Apr 25;2020:6421205. doi: 10.1155/2020/6421205. eCollection 2020.
    • Tissue-Specific Carcinogens as Soil to Seed BRCA1/2-Mutant Hereditary Cancers.
    • Singh AK, Yu X.
    • Trends Cancer. 2020 Apr 23. pii: S2405-8033(20)30105-9. doi: 10.1016/j.trecan.2020.03.004. [Epub ahead of print]
    • Review, Commentary
    • Germline and somatic DNA repair gene alterations in prostate cancer.
    • Dall'Era MA, McPherson JD, Gao AC, DeVere White RW, Gregg JP, Lara PN Jr.
    • Cancer. 2020 Apr 21. doi: 10.1002/cncr.32908. [Epub ahead of print]
    • Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial.
    • McDonald ES, Doot RK, Pantel AR, Farwell MD, Mach RH, Maxwell KN, Mankoff DA.
    • JAMA Oncol. 2020 Apr 16. doi: 10.1001/jamaoncol.2020.0334. [Epub ahead of print]
    • Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
    • Van Marcke C, Helaers R, De Leener A, Merhi A, Schoonjans , Ambroise J, Galant C, Delrée P, Rothé F, Bar I, Khoury E, Brouillard P, Canon JL, Vuylsteke P, Machiels JP, Berlière M, Limaye N, Vikkula M, Duhoux FP.
    • Breast Cancer Res. 2020 Apr 15;22(1):36. doi: 10.1186/s13058-020-01273-y.
    • Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer.
    • André S, P Nunes S, Silva F, Henrique R, Félix A, Jerónimo C.
    • Int J Mol Sci. 2020 Apr 14;21(8). pii: E2715. doi: 10.3390/ijms21082715.
    • Psammoma bodies in Papanicolaou tests and associated factors to predict an underlying malignancy: a clinicopathological analysis of 10 cases.
    • Ersoy E, Kashikar RM.
    • J Am Soc Cytopathol. 2020 Apr 11. pii: S2213-2945(20)30059-4. doi: 10.1016/j.jasc.2020.04.002. [Epub ahead of print]
    • Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
    • Douvdevani A, Bernstein-Molho R, Asraf K, Doolman R, Laitman Y, Friedman E.
    • Cancer Biomark. 2020 Apr 10. doi: 10.3233/CBM-190718. [Epub ahead of print]
    • Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
    • Montfort A, Owen S, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, Böhm S, Pharoah P, McDermott J, Balkwill FR, Brenton JD.
    • Br J Cancer. 2020 Apr 6. doi: 10.1038/s41416-020-0822-x. [Epub ahead of print]
    • Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    • Hussein IA, Ahmed ST, Hameedi AD, Naji RZ, Alharbawi L, Alkhaytt M, Pity IS.
    • Asian Pac J Cancer Prev. 2020 Apr 1;21(4):1025-1029. doi: 10.31557/APJCP.2020.21.4.1025.
    • The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    • Sorscher S, Ansley K, Delaney SD, Ramkissoon S.
    • Breast Cancer Res Treat. 2020 Apr;180(2):511-514. doi: 10.1007/s10549-020-05569-7. Epub 2020 Feb 10.
    • Case report
    • Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer.
    • Wong EM, Southey MC, Terry MB.
    • Br J Cancer. 2020 Apr;122(8):1133-1140. doi: 10.1038/s41416-019-0720-2. Epub 2020 Feb 18.
    • Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.
    • McCrorie AD, Ashfield S, Begley A, Mcilmunn C, Morrison PJ, Boyd C, Eccles B, Greville-Heygate S, Copson ER, Cutress RI, Eccles DM, Savage KI, McIntosh SA.
    • J Pathol Clin Res. 2020 Apr;6(2):146-153. doi: 10.1002/cjp2.155. Epub 2020 Feb 5.
    • Mechanistic basis for microhomology identification and genome scarring by polymerase theta.
    • Carvajal-Garcia J, Cho JE, Carvajal-Garcia P, Feng W, Wood RD, Sekelsky J, Gupta GP, Roberts SA, Ramsden DA.
    • Proc Natl Acad Sci U S A. 2020 Mar 31. pii: 201921791. doi: 10.1073/pnas.1921791117. [Epub ahead of print]
    • [Hereditary breast carcinomas pathologist's perspective].
    • Vincent-Salomon A, Bataillon G, Djerroudi L.
    • Ann Pathol. 2020 Mar 30. pii: S0242-6498(20)30059-6. doi: 10.1016/j.annpat.2020.02.023. [Epub ahead of print]
    • Review, [Article in French]
    • BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
    • Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S.
    • Cancers (Basel). 2020 Mar 30;12(4). pii: E828. doi: 10.3390/cancers12040828.
    • Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma.
    • Kim SI, Jung M, Dan K, Lee S, Lee C, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Han D, Lee M.
    • Cancers (Basel). 2020 Mar 26;12(4). pii: E790. doi: 10.3390/cancers12040790.
    • Molecular Trajectory of BRCA1 and BRCA2 Mutations.
    • Hatano Y, Tamada M, Matsuo M, Hara A.
    • Front Oncol. 2020 Mar 25;10:361. doi: 10.3389/fonc.2020.00361. eCollection 2020.
    • An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube.
    • Boltežar L, Gašljevic G, Novakovic S, Stegel V, Škof E.
    • Hered Cancer Clin Pract. 2020 Mar 19;18:7. doi: 10.1186/s13053-020-00139-w. eCollection 2020.
    • The tubal epigenome - An emerging target for ovarian cancer.
    • Reavis HD, Drapkin R.
    • Pharmacol Ther. 2020 Mar 17:107524. doi: 10.1016/j.pharmthera.2020.107524. [Epub ahead of print]
    • Review
    • Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    • Simmons AD, Nguyen M, Pintus E.
    • BMC Cancer. 2020 Mar 14;20(1):215. doi: 10.1186/s12885-020-6657-2.
    • An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    • Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.
    • BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
    • Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    • Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ.
    • BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
    • Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    • Liontos M, Sotiropoulou M, Kaparelou M, Tzannis K, Tsironis G, Kyriazoglou A, Tsiara A, Zakopoulou R, Koutsoukos K, Zagouri F, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Bamias A.
    • Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224-9. doi: 10.1016/j.ygyno.2020.03.008. [Epub ahead of print]
    • Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family.
    • Sadzeviciene I, Jarmalaite S, Besusparis J, Liaugaudiene O, Asadauskiene J, Brasiuniene B, Kulikiene I, Sabaliauskaite R.
    • Medicina (Kaunas). 2020 Mar 10;56(3). pii: E119. doi: 10.3390/medicina56030119.
    • Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer.
    • Knowlson C, Haddock P, Bingham V, McQuaid S, Mullan PB, Buckley NE.
    • Ther Adv Med Oncol. 2020 Mar 9;12:1758835920906047. doi: 10.1177/1758835920906047. eCollection 2020.
    • RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.
    • Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, Ganapathi RN.
    • Cancers (Basel). 2020 Mar 7;12(3). pii: E620. doi: 10.3390/cancers12030620.
    • Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
    • Chevalier LM, Billaud A, Fronteau S, Dauvé J, Patsouris A, Verriele V, Morel A.
    • Mol Diagn Ther. 2020 Mar 2. doi: 10.1007/s40291-020-00452-z. [Epub ahead of print]
    • Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours.
    • Criscitiello C, Curigliano G.
    • Eur J Cancer. 2020 Mar;127:236-239. doi: 10.1016/j.ejca.2019.12.004. Epub 2020 Jan 20.
    • The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis.
    • Li S, He Y, Li C, Liu X, Shen Y, Wu Y, Bai N, Li Q.
    • Medicine (Baltimore). 2020 Mar;99(10):e19345. doi: 10.1097/MD.0000000000019345.
    • Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.
    • Misra S, Zhang X, Wani NA, Sizemore S, Ray A.
    • Oncotarget. 2020 Feb 25;11(8):784-800. doi: 10.18632/oncotarget.27485. eCollection 2020 Feb 25.
    • Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    • Chen B, Zhang G, Li X, Ren C, Wang Y, Li K, Mok H, Cao L, Wen L, Jia M, Li C, Guo L, Wei G, Lin J, Li Y, Zhang Y, Han-Zhang H, Liu J, Lizaso A, Liao N.
    • Aging (Albany NY). 2020 Feb 24;12(4):3140-3155. doi: 10.18632/aging.102783. Epub 2020 Feb 24.
    • miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
    • Pessôa-Pereira D, Evangelista AF, Causin RL, da Costa Vieira RA, Abrahão-Machado LF, Santana IVV, da Silva VD, de Souza KCB, de Oliveira-Silva RJ, Fernandes GC, Reis RM, Palmero EI, Marques MMC.
    • BMC Cancer. 2020 Feb 22;20(1):143. doi: 10.1186/s12885-020-6640-y.
    • BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
    • Kosaka Y, Yamamoto Y, Tanino H, Nishimiya H, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S.
    • Diagnostics (Basel). 2020 Feb 21;10(2). pii: E119. doi: 10.3390/diagnostics10020119.
    • Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
    • Teraoka S, Muguruma M, Takano N, Miyahara K, Kawate T, Kaise H, Yamada K, Miyazawa K, Ishikawa T.
    • J Surg Res. 2020 Feb 21;250:200-208. doi: 10.1016/j.jss.2019.12.040. [Epub ahead of print]
    • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    • Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D'Andrea AD, Winer EP, Lin NU, Shapiro GI, Wagle N.
    • Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055-5. doi: 10.1016/j.annonc.2020.02.008. [Epub ahead of print]
    • Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups.
    • Askeland C, Wik E, Finne K, Birkeland E, Arnes JB, Collett K, Knutsvik G, Krüger K, Davidsen B, Aas T, Eide GE, Stefansson IM, Foulkes WD, Akslen LA.
    • Sci Rep. 2020 Feb 19;10(1):2914. doi: 10.1038/s41598-020-59728-3.
    • Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
    • Sztupinszki Z, Diossy M, Krzystanek M, Börcsök , Pomerantz MM, Tisza V, Spisák S, Rusz O, Csabai I, Freedman ML, Szallasi Z.
    • Clin Cancer Res. 2020 Feb 18. pii: clincanres.2135.2019. doi: 10.1158/1078-0432.CCR-19-2135. [Epub ahead of print]
    • Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
    • Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N.
    • Sci Rep. 2020 Feb 17;10(1):2757. doi: 10.1038/s41598-020-59671-3.
    • Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation.
    • Tao H, Liu S, Huang D, Han X, Wu X, Shao YW, Hu Y.
    • Am J Transl Res. 2020 Feb 15;12(2):612-617. eCollection 2020.
    • BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis.
    • Chen Q, Lei JH, Bao J, Wang H, Hao W, Li L, Peng C, Masuda T, Miao K, Xu J, Xu X, Deng CX.
    • Adv Sci (Weinh). 2020 Feb 14;7(6):1903616. doi: 10.1002/advs.201903616. eCollection 2020 Mar.
    • Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    • Reijnen C, Küsters-Vandevelde HVN, Ligtenberg MJL, Bulten J, Oosterwegel M, Snijders MPLM, Sweegers S, de Hullu JA, Vos MC, van der Wurff AAM, van Altena AM, Eijkelenboom A, Pijnenborg JMA.
    • Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32907. [Epub ahead of print]
    • BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
    • Teixeira LA, Candido Dos Reis FJ.
    • Target Oncol. 2020 Feb;15(1):37-46. doi: 10.1007/s11523-020-00697-y.
    • Meta-Analysis

    Comment, Letter:

    Comment on: BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.

    Reply, Letter:

    Author's Reply to Jia et al.: "BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis".

    • Identification of immune-enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.
    • Zheng M, Hu Y, Gou R, Liu O, Nie X, Li X, Liu Q, Hao Y, Liu J, Lin B.
    • J Cell Mol Med. 2020 Jan 29. doi: 10.1111/jcmm.14830. [Epub ahead of print]
    • Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers.
    • Karaayvaz-Yildirim M, Silberman RE, Langenbucher A, Saladi SV, Ross KN, Zarcaro E, Desmond A, Yildirim M, Vivekanandan V, Ravichandran H, Mylavagnanam R, Specht MC, Ramaswamy S, Lawrence M, Amon A, Ellisen LW.
    • Sci Adv. 2020 Jan 29;6(5):eaay2611. doi: 10.1126/sciadv.aay2611. eCollection 2020 Jan.

    Press: Breast Cancer Risk Clues Found By Sequencing Cells From BRCA2 Germline Mutation Carriers. (GenomeWeb)

    • Misdiagnosis of High-grade Serous Ovarian Cancer With BRCA Mutation as Endometriotic Cyst Due to Its Unique Gross Morphology: A Case Report and Literature Review.
    • Ma Q, Yuan Y, Wang Y, Shao C, Feng W.
    • Int J Gynecol Pathol. 2020 Jan 23. doi: 10.1097/PGP.0000000000000663. [Epub ahead of print]
    • Case report
    • BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database.
    • Blanter J, Zimmerman B, Tharakan S, Ru M, Cascetta K, Tiersten A.
    • Oncology. 2020 Jan 21:1-4. doi: 10.1159/000504965. [Epub ahead of print]
    • Differentially expressed genes and key molecules of BRCA1/2-mutant breast cancer: evidence from bioinformatics analyses.
    • Li Y, Zhou X, Liu J, Yin Y, Yuan X, Yang R, Wang Q, Ji J, He Q.
    • PeerJ. 2020 Jan 21;8:e8403. doi: 10.7717/peerj.8403. eCollection 2020.
    • Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    • de Boo L, Cimino-Mathews A, Lubeck Y, Daletzakis A, Opdam M, Sanders J, Hooijberg E, van Rossum A, Loncova Z, Rieder D, Trajanoski Z, Vollebergh M, Sobral-Leite M, van de Vijver K, Broeks A, van der Wiel R, van Tinteren H, Linn S, Horlings HM, Kok M.
    • Eur J Cancer. 2020 Jan 16. pii: S0959-8049(19)30855-X. doi: 10.1016/j.ejca.2019.12.003. [Epub ahead of print]
    • Microsatellite instability in Japanese female patients with triple-negative breast cancer.
    • Kurata K, Kubo M, Kai M, Mori H, Kawaji H, Kaneshiro K, Yamada M, Nishimura R, Osako T, Arima N, Okido M, Oda Y, Nakamura M.
    • Breast Cancer. 2020 Jan 6. doi: 10.1007/s12282-019-01043-5. [Epub ahead of print]
    • Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    • Cheng AS, Leung SCY, Gao D, Burugu S, Anurag M, Ellis MJ, Nielsen TO.
    • Breast Cancer Res Treat. 2020 Jan;179(1):3-10. doi: 10.1007/s10549-019-05438-y. Epub 2019 Sep 14.

    Letter, Comment:

    RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.

    • Incorporating immunohistochemical markers into screening methods for BRCA1-mutated breast cancer.
    • Tuzimek A, Fudalej M, Sobiborowicz A, Budzik M, Badowska-Kozakiewicz A.
    • Pol J Pathol. 2020;71(3):261-269. doi: 10.5114/pjp.2020.99793.

Continue to Older References